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CHAPTER 1 INTRODUCTION 
Please note that part of content of this chapter is from a chapter of 
Nanomedicine for Inflammatory Diseases, “Bridging the Gap between Bench and 
Clinic; Asthma” is being copyedited and will be published in Nanomedicine for 
Inflammatory Disease, Taylor & Francis Group, UK, 2016 (in process). The 
authors of this book chapter include Rima Kandil, Dr. Olivia Merkel and me. 
Rima Kandil and me are the joint first authors of this book chapter. 
1.1 Gene therapy 
Gene therapy is the in vivo delivery of therapeutic nucleic acids into cells 
or tissue to treat or prevent a disease. Nucleic acid mediated therapies include: a) 
replacing a malfunctioning gene with a functional wildtype gene; b) silencing a 
mutated gene; c) supplementing a gene encoding a missing protein in cells; d) 
boosting the immune response toward foreign infectious organisms1.  Gene 
therapy is thought to be the solution for hard to cure diseases including genetic 
diseases, cancer, neurodegenerative disease, immunodeficiency and HIV, and 
extensive studies in pre-clinic research and clinical trials have been completed and 
are going-on. Currently, gene therapy can be conducted via two different 
approaches. One is the ex vivo approach, where nucleic acids are transferred into 
autologous target cells collected directly from individuals. These gene- corrected 
cells are returned back to the body and fight the disease. The other is the in vivo 
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approach, where nucleic acids are directly administrated to patients for nucleic 
acid delivery to target cells inside the body2.    
By 2012, over 1800 gene therapy clinical trials were performed in 31 
countries. Most of these trials (64.4%) focus on treatments of different cancers 3 
since the five-year survival rates of certain cancers are still very low, such as liver 
(17.5%), lung (17.7%) and pancreatic cancer (7.7%) according to a report from the 
National Cancer Institute (2009-2013).  Current pre-clinic research and clinical 
trials for gene therapies of cancer include several strategies. The first one is the 
replacement of mutated tumor suppressor genes such as p53. Advexin® is a gene 
p53 encoding plasmid carried by an adenoviral vector. It showed antitumor 
activity and improved survival in clinical trials for treatment of head and neck 
cancer 4.  Another approach is the supplement of a ‘suicide gene’ encoding a 
viral/bacterial enzyme which can covert a pro-drug to an active drug in cancer 
cells 5. Silencing of gene controlling tumorigenesis (e.g. proliferation and survival), 
metastasis and drug resistance is also a common approach 6. In Chapter 4, our 
study reports that silencing of GASC1, an epigenetic factor involved in 
tumorigenesis, can inhibit the proliferation of basal-like breast cancer cells. 
Gene therapy of inflammatory diseases only accounts for small potion in 
gene therapy clinical trials (0.7%) 3. However, a large global market of drugs for 
inflammatory diseases 7 encourage research groups and pharmaceutical companies 
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to develop new therapies consequently increasing the number of pre-clinical 
research approaches and clinical trials of gene therapy for inflammatory diseases.  
For example, gene therapy approaches for asthma include DNA vaccines to induce 
immune tolerance 8, delivery of antisense oligonucleotides 9, small interfering 
RNA (siRNA) 10 and deoxyribozymes (DNAzyme) 11 for the selective silencing of 
asthma related genes. Currently, there is one gene therapy approach for asthma in 
clinical trial using SB010. SB010 is a DNAzyme which can cleave GATA-3, a 
key factor in asthma pathogenesis. It can achieve anti-inflammatory effects and 
improved lung function in asthmatic patient 11. In Chapter 2 & Chapter 3, the 
application of siRNA as novel therapies of asthma will be discussed.   
1.2 Delivery of nucleic acids 
1.2.1 Viral delivery system 
Many viruses naturally have the ability to effectively transfer their genetic 
material and express proteins in host cells as part of their replicate cycle. 
Therefore, they offer the potential to deliver nucleic acids to mammalian cells for 
gene therapy. In a viral delivery system, the gene which is essential for viral 
duplication is deleted and replaced by a therapeutic gene. Viral delivery systems 
show advantages, including high in vivo transduction efficiency and constant 
expression of the target gene 12. Viral vectors, including adenovirus, retrovirus, 
adeno-associated virus, herpes simplex virus and lentivirus, are the most common 
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delivery system of nucleic acid in clinical trials of gene therapy 3.  The number of 
gene therapy clinical trials increased dramatically since the first gene therapy was 
approved in 1990. The first trial aimed to treat a kind of severe combined immune 
deficiency (SCID) which lacks a gene encoding adenosine deaminase (ADA). 
Patients were administrated autologous T cells transduced by retroviral vectors 
carrying genetic material encoding ADA. Even though this trial only showed 
modest results, it demonstrated the feasibility and potential of gene therapy in 
clinical use 13. However, concerns regarding safety of viral vector from the public 
and from researchers arose while increasing numbers of clinical trials of gene 
therapy have been approved. One of the major setbacks of gene therapy was the 
case of Jesse Gelsinger. In 1999, 18-year-old Jesse Gelsinger, who suffered from a 
metabolic disorder due to partially defect ornithine transcarbamylase (OTC), 
entered a clinical trial of gene therapy aiming to supplement OTC using an 
adenoviral vector containing genetic material encoding OTC. Tragically, 
Gelsinger died from a severe and unexpected immune reaction to the viral vector. 
In 2000, the United States Food and Drug Administration (USFDA) stopped this 
trial and some other trials employing gene therapy. The FDA announced new 
programs and restrictions, including the Gene Therapy Clinical Trial Monitoring 
Plan and the Gene Transfer Safety Symposia, to protect patients better 14. Another 
common viral vector, retrovirus vector, was used in a clinical trial to treat 11 
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children who had severe combined immunodeficiency (SCID)-XI disease which 
was the first success in gene therapy 15. However, 5 children developed leukemia-
like illness which was believed to be due to insertion of the retrovirus vector 
which triggered the expression of proto-oncogenes 16. Extensive efforts have been 
devoted to improve the safety of viral vectors and promising progress has been 
made. Several new drugs for gene therapy were approved. Genedicine, an 
adenoviral vector carrying wildtype p53 gene, is the first gene therapy drug in the 
clinic for treatment of head and neck squamous cell carcinoma approved by the 
China Food and Drug Administration (CFDA). Another drug for gene therapy is 
Glybera, an adeno-associated virus carrying gene encoding human lipoprotein 
lipase (LPL), approved by the European Medicines Agency (EMA) and USFDA 
for treatment of lipoprotein lipase deficiency. Despite the improved safety of viral 
vectors and the success in the clinic, concerns of potential severe side effects, such 
as immunogenicity and carcinogenesis, caused by viral vectors never vanished and 
additional care is taken regarding the approval of gene therapy using viral vectors. 
On the other hand, the complexity of viral vectors manufacture and limited DNA 
packaging capacity also limit the large scale clinical use 17.     
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1.2.2 Non-viral delivery system 
1.2.2.1 Challenges of delivery of nucleic acids 
Because of the limitations and concerns mentioned above, the application 
and development of non-viral delivery became more popular. Non-viral vectors 
demonstrate many advantages compared to viral vector. First of all, non-viral 
vectors have better and tunable safety profiles than viral vectors. Biocompatible 
materials can be selected to achieve less immunogenicity and toxicity. Non-viral 
vectors can be also synthesized by biodegradable materials to reduce the toxicity 
and accumulation in the body. Moreover, applications of non-viral vectors for 
gene therapy can avoid insertional mutagenesis. Non-viral vectors have larger 
capacity for delivery of nucleic acid and are less complicated in their manufacture 
process which makes it easier for scaling up the production. More importantly, 
because the relatively simple chemical structure of non-viral vectors, such as 
polymer-based materials, various modifications have been done to achieve 
efficient and selective gene delivery, better safety and optimal pharmacokinetic 
profiles 18.  For example, non-viral vectors are commonly modified with targeted 
ligands such as folic acid 19 and transferrin 20 to achieve cell/tissue specific 
delivery. PEGylating non-viral vectors has been utilized to increase the 
biocompatibility and circulation time 21 and to achieve tissue specific 
accumulation 22. Despite the numerous studies which have been performed to 
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develop and optimize non-viral vectors, their gene delivery efficiency is still 
relatively poor especially compared to their viral counterparts. Consequently, only 
a few non-viral vectors are mature enough to enter clinical trials 18. 
Non-viral vectors will encounter various challenges when they are applied 
to deliver nucleic acids systemically. Nucleic acids are easily degraded by 
endogenous nucleases in the circulation. The half-life of nucleic acids in the blood 
stream is short, for instance, the half-life of naked plasmid DNA injected 
intravenously (i.v.) has been reported to be 10 minutes in mice. Nucleic acids 
carried by non-viral vectors are not readily degraded by nucleases and have longer 
circulation half-lives. Chemical modification in nucleic acid can also facilitate to 
protect them against the cleavage by nuclease and increase their in vivo stability. 
Common modification include incorporation of  2’-O- methyl to replace the 2’-
OH group in the ribose in siRNA and combination of 2-thiouridine and 5- 
methylcytidine in mRNA 18.  
Non-viral vectors need to overcome several biological barriers to deliver 
nucleic acids to target cells/tissues. Most non-viral vectors contain polycations or 
cationic lipids to condense nucleic acids which have negatively charged backbones. 
Nucleic acids can electrostatically interact with non-viral vectors and form 
polyplexes or lipoplexes which commonly have a net positive surface charge. This 
positive charge can induce non-specific association with non-target cells and 
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interaction with serum proteins in circulation. Vectors covered with a corona of 
serum proteins are easily recognized and trapped by the reticuloendothelial system 
(RES), such as liver, spleen and bone marrow. Consequently, only a small dose of 
i.v. administrated cationic nanoparticles can be delivered and accumulate at the 
target site. One of the strategies to reduce the positive charge and non-specific 
delivery is to decorate the vectors with polyethylene glycol (PEG), a hydrophilic 
and charge-neutral polymer. PEG shields the polyplexes/lipoplexes in the blood 
stream and avoids non-specific delivery. Most importantly, it prevents interaction 
with serum proteins and reduces accumulation in the RES which significantly 
increases the circulation time of polyplexes/lipoplexes 23.   
 Another challenge is selective accumulation in the tissue of interest. The 
behavior of non-viral vectors of nucleic acids in the body is highly dependent on 
their size, shape and surface properties. Typical non-viral vectors carrying nucleic 
acids, such as lipoplexes and polyplexes, are of spherical shape and in the 
nanometer range. Large lipoplexes/polyplexes (> 200 nm) tend to accumulate in 
liver and spleen and micrometer size particle (2-5 um) rapidly accumulate in the 
capillaries of the lung. Therefore, particle sizes around 100 nm are preferred 24. 
Normal blood vessels have tight interendothelial junctions and prevent 
extravasation of lipoplexes/ polyplexes from the blood stream. In certain cases, 
such as inflammation and injury, leakage and dysfunction occur in the blood 
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vessel and lead to accumulation of lipoplexes/polyplexes at these sites. This 
strategy is commonly utilized to target tumors. The blood vessels supporting 
tumor growth are fenestrated, and tumors often lack efficient lymphatic drainage. 
This phenomenon is termed the “enhanced permeability and retention (EPR) 
effect”. Modifications in vectors to prolong circulation time, such as PEGylation, 
can increase the accumulation at the tumor site. Another consideration is fluid 
dynamics of lipoplexes/ polyplexes. Particles with spherical shape demonstrate 
less lateral drift in the blood stream compared to non-spherically shaped particles 
which result in lower association with endothelial cells and extravasation from the 
blood stream 24.     
Once the lipoplexes/polyplexes reach their selective site, even if some 
hydrophobic vectors can diffuse directly through the cellular membrane, most 
vectors require active internalization. Ligand modification in vectors can enhance 
cellular uptake via receptor mediated internalization. Moreover, vectors equipped 
with cell penetration peptides, such as trans-activating transcriptional activator 
(TAT) from the human immunodeficiency virus 1 (HIV-1), can also mediate 
efficient cellular uptake. Endocytosis of lipoplexes/polyplexes involves formation 
of intracellular vesicles termed endosomes. Endosomes eventually merge with 
lysosomes, which are vesicles that contain a highly acidic and enzyme rich 
environment and are capable of degrading the vectors and therapeutic nucleic 
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acids. Therefore, escape from the endosome is required for vectors to avoid 
degradation and to release nucleic acids into cytoplasm. To facilitate endosomal 
escape, the vectors can be modified with endosomolytic peptides, such as melittin, 
to disrupt the endosomal membrane 25. Cationic polymers which have a high 
buffer capacity, such as poly ethyleneimine (PEI), can absorb protons and lead to 
an increased influx of counter ions (chloride) and water. Eventually, the increased 
osmotic pressure leads to bursting of the endosome and the release of materials 
inside the vesicles. This theory is called “proton sponge effect”. Another reason 
why cationic polymers and lipids can achieve efficient endosomal escape is called 
“flip-flop” mechanism. The polymer/lipid with positive charge can 
electrostatically interact with vesicle membranes with negative charge and lead to 
membrane flipping and destabilization 23.     
Different kinds of therapeutic nucleic acids face different challenges in the 
cytosol. Plasmid DNA (pDNA) needs to be delivered into the nucleus and requires 
access to the transcriptional machinery to express protein. Direct microinjection of 
pDNA carrying the thymidine kinase genetic information into nuclei of cells 
lacking  thymidine kinase induces thymidine kinase expression in 50-100% of the 
cells. However, little activity of thymidine kinase was observed in the cells 
microinjected with pDNA into the cytoplasm. Furthermore, pDNA can express 
proteins efficiently in fast proliferating and dividing cells, since during mitosis the 
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nuclear envelope breaks down and the nucleus becomes more accessible to pDNA 
in the cytoplasm. In contrast, pDNA transfection results in poor protein expression 
in slow dividing cells due to their nucleic envelope being intact. These studies 
indicate that the nuclear envelope is the major barrier for delivery of pDNA to the 
nucleus. To overcome this barrier, modification with nuclear localiztion signal 
(NLS) sequences in non-viral vectors have been prepared and result in enhanced 
nuclear delivery efficiency and protein expression 26. Small interfering RNA 
(siRNA) requires to be successfully incorporated into the RNA-induced silencing 
complex (RISC) to achieve gene silencing. The least stably hybridized 5’ terminal 
of siRNA tends to load into the RISC, therefore, modification of the 5’ end of 
siRNA is not recommended 18. Application of longer double stranded RNA 
(dsRNA) to trigger gene silencing results in higher gene silencing efficiency. 
Synthetic long dsRNA (25-30 base pair) demonstrated 100-fold higher gene 
silencing efficiency compared to corresponding shorter siRNA (21 bp). It is 
believed that long dsRNA is a substrate of Dicer, a RNase-III class 
endoribonuclease, involved in RNA interference. Dicer can facilitate siRNA 
loading into the RISC and plays a role in RISC assembly. Therefore, more 
efficient gene silencing can be achieved when its substrate, long dsRNA, is 
provided to Dicer compared with delivery of conventional synthetic siRNA (21 bp) 
to RISC 27.  
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1.2.2.2 Synthetic non-viral vector 
Non-viral vectors include polymers, cationic lipids, synthetic peptides, 
RNA/DNA chimera and inorganic nanoparticles (e.g. gold, magnesium) 28. This 
section will focus on introducing the application of polymeric vectors for gene 
delivery.  
There are three strategies of how polymeric vectors can carry nucleic acids: 
encapsulation, adsorption and electrostatic interaction. Nucleic acids can be 
encapsulated into biodegradable polymers, such as poly lactide-co-glycolide 
(PLGA), poly lactic acid (PLA) and poly beta-amino esters, to prevent enzymatic 
degradation in vivo and to achieve controlled release. The backbone of 
biodegradable polymers usually contains ester linkages which can be hydrolyzed 
and cleared easily in the body. The kinetics of nucleic acid release is tunable via 
adjustment of the hydrolysable parts in the polymer 29. PLGA is a popular 
biodegradable polymer for gene delivery since it is approved for human use 
worldwide. PLGA can successfully encapsulate plasmid DNA, a relatively large 
nucleic acid, and achieve efficient transfection 30. Small nucleic acid such as 
siRNA can be also encapsulated into PLGA. However, there are several 
challenges in this process including leakage of siRNA from PLGA particles, low 
loading efficiency and encapsulation efficiency 31. Moreover, degradation of 
nucleic acids may happen during the encapsulation process since they are exposed 
13 
 
 
 
 
to organic solvents and sonication or long term solvent evaporation may be 
required. Degradation may also happen inside the particle due to the low pH 
environment caused by hydrolyzation of esters in the polymer 29. To overcome 
these limitations, an adsorption loading strategy has been developed. Adsorption is 
a technique that combines both encapsulation and electrostatic interaction 
strategies. A cationic polymer can be incorporated into a biodegradable polymer 32 
or adsorbed onto the surface of formed particles 33. Therefore, nucleic acids can 
efficiently be loaded by the cationic moiety to avoid the harsh encapsulation 
process and hydrolyzation environment 29.  The most common strategy to pack 
nucleic acids using polymers is electrostatic interaction. This technique takes 
advantage of the anionic nature of nucleic acids, contributed by the phosphate 
group connecting the ribose molecules. Nucleic acids can electrostatically interact 
with cationic polymers and form particles suitable for efficient gene delivery 29.  
Many cationic polymers are exploited for gene delivery including poly- L-
lysine (PLL), acrylate based polymers, poly(amino-ester) based polymers, 
polyamidoamine (PAMAM) dendrimers and PEI based polymers. For example, 
PLL is a biodegradable polymer which is one of the first cationic polymers to be 
utilized in gene transfer. Despite the favorite biocompatibility of PLL, the short 
half-life in circulation and low transfection efficiency limit its use. PAMAM 
dendrimer is a symmetric macromolecule which has repetitive units of amido-
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amines and primary amines located at the terminal surface. The controlled 
synthesis process of PAMAM dendrimers results in its narrow molecular weight 
range and defined spheroidal shape. Surface primary amine can efficiently 
condense nucleic acids and can easily be chemically modified with functional 
groups (e.g. targeting ligands, PEG, cyclodextrin). More importantly, large 
amount of internal tertiary amino group can serve as “proton sponge” to buffer pH 
change in endosome resulting better endosomal escape 34.  
Among the cationic polymers, PEI is one of the most extensive studied 
polymers for gene delivery and is considered as the gold standard transfection 
reagent. PEI can be synthesized in different molecular weight and structure such 
as linear and branched. PEI usually contains primary amines and secondary 
amines as well as tertiary amines if its structure is branched. This amine rich 
structure renders PEI the ability to efficiently compact nucleic acids and protect 
them from degradation. Similar to PAMAM dendrimers, PEI has a large buffer 
capacity leading to high transfection efficiency. Researchers have developed 
various PEI based polymers to achieve better transfection efficiency and better 
biocompatibility. S. Kim et al. reported that low molecular weight PEI (2000 Da) 
conjugated with hydrophobic lipids such as cholesterol and myristate 
demonstrated enhanced transfection efficiency of plasmid DNA encoding β-
galactosidase in 293 cell lines. The exact mechanism of how lipid modification of 
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PEI increases transfection efficiency is still unclear. It is hypothesized that the 
hydrophobic lipid increases the association with the lipophilic cell membrane 35. 
Other hydrophobic modifications have been used for PEI, including phospholipids 
36, alkanes 37, fatty acids 38 and hydrophobic poly (amino acids) 39. M. Zheng and 
her co-workers described that grafting PEI with poly-caprolactone-b-PEG (PCL-b-
PEG) increased the buffer capacity of copolymers compared to non-modified PEI 
and resulted in corresponding enhanced transfection efficiency. Biodegradable 
PCL served as a linker between PEI and PEG. Moreover, the hydrophobicity of 
PCL is believed to facilitate the association between the PEI-PCL-PEG 
copolymers and the cellular and endosomal membrane 40. To increase the 
endosomal escape, endosomolytic peptides modifications (e.g. mellitin 41 and 
truncated HGP 42) and cell penetration peptide modifications (e.g. TAT 43) in PEI 
have been developed and demonstrated enhanced transfection efficiency. One of 
the limitations of endosomolytic peptides is their lytic activity under physiological 
conditions which can lead to destabilizations of plasma membrane and cell lysis. S. 
Boeckle et al. developed a PEI based polymer equipped with mellitin analogs. The 
neutral glutamines in mellitin (Mel) were replaced by glutamic acid residues 
resulting in high lytic activity at endosomal pH (pH 5) rather than physiological 
pH (pH 7). Different mellitin analogs (MA) were conjugated to PEI at cysteine 
modified C-termini (CMA-PEI).  At endosomal pH 5, strong erythrocyte lysis was 
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observed after the treatment with CMA-2-PEI and CMA-3-PEI but not with 
CMA-4–PEI, CMA-1-PEI and Mel-PEI. Accordingly, CMA-2–PEI and CMA-3–
PEI mediated more efficient transfection of plasmid DNA encoding a reporter 
protein Luciferase in 4 different cell lines (CT 26, HeLa, Neuro2A and A-10 cells) 
compared to Mel-PEI, unmodified PEI, CMA-1-PEI and CMA-4-PEI. However, 
increased corresponding toxicity was observed at high DNA doses (4 and 8 μg/ml) 
41. Another attempt to attenuate the toxicity of Mel under physiological condition 
has been approached by the same group. M. Meyer et al. utilized dimethyl maleic 
anhydride (DMMAn) to reversibly react with the lysines in Mel which could 
reduce the lytic activity. Since the DMMAn can be cleaved from Mel in acidic 
environment, this modified Mel (Mel-DMMAn) is believed to only demonstrate 
lytic activity in the endosomal environment. The author conjugated Mel-DMMAn 
to PLL and evaluated the transfection efficiency of plasmid DNA encoding 
luciferase in Neuro2A cells. As expected, Mel-DMMAn-PLL induced less 
erythrocyte lysis and cytotoxicity compared to Mel-PLL. Moreover, it mediated 
higher luciferase expression compared to Mel-PLL and unmodified PLL at 
different polymer and nucleic acid ratios (N/P ratios) 25.  We were able to modify 
25k Da PEI with Mel-DMMAn following the same strategy. This Mel-DMMAn-
PEI can deliver siRNA against green fluorescent protein (GFP) and mediate 
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significantly more GFP knockdown compared to unmodified PEI in H1299 cells, a 
lung cancer cell line, expressing GFP (Figure 1). 
 
GFP knockdown in H1299
P
EI
 N
P 
5
P
EI
  N
C
M
E
L-
D
M
M
A
n-
P
E
I N
P
 5
M
E
L-
D
M
M
A
n-
P
E
I N
C
0
50000
100000
150000 ***
M
F
I 
o
f 
G
F
P
 
Figure 1 GFP knockdown in H1299 using Mel-DMMAn-PEI. The GFP 
knockdown mediated by PEI and Mel-DMMAn-PEI polyplexes containing siRNA 
against GFP or scramble siRNA (NC) in H1299/GFP cells. Polyplexes were 
prepared with 50 pmol of siRNA at N/P= 5 and transfected for 48 h. The MFIs 
were quantified by flow cytometry. (Data points indicate mean +/- SD, n= 3.  One-
way ANOVA, Newman-Keuls post-test, *** p <0.001).  
To increase the selectivity to certain tissue/cells. PEI has been modified 
with different targeting moieties. For example, to target cancer cells, transferrin 44, 
folic acid 19a, tripeptide motif Arg-Gly-Asp (RGD) in vitronectin, fibronectin and 
fibrinogen 45 and epidermal growth factor (EGF) 46 were conjugated to PEI or PEI 
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based polymers. In 2009, our group demonstrated two different approaches to 
conjugate RGD mimics to PEI. In the first one, RGD mimics with maleimide 
modification were reacted directly with the primary amines in PEI-PEG. In the 
other approach, a PEG linker containing two functional groups, orthopyridyl-
disulfide and succinimidyl propionic acid (NHS-PEG-OPSS) were used for 
coupling the RGD mimetic. NHS functional groups can react with the primary 
amines in PEI and the OPSS group can couple to the thiol group in the sulfhydryl 
derivative of the RGD mimics. Different RGD-PEIs were evaluated MeWo cells, a 
human malignant skin melanoma cell line, overexpressing integrin receptors and 
A549 cells, a lung epithelial cell line, expressing low levels of integrin receptors. 
Results suggested that RGD-PEI can preferentially bind to MeWo cells and 
efficiently deliver radio labeled plasmid DNA into MeWo cells rather than A549 
cells. RGD-PEI polyplexes containing plasmid DNA encoding luciferase also 
mediated significantly higher luciferase expression in MeWo cells compared to 
unmodified PEI47.    
 Despite the high transfection efficiency of PEI-based polymers, potential 
toxicity induced by high density of cationic charges arose concern regarding 
applying PEI in vivo. To avoid the toxicity caused by positive surface charge, 
several ways were developed to shield the particle, including PEGylation, coating 
with serum protein transferrin 44 or hydroxyl rich “skin”, termed “hydroxylation 
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camouflage” 48.  X. Luo et al. modified 25k Da PEI with 5-ethyl-5-
(hydroxymethyl)-1,3-dioxan-2-oxo (EHDO) via an aminolysis reaction. The 
properties of PEI-EHDO directly depended on the hydroxylation degree on the 
surface. A high percentage of hydroxyl substitution on polymer PEI-EHDO34.5% 
yielded polyplexes with plasmid DNA and demonstrated reduced surface charge 
compared to unmodified PEI and PEI-EHDO19.9% polymer with lower percentage 
of hydroxyl substitution. Accordingly, reduced cytotoxicity in 293T and Hela cells 
and minimal hemolytic effects were observed after PEI-EHDO34.5% treatment. 
Furthermore, less BSA protein was absorbed on the surface of PEI-EHDO34.5% 
polyplexes compared to PEI and PEI-EHDO19.9 % complexes, indicating a good 
serum tolerance ability. This property lead to high efficiency of PEI-EHDO34.5% to 
deliver plasmid DNA carrying luciferase gene in 293T and Hela cells in the 
presence of serum 48.           
On the one hand, the transfection efficiency and potential toxicity are both 
related to the molecular weight of PEI. High molecular weight PEI (> 25k Da) can 
mediate efficient transfection but demonstrates cytotoxicity. On the other hand, 
low molecular weight PEI (600 – 25k Da) is less efficient and less toxic. To 
reduce the potential toxicity, high molecular weight PEI synthesized from low 
molecular weight PEI and crosslinked via reducible disulfide bonds or 
inert/biodegradable polymers has been developed. These PEI based polymers are 
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sensitive to redox stimuli. Glutathione (GSH) is a main reducing factor inside and 
outside the cellular environment. The concentration of GSH in the extracellular 
(2.8 µM) and intracellular (10 µM) environment differs strongly. Therefore, these 
biodegradable polymers can breakdown once they enter cells, especially in the low 
pH endosomal environment, and release their gene cargo 49.  Disulfide bond-
crosslinked low molecular weight PEI was first reported by M. Gosselin. The 
author crosslinked 800 Da PEI using two crosslinkers, dithiobis- 
(succinimidylpropionate) (DSP) and dimethyl-3,3′-dithiobispropionimidate 2HCl 
(DTBP). The transfection efficiency of PEI-DSP and PEI-DTBP polyplexes 
containing plasmid DNA encoding luciferase gene was evaluated in CHO cells. 
The results suggested that transfection efficiency depended on the linker, crosslink 
degree and N/P ratio. Crosslinked PEI at low N/P ratios (5 and 9) mediated less 
luciferase expression compared to 25k PEI, while at high N/P ratios (13 and 18), 
crosslinked PEI with crosslinking degree of 1 mediated comparable luciferase 
expression to 25k PEI 50. Q. Peng et al. synthesized thiolated PEI (800 Da) which 
can be oxidized by DMSO and yields disulfide crosslinked PEI (PEI-SS). Less 
cytotoxicity of PEI-SS-PEI in Hela cells compared to 25k PEI was observed as 
well 51.  
Because of the promising properties of PEI, PEI is commonly used in proof 
of concept studies or pilot studies for optimizing experimental conditions. In 
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Chapter 3, 4 & 5, the application of branched PEI modified with targeteing 
moieties to deliver siRNA for potential treatment of  asthma and cancer will be 
discussed.    
1.3 RNAi for gene therapy 
1.3.1 RNAi 
RNA interference (RNAi) is endogenous sequence- specific mRNA 
degradation process and first discovered in plant but later RNAi was reported as a 
universal process in most eukaryotic organisms. On 1998, Andrew Fire and Craig 
C. Mello discovered that double strand RNA (dsRNA) can efficiently suppress 
expression of gene in the nematode worm Caenorhabditis elegans and later were 
awarded the 2006 Nobel Prize in Physiology or Medicine for this contribution. 
Many cellular components are involved in RNAi. Dicer is an enzyme 
belonging to RNase III family and specifically cleaves dsRNA. Cleavage of Dicer 
generate small interference RNA (siRNA) in a range of 21- 25 nucleotides. siRNA 
is loaded in a protein complex termed RNA- induced silencing complex (RISC). 
The sense strand (passenger strand) in siRNA is degraded in RISC while antisense 
strand is integrated into RISC and serves as a guide strand. mRNA containing 
complementary sequence of antisense strand can be recognized by siRNA/RISC 
complex and cleaved by Argonaute 2 (Ago2), the component that has cleavage 
activity in RISC. Another kind of small RNA (21-28 nucleotides) called micro-
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RNA (miRNA) can also induce gene silencing. A long miRNA precursor called 
primary miRNA (pri-miRNA) is cleaved by an enzyme Drosha in the nucleus to 
generate precursor-miRNA (pre-miRNA). The pre-miRNA is exported from 
nucleus and incorporated into microribonucleoprotein complex (miRISC) or RISC 
in some cases to cleave the mRNA containing complementary sequence (Figure 2). 
miRNA and siRNA are in similar size range and both processed by Dicer followed 
by gene silence. However, there are clear differences between siRNA and miRNA. 
miRNA is single stranded but siRNA is found in double strands which is relative 
more stable. The pair with mRNA of miRNA don’t require perfect complementary 
match but do in siRNA induced gene silencing. Furthermore, many targets of 
discovered miRNA haven’t been identified. Therefore, siRNA attracted extensive 
attention to exploit its therapeutic application 52.    
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Figure 2 Gene silence pathway. 
1.3.2 siRNA for gene therapy 
In 2001, S. Elbashir et al. first described that delivery of synthetic 
siRNA against luciferase was sufficient to suppress the expression of luciferase in 
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different mammalian cell lines including HeLa (human), NIH/3T3 (mouse) and 
CHO (Chinese hamster) 53. Ever since, numerous siRNA sequences targeting 
traditional non-drugable biological molecules have been in preclinical 
development as potential therapies of difficult to treated diseases, and some have 
entered clinical trials. Diseases which have been targeted by siRNA therapy in 
clinical trials include cancer, ocular diseases, asthma, infectious diseases and skin 
disorders. Local delivery of siRNA was the major administration approach in 
initial clinical trials. Extensive effort has been put into the development of non-
viral delivery systems of siRNA, increasing the number of clinical trials utilizing 
systemic administration of siRNA and its vectors.   
The first clinical trial of siRNA therapy was for the treatment of ocular 
disease initiated by Opko Health Inc. In this trial, siRNA against vascular 
endothelial growth factor (VEGF), named Bevasiranib, was administrated 
intravitreally (IVT) to inhibit retinal neovascularization for the treatment of age-
related macular degeneration (AMD), a leading cause of blindness among people 
age 60 and older, and diabetic macular edema (DME). However, its Phase III 
results suggested that Bevasiranib can’t efficiently prevent vision loss in AMD. 
Afterward, two other siRNA formulations, administrated IVT, for therapy of 
AMD and DME which target VEGF receptor-1 (VEGFR1) entered clinical trials. 
Neither formulation could achieve sufficient therapeutic effects to prevent vision 
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loss. However, Macugen, a RNA aptamer against VEGF for AMD therapy, as the 
only RNA therapy approved by the USFDA encouraged pharmaceutical 
companies to keep exploiting this field. PF-655 is a siRNA formulation targeting 
an upstream regulator, apoptosis stress-response gene RTP801/REDD1, 
controlling VEGF production. Phase II results suggested that IVT administration 
of PF-655 can improve the mean visual acuity. Another formulation of siRNA for 
ocular disease is based on eye drops. SYL040012, a siRNA formulation against 
β2-adrenergic-receptor (ADRB2), was developed by Sylentis, S.A. for treatment 
of open angle glaucoma. It demonstrated well tolerability in patients with ocular 
hypertension or glaucoma in a Phase I study. A completed Phase II study 
suggested that SYL040012 (300 µg/ eye/ day) can significantly reduce intraocular 
pressure compared to placebo. The same company initiated another clinical trial of 
an siRNA eye drop formulation, SYL1001, targeting transient receptor potential 
cation channel subfamily V member 1 (TRPV1) for alleviation of ocular pain 
related to dry eye syndrome. Its recent Phase II results reported that one dose 
(1.25 %) among four different doses (0.375%, 0.75%, 1.125% and 2.25%) can 
alleviate ocular pain and hyperaemia compared to placebo 54. 
An intranasal delivery formulation of siRNA against nucleocapsid protein 
of respiratory syncytial virus (RSV), ALN-RSV01, was developed by Alnylam 
Pharmaceuticals. ALN-RSV01 was proposed to be used in lung transplant patients 
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with RSV infection. Phase II results indicated that ALN-RSV01 treatment 
achieves a promising clinical outcome including reduction of incidence of 
new/progressive bronchiolitis obliterans syndrome on day 90 and day 180 post-
treatment. However, there hasn’t been a Phase III trial initiated since 2012 54b. 
Another approach to locally deliver siRNA to the lung is inhalation. 
ExcellairTM is an inhaled siRNA formulation targeting spleen tyrosine kinase 
(Syk), an important factor involved in the inflammation process, for treatment of 
asthma. As reported by ZaBeCor Pharmaceuticals, the Phase I study suggested 
that ExcellairTM was well tolerated and safe. Furthermore, ExcellairTM treatment 
can improve the lung function of patients with asthma and reduced frequency of 
using immediate relief medication. The Phase II trial of ExcellairTM has been 
announced in 2009, however, there have not been any results reported yet54b. 
In 2007, Quark Pharmaceutical initiated the first clinical trial in which a 
siRNA formulation was proposed to be systemically administrated in humans. 
This siRNA therapy, QPI-1002, targets stress-response gene p53 for prevention of 
Delayed Graft Function (DGF) in patients undergoing deceased donor kidney 
transplantation. QPI-1002 treatment can reduce the incidence of DGF and reduced 
the frequency of dialysis for 30 days post-transplant. A Phase III trial to evaluate 
the safety and therapeutic efficacy of QPI-1002 in large groups of patients 
(estimated 634 people) is currently recruiting participants54b. 
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Currently, systemic siRNA therapies in clinical trials are mostly carried 
by lipid nanoparticles (LNP). LNP preferentially accumulate in liver and kidneys. 
Therefore, many clinical developments of siRNA aim to target hepatic genes. 
TKM-ApoB is a siRNA therapy targeting apolipoprotein B (ApoB), the major 
apolipoproteins in low-density lipoprotein particles (LDL) which are generated 
primarily in the liver, for the treatment of hypercholesterolemia. This formulation 
is administrated i.v. and therapeutic siRNA is carried by the first generation of 
stable nucleic acid lipid particles (SNALP). Reduced ApoB/LDL was observed 
after TKM-ApoB treatment, however, some patients experienced flu-like symptom 
indicating potential immunostimulation by TKM-ApoB. Later, Alnylam 
Pharmaceuticals initiated a clinical trial using the same carrier SNALP to pack two 
sequences of siRNA against VEGF and kinesin spindle protein (KSP), important 
factors involved in cell survival and proliferation, as therapy for primary and 
secondary liver cancer. Successful suppression of VEGF has been achieved in 
some patients who received siRNA treatment. A liver targeted strategy has been 
developed to more selectively deliver siRNA to the liver with lower doses and 
reduced toxicity. siRNA conjugated with triantennary N-acetylgalactosamine 
(GalNAc) can trigger internalization of hepatocyte-restricted asialoglycoprotein 
receptor (ASGPR). A GalNAc conjugated siRNA (ALN–PCS02) targeting 
proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme specifically 
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degrading LDL receptor, was developed by Alnylam Pharmaceuticals for 
treatment of hypercholesterolemia. In a Phase I trial, a single dose of i.v. 
administration of ALN–PCS02 can reduce PCSK9  by 70% and LDL in 
circulation by 40%. A subcutaneous administrated formulation of the drug, ALN–
PCSsc, entered a Phase I study to evaluate its efficacy in terms of reducing blood 
LDL. Treatment of ALN–PCSsc was well tolerated and can achieve up to 83% 
reduction of LDL. More importantly, Phase I results suggested a potential for a bi-
annual dosing 54b. 
Application of siRNA therapies in cancers attracts large attention since 
there is no effective treatment for some cancers which lead to high mortality rates. 
A siRNA carried by anionic liposomes and targeting breakpoint cluster region–
Abelson murine leukemia oncogene (bcr-abl) tyrosine kinase was proposed as 
therapy of Chronic Myeolid Leukemia (CML). A patient with imatinib-resistant 
CML received siRNA formulation i.v. (10 μg/kg body weight) on day 426 post-
transplantion of blood stem cells. Additionally, 300 μg siRNA was injected into 
one subcutaneous CML node. Later, 2 additional doses were given to the patient 
within 32 days after the first dose. The siRNA treatment transiently slightly 
reduced the bcr-abl mRNA in CML cells and ex vivo results suggested that the 
treatment can inhibit proliferation and induce apoptosis in CML cells. However, 
ex vivo transfection results also suggest that CML cells may develop resistance to 
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siRNA application 55. Ligand coated nanoparticles have been applied to increase 
the delivery efficiency of siRNA targeting tumors in the clinic.  Calando 
Pharmaceuticals developed a delivery system containing three components in the 
carrier including 1) a cationic cyclodextrin based polymer to carry siRNA, 2) an 
adamantane polyethylene glycol could enhance the stability in the blood stream 
and 3) a human transferrin to target the tumor. This formulation CALAA-01 
targeting the M2 subunit of ribonucleotide reductase, an important factor involved 
in cancer cells proliferation, was evaluated in the clinic for treatment of relapsed 
or refractory cancers/solid tumors. The siRNA induced mRNA cleavage was 
confirmed by a rapid amplification of complementary DNA ends (RACE) PCR. 
However, two patients experienced dose-limiting toxic events. Moreover, no 
objective anti-tumor effect was observed, and 29% patients showed increased 
tumor sizes which lead to termination of this trial. Despite more optimization still 
being required to achieve efficient in vivo gene knockdown using nanoparticle, 
this trial demonstrated the feasibility to systemically administrate ligand guided 
polymeric nanoparticles 56.  
1.4 Transferrin receptor 
Transferrin (80k Da) (Tf) is a glycoprotein present in serum and contains 
two subunits linked by a spacer. Tf can deliver iron into cells mediated by 
interaction with its receptor, the transferrin receptor (TfR). Iron is a factor 
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involved in essential cellular procesess including DNA synthesis and metabolism. 
Therefore it is essential for cell proliferation and differentiation. Dietary iron is 
taken up through the intestine and becomes the oxidized form Fe 3+. However, 
cellular processes require Fe 2+ and Fe 3+ can be toxic to the cells. Tf can bind Fe 3+ 
and transport it as a non-toxic complex in circulation. Each subunit of Tf can bind 
to one iron ion, therefore, there are two forms of Tf/iron complexes, monoferric Tf 
and diferric Tf (holo-Tf). Additionally, apo-Tf represents Tf that is not bound with 
iron or other metals. Tf/ iron complexes demonstrat higher binding affinity with 
TfR compared to apo-Tf. For example, the association constant of holo-Tf with 
TfR is 500 fold higher than apo-Tf with TfR. 
TfR is a transmembrane receptor that can mediate endocytosis of Tf/iron 
complexes. Holo-Tf can bind to TfR and be endocytosed in clathrin-coated pits. 
The pH is reduced inside the endosome leading to a conformation change of holo-
Tf. Consequently, Fe 3+ is released from holo-Tf and reduced to Fe 2+ in the 
endosomal environment before it enters the cytoplasm. Apo-Tf/ TfR complexes 
are recycled back to the cell surface and apo-Tf is readily dissociated from TfR 
due to its low affinity.  The expression of TfR is regulated by the intracellular iron 
level. Cellular events, such as DNA synthesis that consume iron lead to reduced 
intracellular iron levels eventually resulting in an upregulation of TfR. TfR is 
universally expressed at low level in most cells/ tissues and upregulated in certain 
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cells such as actively proliferating cells, vascular endothelium of brain capillaries, 
and activated peripheral blood mononuclear cells. Additionally, upregulation of 
TfR is also observed in various cancer cells including glioma, breast cancer, lung 
adenocarcinoma and lymphoma.     
1.4.1 TfR and diseases 
Tf has been utilized as a targeted ligand for selective delivery of therapeutic 
cargos in various diseases. Conventional therapies of cancer can eliminate cancer 
cells but also commonly cause toxic effects in normal cells/ tissue. Since TfR is 
often upregulated in cancer cells, Tf or TfR targeted moieties have been 
conjugated to chemotherapies, toxic proteins and large molecules including 
liposomes and nanoparticles. For example, Cisplatin, an anti-cancer drug 
interrupting DNA synthesis, is a common chemotherapy used in various cancers 
including breast cancer, brain tumors and lung cancer. To reduce the side effect 
and increase tumor selectivity, Cisplatin conjugated with Tf (MPTC-63) was 
developed and evaluated in pre-clinical research and clinical trials. MPTC-63 
demonstrated higher cytotoxicity in Hela cells compared to non-modified cisplatin. 
In a murine tumor model, suppressed growth of the tumor and reduced metastasis 
of the tumor in the lung were observed in the MPTC-63 treated group. Later, in a 
Phase I clinical trial, MPTC-63 treatment achieved positive response in 36% of 
patients with advanced breast cancer57. Polymers and liposomes are common non-
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viral carriers for therapeutic cargos such as chemotherapies, macromolecules (e.g. 
DNA, RNA and proteins). A Tf modified liposome encapsulating oxaliplatin (L-
OHP), MBP-426, was developed to increase the circulation time and tumor cell 
selectivity by targeting TfR eventually to achieve enhanced anti-tumor efficacy. 
Safety and pharmacokinetics of MBP-426 were evaluated in a Phase I clinical trial 
and a favorable safety profile was achieve 57b, 58. Currently, an ongoing Phase Ib/II 
trial is evaluating the therapeutic efficacy of MBP-426 combined with leucovorin 
and 5-fluorouracil in patients with advanced or metastatic solid tumors. SGT-53 is 
another TfR targeted liposome under clinical evaluation. SGT-53 is a liposome 
formulation decorated with antibody fragments that target TfR and carrying DNA 
encoding p53. A phase I clinical trial suggested that SGT-53 is well tolerated in 
patients bearing advanced solid tumors. SGT-53 demonstrated targeted delivery to 
tumor cells and achieved anti-tumor activity. There are 4 active clinical trials of 
SGT-53 ongoing to evaluate its efficacy in refractory or recurrent solid tumors57b. 
The blood–brain barrier (BBB) is a barrier that separates the circulation 
system from the brain and prevents most macromolecules from entering the brain. 
Certain receptors, such as TfR, are expressed on the endothelium of brain 
capillaries for the introduction of essential nutrients and proteins (e.g. Tf). 
Therefore, TfR has been exploited extensively in preclinical studies as a potential 
entry for therapeutic reagent, particularly for macromolecules, to the brain. For 
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proof of concept studies, a mouse monoclonal antibody against rat TfR, OX26, has 
been conjugated to various molecules including neuroprotective agents, 
neurotrophic factor and liposomes for brain delivery. For example, brain-derived 
neurotrophic factor (BDNF), a neuroprotective agent, was coupled to OX26 and 
evaluated in a rat stroke model. Animals administrated i.v. with OX26-BDNF 
demonstrated 243% improvement in their ability of motor function compared to 
unmodified BDNF. This result suggested more efficient brain delivery was 
achieved by OX26-BDNF. OX26 has also been utilized to decorate liposomes for 
gene delivery to the brain. Intravenous delivery of OX26-liposomes carrying DNA 
encoding β-galactosidase resulted in β-galactosidase expressed in the brain of rats 
59. 
Activated T cells (ATCs) overexpress TfR and play an important role in 
inflammatory diseases. Our group is the first to exploit the possibility to deliver 
nucleic acids in a targeted  manner to ATCs as potential treatment of inflammatory 
diseases, for instance, asthma. We demonstrated that Tf modified PEI can 
selectively deliver siRNA to human primary ATCs ex vivo 60 and ATCs in the lung 
of asthmatic mice in vivo 61.    
1.5 Conclusion & significance 
In the following chapters of this dissertation, I will discuss the most 
important findings in my development and optimization of TfR targeted polymers 
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for delivery of siRNA in various diseases. In Chapter 2, the progress and current 
status of application of siRNA therapies in asthma is summarized. In Chapter 3, 
the development and characterization of Tf conjugated PEI (Tf-PEI) as a potential 
therapy of asthma is described. Also, the selective delivery of siRNA to ATCs is 
confirmed ex vivo and in vivo. In this chapter, we proved the feasibility of 
efficiently delivering siRNA to ATCs via TfR targeted strategy which would 
benefit the development of a novel therapy for inflammatory diseases involving 
ATCs. This approach could also be utilized to transfect ATCs in fundamental 
studies since ATCs are difficult-to-transfect cells. Besides targeting ATCs in 
asthma, the TfR selectivity of Tf-PEI is evaluated in breast cancer cells in 
Chapter 4. Tf-PEI can achieve more efficient delivery of therapeutic siRNA 
against GASC1, to basal-like breast cancer cells, an aggressive phenotype of 
breast cancer, compared to unmodified PEI. In this chapter, we investigated a 
potential siRNA therapy of basal-like breast cancer via suppressing a novel 
epigenetic target, the histone demethylase GASC1. This potential treatment may 
demonstrate a better safety profile in vivo due to its TfR selectivity and may be 
combined with current anti-cancer therapy to achieve a better therapeutic outcome. 
In Chapter 5, two peptides against TfR, alternative TfR targeting moieties, are 
conjugated to PEI and both peptide-PEI conjugates are evaluated in lung cancer 
cell lines. One of the targeted conjugate, HAI-PEI, demonstrated higher 
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transfection efficiency in lung cancer cells overexpressing TfR compared to 
unmodified PEI. In this chapter, the feasibility of selectively delivering siRNA to 
lung cancer cells overexpressing TfR using peptide-PEI was confirmed. This 
peptide could be an alternative for holo-Tf to modify particles. Because of the high 
stability of peptides and their ability to non-competitively bind to TfR, peptide 
modified nanoparticles could be a better approach to achieve in vivo TfR targeted 
delivery.  
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CHAPTER 2 PULMONARY DELIVERY OF SIRNA VIA 
POLYMERIC VECTORS AS THERAPIES OF ASTHMA 
Please note that part of the content of this chapter is from a review article, 
“Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma”, 
was published in Archiv der Pharmazie (Y. Xie, O.M. Merkel, 2015). The authors 
of this article include Dr. Olivia Merkel and me. I am the first author of this 
review article, searched the literature, and wrote the review. 
2.1 Introduction 
Asthma is one of the major worldwide public health problems affecting 334 
million people 62 and accounting for 250,000 annual deaths 63. It is estimated that 
there would be additional 70 million asthmatic patients in 202562 and that the 
global market for asthma and chronic obstructive pulmonary disease (COPD) 
drugs would increase to $47.1 billion in 201764. Asthma can be effectively 
controlled in most of the patients by current therapies including inhaled β2-
adrenergic receptor agonists, inhaled corticosteroids and injected immunoglobulin 
E (IgE) antibody 65. Nevertheless, compliance of inhaled corticosteroids is poor 
due to the requirement of frequent inhalation and concerns of long-term side effect 
66. In contrast, common overuse of β2- adrenergic receptor agonists (CDC,2007) 
increases the risk of systemic side effects 67. Moreover, there are 5-10% asthmatic 
patients who lack adequate response to current therapies of asthma. The patients 
within that group who also have common asthmatic comorbid conditions, such as 
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rhinosinusitis and chronic infections, will experience worse symptoms of asthma 
and a higher risk of morbidity 68. Thus, it is necessary to develop safer and more 
efficient additional treatments for asthma. 
Asthma is a chronic inflammatory disorder and airway disease 
characterized by limitation of airflow, airway hyperresponsiveness (AHR), mucus 
hypersecretion and infiltration of inflammatory cells. In the pathogenesis of 
asthma, common environmental stimuli (e.g. dust, pollen) are recognized 
inappropriately by the immune system as antigen and consequently induce IgE-
dependent inflammatory response. The asthmatic symptoms are majorly driven by 
inflammatory cells, for example, mast cells, eosinophils, dendritic cells, 
lymphocytes, macrophage and their cytokines 69,70. Dendritic cells, the most 
efficiently antigen presenting cells (APCs), can present allergens to naïve T helper 
cells (Th0) and promote the differentiation of T helper 2 cells (Th2). Th2 cells can 
orchestrate the allergic response of asthma via secretion of Th2 interleukins (IL-4, 
IL-5 and IL-13) 69. For instance, IL- 4 can promote differentiation and 
proliferation of Th2 cells and together with IL-13 stimulates B cells to proliferate 
and produce IgE. IL-5 can recruit and activate eosinophils as well as maintain their 
proliferation and survival. IL-13 is associated not only with IgE synthesis but also 
with chemoattraction of eosinophils, AHR, airway remodeling and mucus cell 
hyperplasia 69,70-71,72. Other than Th2 cells, mast cells also contribute to asthmatic 
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inflammation by secreting histamine, tryptase and prostaglandin D2 (PGD2) which 
can induce potent bronchoconstriction, airway edema and lung fibroblast 
proliferation as the result of IgE-dependent stimulation by allergens 69. Another 
essential type of inflammatory cells are eosinophils which can produce lipid 
mediators and pro-inflammatory cytokines to directly damage epithelial cells, 
induce bronchoconstriction and amplify inflammatory responses 73.  
New drugs for asthma in pre-clinic research or clinic trails include new 
bronchodilators and corticosteroids as well as inhibitors of novel therapeutic 
targets, for example, kinase inhibitor and cytokine/chemokine blockage.  siRNA 
induced gene silence is thought to be an efficient approach to block the functions 
of molecular targets. siRNA mediated therapies are post-transcriptional, transient 
and based on sequence-specific gene silencing, hence they are believed to offer a 
more potent and specific treatment with less side effects for different diseases 74. 
Pulmonary delivery of siRNA as a non-invasive and local administration can 
reduce systemic side effects and prolong the lung retention period for the 
treatment of lung diseases like asthma. Furthermore, rapid therapeutic effects and 
lower dose requirement can be achieved due to the physiological properties of the 
lung such as the large alveolar surface, absence of serum proteins and the presence 
of a thin epithelium 75. Despite of the advantages of pulmonary delivery of siRNA, 
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the biggest obstacle of clinical application of siRNA in asthma is the lack of 
biocompatible vectors to efficiently deliver siRNA into target cells.    
In this chapter, we will discuss the molecular targets for siRNA mediated 
therapies and the formulation of siRNA applied in experimental asthma and will 
summarize available siRNA delivery systems that are targeted to immune cells. 
2.2 Therapeutic Molecular Targets of siRNA in Asthma 
As described in the introduction, asthma is a very complex inflammatory 
disease implicating numerous cells and cellular factors. The common therapeutic 
molecular targets for RNAi therapy include cytokines/chemokines, transcription 
factor, tyrosine kinase/ tyrosine kinase receptor, costimulatory molecules. 
Additionally, new biological targets have been discovered, such as the transient 
receptor potential cation channel (TRPV1) 76, nerve growth factor 74b, soluble 
membrane N-ethylmaleimide-sensitive factor attachment protein receptor protein 
(syntaxin4)77.  
2.2.1 Cytokines and chemokines 
It is known that cytokines/chemokines, particularly Th2 cytokines, play 
prominent roles in airway inflammatory response and remodeling, thus, blockage 
of cytokines/chemokines and their corresponding receptors by using siRNA has 
been reported. Examples are the downregulation of suppressor of cytokine 
signaling 3 (SOCS3) 78, IL-479 and IL-5. Given that presence of eosinophils is 
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implicated in airway hyperresponsiveness and remodeling and IL-5 is the most 
important cytokine involved in eosinophils growth, activation as well as 
recruitment, siRNA against IL-5 was applied to reduce inflammatory response in 
ovalbumin (OVA)-induced murine asthma model.  Huang et al. showed that 
intratracheal (i.t.) administration of lentivirus containing a siRNA against IL-5 
expressing cassette (SEC4) to asthmatic mice for three consecutive days reduced 
the expression of IL-5 in the lung by 50% quantified by real time PCR (RT-PCR). 
Reduced eosinophilia was observed in SEC4 treated animals confirmed by less 
eosinophils in the bronchoalveolar lavage fluid (BALF) cells and H&E staining 
slides as well as less eosinophils chemoattractive cytokine (eotaxin) in the BALF. 
Consequently, The AHR was significantly relieved according to non-invasive 
whole body plethysmography (PenH) and invasive techniques 80. 
2.2.2 Transcription factors 
Blockage of a single mediator or receptor cannot achieve great therapeutic 
effects due to the complexity of asthma. Therefore, the upstream molecules of the 
inflammatory process have become more attractive therapeutic targets. 
Transcription factors that control the production of cytokines/chemokines and are 
involved in the growth and differentiation of major inflammatory cells were 
reported as targets for siRNA mediated treatment, such as GATA-3, transducer 
and activator of transcription 6 (STAT6), and receptor interacting protein 2 
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(Rip2)81. GATA-3, a transcription factor highly expressed in Th2 cells, can 
determine the differentiation of Th2 cells and promote the production of Th2 
interleukins 82. Antisense therapeutic intervention of GATA-3 in experimental 
asthma has been achieved not only with siRNA. Finotto et al. reported that 200 µg 
intranasally (i.n.) administrated GATA-3 anti-sense oligonucleotides for four 
continuous days to mice with OVA-induced inflammation can achieve local anti-
inflammatory effects which were comparable to the positive control group treated 
with the first-line drug dexamethasone 83. This report of therapeutic effect of 
blockage of GATA-3 in asthma is in line with the observation by Lee et al. who i.n. 
delivered GATA-3 small hairpin RNA with a lentiviral vector (2.2×106 IFU) to 
OVA-induced asthmatic mice 84. The only asthma therapy study involving GATA-
3 siRNA was published by Sel et al. To assess the efficacy of GATA-3 specific 
DNAzyme (Gd21) to prevent and treat experimental allergic asthma, they i.n. 
applied 200 µg Gd21 to mice with acute experimental asthma and compared to 
animals that were i.n. treated with 200 µg siRNA against GATA-3 or GATA-3 
anti-sense oligonucleotides. These treatments were alternative antisense strategies 
in contrast to the DNAzyme. They concluded that Gd21 can more effectively 
reduce the inflammation than GATA-3 specific oligonucleotide and siRNA 
because these alternative antisense therapies showed a less efficient reduction of 
the number of eosinophils in the BAL cells and decreased the IL-5/IFN-γ ratio less 
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successfully 85. However, their results also showed that GATA-3 specific siRNA 
treatment can reduce the number of mucus-producing goblet cells and AHR 
comparably to the Gd21 treatment. In addition, the authors did not use any 
delivery system for siRNA, anti-sense nucleotides or DNAzyme administration, 
and “naked” nucleic acids were applied directly. The approach of delivering free 
nucleic acids has been reported to lead to less efficiency in silencing genes in vivo 
and in vitro compared with the delivery via any kind of vector. Therefore, the 
therapeutic effect of GATA-3 siRNA or even anti-sense oligonucleotides is worth 
to be further evaluated in vivo. STAT-6, another promising target, is the 
transcription factor that controls the onset and maintenance of GATA-3 expression 
and is involved in T cells differentiation and IgE production 86. The anti-
inflammatory effect of i.n. administration of 100 µg siRNA against STAT-6 to 
asthmatic mice was described by Darcan-Nicolasien et al. They showed a 
decreased amount of infiltrated leukocyte in the BALF and reduced AHR in the 
STAT-6 siRNA treatment group compared with animals treated with siRNA 
against green fluorescent protein (GFP) which served as a negative control. 
Additionally, decreased levels of IL-4, IL-5, IL-13 and less histological alterations 
as well as less T cells infiltration were observed in lung tissue from the STAT-6 
siRNA treatment group. However, the biodistribution of nanoparticles in the 
central and peripheral area of the lung was majorly in airway epithelial cells 
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instead of lymphocytes, where the expression of STAT-6 is most important in 
asthma. This observation may lead to higher required doses to obtain efficient 
therapeutic effects 87. 
2.2.3 Tyrosine kinase / tyrosine kinase receptor 
Other upstream targets are kinases involved in the inflammatory process 
such as spleen tyrosine kinase (Syk) and the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB)88. Spleen tyrosine kinase (Syk) is widely 
expresses in immune cells and can initiate or mediate various cellular signaling 
pathways, including the development and maturation of B cells, proliferation of T 
cells, and production of inflammatory mediators from macrophages and mast cells 
89. It was described by Stenton et al. that three i.n. aerosolized doses of Syk 
antisense oligodexoynucleotides (ASO)/ liposome to OVA-induced asthmatic rats 
can reduce the infiltration of leukocytes found in the BALF and inhibit the antigen 
induced up-regulation of adhesion molecules in eosinophils, neutrophils and 
macrophages. However, there was no statistical difference of pulmonary 
inflammation between the Syk-ASO treatment and the saline treatment group 
according to the histological analysis of lung sections, and two doses of Syk-ASO 
treatments were not sufficient to inhibit the airway inflammation like three 
treatments did. Therefore, Syk-ASO is not a very efficient anti-inflammatory 
therapy but Syk was provento be a valuable target 90. Inspired by this study, Huang 
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et al. i.n. instilled 10 µg siRNA against Syk on three consecutive days before the 
induction of acute lung inflammation and correlated less infiltration of 
inflammatory cells with the treatemnt91. Moreover, ExcellairTM (ZaBeCor, Bala 
Cynwyd, PA, USA), a therapeutic siRNA against Syk, moved to Phase II clinical 
trials as a new drug for asthma in 2009 and confirmed the potential of Syk as a 
therapeutic target in asthma. A different potential target is the tyrosine kinase 
receptor C-kit of which the ligand is stem cell factor (SCF). Wu et al. reported that 
i.n. administration of methylation modified siRNA against C-kit (35 µg/day) for 
three days to mice with experimental allergic asthma can significantly reduce the 
levels of IL-4, IL-5 and SCF in the BALF and inhibit the infiltration of eosinophils 
as well as histology alteration due to pulmonary inflammatory 92. 
2.2.4 Costimulatory molecules 
APCs can initiate and maintain the airway inflammatory response, 
particularly a Th2-mediated response. The interaction between APCs and T cells 
requires the facilitation of costimulatory molecules such as CD86 and CD4093. 
Asai-Tajiri et al. reported that bone marrow derived dendritic cells (DCs) in vitro 
transfected with siRNA against CD86 can lose their ability to activate Th2 cells. In 
an OVA-induced murine asthma model, after i.n. administration of Texas Red 
labeled CD86 siRNA (12.5 µg), it was observed that Texas Red-siRNA was able 
to pass through the epithelial barrier and co-localized with DCs. With this 
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biodistribution result in mind, they i.n. applied siRNA against CD86 (12.5 µg/ day) 
for three days and achieved reduction of Th2 interleukins levels, less eosinophils 
infiltration and reduced AHR. However, treatment of CD86 specific siRNA did 
not reduce the goblet cell-mediated hyperplasia, indicating that higher dose of 
CD86 specific siRNA may be required to alleviate sufficiently the symptoms of 
asthma 94.   
2.3 Targeted Polymeric Delivery of siRNA for asthma therapy 
As summarized in Table 1, pulmonary delivery of siRNA is the most 
common administration approach for the treatment of experimental asthma and the 
majority of the formulations is either naked/modified siRNA or use lentiviral 
vectors.  
Table 1 Summary of biological molecular targets for siRNA therapies of asthma 
Administration Formulation/vector Target Molecule Ref 
Intratracheal 
Naked/Modified siRNA 
 
CD86 94 
Rip2 81 
Lentivirus 
IL-5 80 
Nerve growth 
factor 
74b 
Atelocollagen Syntaxin4 77 
Intranasal 
 
Lentivirus GATA-3 84 
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Naked/Modified siRNA 
 
GATA-3 85 
STAT-6 87 
Syk 91 
c-kit 92 
SOCS-3 78 
IL-4 79 
Intravenously Plasmid CD40 93 
Considering the large size, instability and negative surface charge, siRNA 
is easily enzymatically degraded, phagocytically cleared, aggregates with serum 
proteins, and does not readily cross physiological membranes22,95. Hence, viral or 
non-viral carriers are needed, even though there are many reports in the literature 
of pulmonary delivery of naked/modified siRNA96. Due to the safety issues of 
viral vectors such as immunogenesis and insertional mutagenesis, non-viral 
delivery vectors, particularly polymeric carriers, are more attractive and favorable 
approaches to deliver siRNA. With the flexible and modifiable chemical structure, 
polymeric carriers have the potential to overcome extracellular barriers including 
instability in the blood stream, cell/tissue targeted delivery and biological 
membranes as well as intracellular barriers like endosomal escape and cytoplasmic 
siRNA release. Additionally, polymeric vectors can maintain a high capacity of 
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siRNA loading, biocompatibility and the ability to co-deliver small molecular 
drugs 97. 
There are many polymeric delivery carriers that have been prepared and 
optimized for pulmonary delivery of siRNA, such as polyethylenimine (PEI) and 
chitosan 96. However, administration of polymeric nanoparticles encapsulating 
siRNA is limited in asthma therapy, due to the potential side effects induced by 
non-specific cellular uptake and the difficulty to transfect differentiated immune 
cells like lymphocytes in vivo. Receptor-ligand mediated targeted delivery of 
siRNA could be a solution. 
2.3.1 T cell targeted delivery systems 
It is believed that Th2 cells can initiate and aggravate symptoms of asthma 
via the production of Th2 interleukins. For this reason, there are many studies that 
aim to block the effects of Th2 responses via RNAi. Currently, the most popular 
lymphocytes transfection method is electroporation/nucleofection which, however, 
is not suitable for in vivo application98. Moreover, T cells generally resist the 
transfection of conventional polymeric or lipid-based (e.g.lipofectamine) vectors. 
Therefore, the difficulty to efficiently transfect T lymphocytes hinders the clinical 
application of RNAi in asthma.  Recently, a few polymeric siRNA delivery 
systems specific for T lymphocytes have been discovered. CD7 is a surface 
antigen of human T cells which rapidly internalizes upon binding of an antibody. 
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To target and deliver nanoparticles encapsulating siRNA to T cells for the therapy 
of HIV infection, Kumar et al. conjugated a CD7 specific single-chain variable 
fragment with oligo-9-arginine peptide (scFvCD7-9R). Oligo-arginine is a 
positively charged cell-penetrating short peptide which has been reported to 
efficiently encapsulate siRNA and enhance the membrane permeability of 
nanoparticles 99. scFvCD7-9R was accordingly able to transduce FITC-labeled 
siRNA selectively to primary human CD3+ T cells but not macrophages or B cells 
in vitro. The in vivo specificity of nanoparticles was tested in two kinds of 
humanized mice models implanted with human peripheral mononuclear cells (Hu-
PBL and Hu-HSC). The i.v. injection of 50 µg siRNA against CD4 with 
scFvCD7-9R on two consecutive days significantly reduced the expression of CD4 
on activated CD3+ T cells in Hu-PBL mice as well as on the rest/naïve CD3+ T 
cells in Hu-HSC mice. Additionally, to test the therapeutic effect, the authors 
systemically administrated scFvCD7-9R encapsulating a mixture of anti-viral 
siRNA including CCR5, Vif and Tat to Hu-PBL mice. Nanoparticles were shown 
to protect Hu-PBL mice implanted mit HIV-seronegative donor’s PBMCs from 
HIV-1 challenge and significantly inhibited the viral replication. Furthermore, 
treatment of antiviral-nanoparticles of the Hu-PBL mice implanted with HIV-
seropositive donor’s PBMCs can protect the CD4+ cell loss compared with the 
animals treated with nanoparticles encapsulating siRNA against luciferase, which 
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served as a negative control. When PBMCs were exposed to nanoparticles in vitro, 
negligible toxicity was confirmed by percentage of Annexin V positive cells and 
production of IFN-γ. However, this scFvCD7-9R conjugate was optimized for i.v. 
administration for the therapy and prevention of HIV infection so it remains to be 
answered whether this conjugate can also efficiently and selectively deliver siRNA 
to T lymphocytes through pulmonary administration. This study should be 
highlighted because it demonstrates the feasibility to selectively deliver siRNA to 
T lymphocytes in vitro and in vivo which could be potentially applied in different 
inflammatory diseases like asthma and arthritis100. Another scFvCD7 conjugate 
was described by Lee et al. who conjugated scFvCD7 with chitosan and measured 
the in vitro transfection efficiency in T cell lines (Jurkat and A3.01 cells). 
Chitosan is a biocompatible and biodegradable polymeric vector, and 
chitosan/modified chitosan have been widely studied for pulmonary delivery of 
siRNA. It is thus a promising candidate to deliver siRNA in asthma therapy. The 
scFvCD7-chitosan/siRNA nanoparticles were around 300 nm in size and had a 
slightly positive zeta-potential of +17 mV. There was significantly higher uptake 
of scFvCD7-chitosan encapsulating FITC-siRNA compared with that of chitosan 
in T cell lines and increased uptake was observed as the molar ratio of scFvCD7 
per total chitosan increased. scFvCD7-chitosan nanoparticles prepared with 
siRNA against CD4 were tested for in vitro gene silencing, and the CD4 gene 
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knockdown efficiency was similar to that of Lipofectamine 2000 but significantly 
higher than that of chitosan measured by flow cytometry and RT-PCR. However, 
scFvCD7-chitosan condensed CD4 siRNA at a weight ratio of chitosan to CD4 at 
40:1 indicating that the siRNA encapsulation efficiency of the conjugate was fairly 
low. Additionally, scFvCD7-chitosan did not show better transfection efficiency in 
T cells lines than Lipofectamine 2000, thus high doses of nanoparticles may be 
required to achieve efficient gen silencing. Furthermore, the authors have not 
performed any in vivo study, and the pulmonary delivery efficiency of siRNA via 
scFvCD7-chitosan remains to be tested101.  
In asthma pathogenesis, activated T cells, particularly Th2 cells, play an 
essential role but not naïve T cells. However, CD7 is expressed on the majority of 
mature T cells resulting in the fact that a CD7 targeted siRNA delivery system will 
non-selectively deliver siRNA to both naïve and activated T cells. Therefore, a 
pulmonary siRNA delivery system that can selectively transport siRNA to 
activated T cells but not naïve T cells could achieve more efficient anti-
inflammatory effect and reduce potential side effects. In 2013, our group described 
a selectively pulmonary delivery system of siRNA for activated T cells in which 
the transferrin receptor (TfR) was targeted instead of CD7. TfR is an iron uptake 
membrane receptor universally express at low level on most cells/tissues, in 
contrast, it is overexpressed on highly proliferating and differentiating cells. It was 
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reported that activated T lymphocytes highly express TfR to meet the iron 
requirement for further differentiation and growth while naïve T lymphocytes do 
not. For this reason, we linked transferrin (Tf), the native ligand which can trigger 
TfR internalization, with low molecular weight PEI (LMW-PEI). PEI is the most 
popular polycation for pulmonary delivery of siRNA, and applying low molecular 
weight PEI can dramatically reduce the toxicity induced by the high density of 
cations, which is the biggest obstacle limiting the clinical application of PEI.  To 
determine the selective delivery efficiency of Tf-LMW-PEI in vitro, primary 
human activated T cells (ATC) or naïve T cells were transfected by Tf-LMW-PEI 
encapsulating Alexa Fluor488-labeled siRNA. Flow cytometry quantified cellular 
uptake of Tf-LMW-PEI/siRNA in ATCs was significantly higher than that of non-
modified LMW-PEI as well as Lipofectamine 2000. Additionally, the uptake of 
Tf-LMW-PEI and LMW-PEI was minimal on naïve T cells compared with that on 
ATCs indicating that the conjugate can distinguish ATCs from naïve T cells60. Our 
group also determined the biodistribution of Tf-LMW-PEI formulated with Alexa 
Fluor 647 labeled siRNA in OVA-induced asthmatic mice. Significantly higher 
cellular uptake of Tf-LMW-PEI nanoparticles in CD4+ T cells in asthmatic mice 
compared with that of LMW-PEI was observed. In addition, there was no 
difference in terms of cellular uptake of Tf-LMW-PEI/siRNA, LMW-PEI/siRNA 
and free siRNA-AF647 on CD4+ T cells in healthy control animals. In vitro and in 
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vivo studies proved that Tf-LMW-PEI is another promising candidate for 
pulmonary delivery of siRNA for asthma treatment.  
2.3.2 Macrophage targeted delivery systems 
Macrophages are the most abundant inflammatory cells in the lung and are 
potentially involved in airway remodeling and eosinophilic inflammation in 
asthma. However, macrophages can perform anti-inflammatory as well as pro-
inflammatory effects, so the role of macrophage in asthma is not yet clear 102. A 
delivery system of siRNA that targets macrophages can be not only a therapeutic 
delivery vector but also a tool to facilitate the understanding of the role of 
macrophage in asthma. Kim et al. described a siRNA delivery system targeting 
macrophages through a macrophage expressing nicotinic acetycholine receptor 
(AchR) that binds the peptide rabies virus glycoprotein (RVG). To target and 
deliver siRNA to the macrophages in the nerve system for the treatment of 
neuroinflammatory diseases, RVG was linked with nona-D-arginine residues 
(RVG-9R). The authors first confirmed that RVG-9R can selectively deliver 
FITC-labeled siRNA to primary splenic murine macrophage (CD11b+) in vitro. 
Then the in vivo targeted delivery to peripheral and nerve system macrophages 
mediated by AchR were shown by comparing the median fluorescent intensity of 
CD11b+ macrophages from wild type or AchR knock out mice that had been i.v. 
administrated with RVG-9R/FITC-siRNA. The therapeutic effect of RVG-9R 
53 
 
 
 
 
prepared with siRNA against TNF-α was test in a lipopolysaccharide (LPS)-
induced murine inflammatory model.  I.v. administration of RVG-9R/ siTNF-α 
was reported to significantly inhibit the increased secretion of TNF-α in blood and 
brain compared with RVG-9R/luciferase siRNA and was shown to protect the 
neurons from LPS-induced apoptosis 103. Another macrophage targeting system is 
mediated by folic acid as it has been discovered recently that folate receptors are 
upregulated on activated macrophage during the inflammatory process 104. 
Inspired by this property, Yang et al. linked folic acid with chitosan (FA-chitosan) 
to target macrophages for anti-inflammatory effects. Up to 62% in vitro gene 
silencing was achieved with FA-chitosan nanoparticles prepared with siRNA 
against GAPDH on LPS activated RAW 264.7 cells. The biodistribution of i.v. 
injection of FA-chitosan encapsulating Cy5 labeled siRNA was monitored in a 
murine subcutaneous inflammation model using an IVIS® 200 imagine system. 
Accumulation of Cy5-siRNA/FA-chitosan nanoparticles was observed in the LPS 
induced lesion site while no clear fluorescent signal was detected in the Cy-
5siRNA/chitosan group 105.  
2.3.3 Targeted delivery systems for other cell types 
Dendritic cells (DCs), the most efficient antigen presenting cells (APCs), 
can initiate and maintain the inflammatory response; hence they are another 
popular target cell type in asthma. A strategy to target DCs was described by 
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Zheng et al who encapsulated siRNA in liposomes decorated with DC-specific 
antibody DEC-205 which are so-called immunoliposomes (siILs). The siILs 
prepared with siRNA against CD40 were shown to more efficiently silence the 
expression of CD40 in DCs derived from bone marrow (BMDCs) compared with 
GenePORTER® in vitro. The biodistribution of siILs encapsulating Cy3-labeled 
siRNA after i.v. injection was observed on the tissue sections of liver, spleen and 
kidney. was Accumulation of siILs/Cy3-siRNA in the spleen at 4 hours and even 
stronger accumulation at 8 hours after injection was observed, but no detectable 
siILs were found in the kidney at any time point. In contrast, naked Cy3-siRNA 
was cleared through kidney soon after injection, suggesting siILs nanoparticles 
may selectively accumulate in the DCs-rich tissues like the spleen and have a long 
circulation time with slower clearance via kidney. The in vivo gene silencing of 
siILs prepared with CD40 siRNA was determined in  mice with inflammation 
induced by keyhole limpet hemocyanin/complete Freund adjuvant. Significant 
CD40 knockdown in DCs was achieved in animals treated with siILs/CD40 
siRNA or naked CD40 siRNA compared to mice administered with siILs/ negative 
control siRNA, IgG coupled non-targeted liposome and PBS. However, silencing 
of CD40 expression induced by siILs/CD40 siRNA can last at least 12 days while 
that induced by naked CD40 siRNA did not last this long. Meanwhile, the authors 
also measured the expression of CD40 in B cells and concluded that the CD40 
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silencing of siILs nanoparticles selectively happened in DCs106. In contrast, 
another APC-targeted delivery system can transport siRNA to more than just DCs. 
TLR9 is an endosomal location toll like receptor (TLRs) which can bind with CpG 
oligonucleotides and facilitate the uptake of siRNA to the cytosol. This receptor is 
as well expressed on various APCs including DCs, B cells and macrophages. 
Uncontrollable growth of immune cells can result in blood cancer, for example, B 
cells lymphoma. Immunosuppression is a common obstacle in cancer therapy, and 
therefore, immune cells are important therapeutic targets in anti-cancer treatment. 
To target and deliver siRNA to human hematopoietic cells for anti-tumor therapy, 
siRNA against STAT3 was covalently linked to CpG oligonucleotides by Zhang et 
al.  The selective cellular uptake of CpG-Cy3-siRNA in primary human DCs, 
monocytes and B cells was observed via flow cytometry but not in T cells and 
natural killer cells. After intratumoral injection of the CpG-siSTAT3 in murine 
subcutaneous tumor models (established by KMS-11, MonoMac6, MV4-11 or 
A20 tumor cells), the in vivo gene silencing in tumor cells and the inhibition of 
tumor growth were significantly higher than with the control CpG- luciferase 
specific siRNA 107.  
Except inflammatory cells, lung structure cells are thought to be therapeutic 
targets for asthma. Beta2-adrenergic receptor (β2-AR) is abundant on bronchial 
smooth muscle cells and is the target for β2-AR agonist bronchodilators. Therefore, 
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Luo et al. conjugated β2-AR agonist salbutamol to guanidinylated chitosan (SGCS) 
as a pulmonary delivery carrier of siRNA to improve the efficacy of gene silence. 
SGCS formulated with siRNA against EGFP yielded nanoparticles with sizes of 
around 100 nm and zeta-potentials of 2-4 mV. Nanoparticles were nebulized and 
the aerosol was collected and was i.t. sprayed into the lung of EGFP transgenic 
mice on three consecutive days. The in vivo GFP gene silencing of SGCS was 
significantly better than that of non-targeted GCS determined by confocal 
microscope and western blot 108. 
2.4 Conclusion 
In the last decades, many groups have tried to translate siRNA mediated 
RNAi into a biocompatible, efficient and long term therapy to treat the airway 
inflammation in asthma. Lots of novel therapeutic targets have been discovered 
and numerous studies have been performed with the results of significant anti-
inflammatory effects. However, asthma is such a complex inflammatory disorder 
which involves various factors, thus blockage of a single mediator or receptor 
cannot efficiently relieve the symptoms. Accordingly, the delivery of siRNA 
mixtures against multiple genes or against the upstream factors in the 
inflammatory process such as transcription factors, kinases or costimulatory 
molecules may be more effective. Furthermore, the lack of efficient and specific 
siRNA delivery systems results in low therapeutic efficiency and high potential of 
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side effects. Although, there are several ligand-receptor mediated targeted delivery 
systems of siRNA that could potentially be applied in asthma, none of the current 
immune cell targeted delivery systems has been optimized for asthma disease 
except the Tf-LMW-PEI conjugate reported by our group. Therefore, further 
studies and tests are required to develop an efficient siRNA delivery system for 
asthma therapy. 
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CHAPTER 3 TARGETED DELIVERY OF SIRNA TO 
ACTIVATED T CELLS VIA TRANSFERRIN-
POLYETHYLENIMINE (TF-PEI) AS A POTENTIAL 
THERAPY OF ASTHMA 
Please note that part of the content of this chapter is from a research article, 
“Targeted Delivery of siRNA to Activated T Cells via Transferrin-
Polyethylenimine (Tf-PEI) as a Potential Therapy of Asthma”, was published in 
Journal of Controlled Release (Y. Xie, et al., 2016). The authors of this article 
include Na Hyung Kim, Venkatareddy Nadithe, Dana Schalk, Archana Thakur, 
Ayşe Kılıç, Lawrence G. Lum, David JP Bassett, Olivia M Merkel and me. I am 
the first author of this research paper. I performed the experiments and wrote the 
paper. 
3.1 Introduction 
siRNA mediated gene therapy could potentially be an alternative and safer 
therapy for asthma. However, as discussed in Chapter 2, lack of an efficient in 
vivo delivery system of siRNA and an effective molecular biological target limits 
the clinic application of siRNA in asthma. Inflammation in asthma is driven by an 
infiltration of inflammatory cells such as activated T cells (ATCs), eosinophils and 
mast cells. Among infiltrated inflammatory cells, ATCs, specifically, T helper 2 
cells (Th2) play a critical role in orchestrating pathological processes of asthma via 
the production of Th2 cytokines 69-70, 109. Therefore, blockage of the functions of 
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Th2 interleukins (e.g. IL-5 110) or silencing of upstream transcription factors which 
promote the production of Th2 interleukins (e.g. GATA-3 11) have been 
investigated as potential therapies of difficult-to-treat asthma. 
Substantial investigations have been undertaken for applying siRNA to 
silence asthma related genes in Th2 cells (e.g. IL-5 80 and GATA-3 111). 
Nevertheless, safe and effective delivery of siRNA is facing several challenges. 
The hurdles are to overcome various physiological barriers including enzymatic 
degradation, non-specific binding to non-target tissues or cells, negatively charged 
cellular membranes, endosomal escape after endocytosis, and many more 112. 
Moreover, delivery of siRNA to Th2 cells is particularly difficult because T cells 
are in general resistant to non-viral vector-based transfection methods 98a. T cells 
do not actively endocytose nanoparticles because they do not express caveolin and 
are devoid of caveolae 113. Conventional transfection approaches of T cells are 
viral delivery systems 114 or electroporation 98b. However, the fabrication of viral 
vectors is time and cost consuming, and their potential safety issues limit their 
clinical application 97a. On the other hand, electroporation is not a suitable method 
for in vivo administration of siRNA 115. Various delivery systems have been 
discovered to target T cells, including CD3 targeted polyethylenimine (PEI) 116, 
CD40L targeted liposomes 117, CD7 targeted chitosan 101 or oligo-arginine 100. 
However, their efficiency and potential systemic side effects for asthma therapy 
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remain to be tested. Since CD7 and CD3 are pan T cell surface antigens and since 
nanomedicines targeting these receptors were all applied through systemic 
administration in their respective in vivo studies, it would be expected to observe 
side effects with these strategies.    
In order to avoid potential systemic side effects and to increase the 
selectivity for activated T cells, the key mediators in asthma pathogenesis and 
development, our group has developed a pulmonary siRNA delivery system based 
on transferrin-polyethylenimine (Tf-PEI). This ligand-polymer conjugate takes 
advantage of the increased expression of transferrin receptors (TfR) on T cells 
after activation 118. TfR is a membrane protein expressed at low level on most cells 
and can bind to the iron transport glycoprotein Tf, which consequently triggers 
fast internalization 57b 
. Previously, we showed that only activated primary T cells take up siRNA 
delivered by Tf-PEI, while naïve T cells with a basal level of TfR expression 
cannot be reached efficiently with the Tf-PEI conjugate for siRNA delivery 91. 
Low molecular weight PEI (5k Da) is used as a carrier of siRNA to facilitate 
cellular internalization and endosomal escape 119 with minimal toxicity 51, 120. N-
succinimidyl 3-(2-pyridyldithio) propionate (SPDP) as a crosslinker can introduce 
a disulfide bond between Tf and PEI. Disulfide bonds are stable extracellularly but 
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can be reduced in the endosome compartment 101 and allow PEI/siRNA polyplexes 
to be released from the Tf/TfR complex prior to rapid recycling of TfR.  
In this chapter, a pulmonary delivery system that can selectively and 
efficiently deliver siRNA to activated T cells in the lung was developed and could 
be potentially applied for asthma therapy. In the following present work, Tf-PEI 
exhibited optimal physicochemical properties in terms of siRNA condensation 
efficiency, size, zeta-potential and stability in the presence of lung surfactant and 
mucin. In vitro studies revealed that Tf-PEI can efficiently deliver siRNA to 
primary human ATCs or Jurkat cells and mediated significant gene knock down. 
Biodistribution of Tf-PEI polyplexes formulated with fluorescently labeled siRNA 
in a murine asthmatic model after intratracheal administration confirmed that Tf-
PEI can selectively deliver siRNA to ATCs in vivo.   
3.2 Material and Method  
3.2.1 Materials 
N- succinimidyl 3-(2-pyridyldithio) propionate (SPDP) was purchased from 
Pierce (Rockford, IL), SYBR Gold dye and Lipofectamine 2000 were obtained 
from Life Technologies (Grand island, NY), branched low molecular weight 
(LMW) 5k Da PEI (Lupasol® G100) was from BASF (Ludwigshafen, Germany), 
murine transferrin, picrylsulfonic acid solution (TNBS, 5% w/v), Dulbecco’s 
phosphate buffered saline (PBS), dimethyl sulfoxide (DMSO), 
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ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA), type II mucin 
from porcine stomach, and albumin from chicken egg white (OVA) were bought 
from Sigma-Aldrich (St. Louis, MO). Chloroquine diphosphate was from MP 
biomedicals (Santa Ana, California), human holo-transferrin was purchased from 
EMD Millipore (Billerica, MA), 1,4-Dithio-DL-threitol (DTT, 99%) was obtained 
from Alfa Aesar (Ward Hill, MA). Amine modified siRNA (5´- 
pACCCUGAAGUUCAUCUGCACCACcg, 3´-
ACUGGGACUUCAAGUAGACGUGGUGGC), human glyceraldehyde- 3- 
phosphate- dehydrogenase (GAPDH) siRNA (5´-
pGGUCGGAGUCAACGGAUUUGGUCgt, 3´-
UUCCAGCCUCAGUUGCCUAAA- CCAGCA), and scrambled siRNA (5´-
pCGUUAAUCGCGUAUAAUACGCGUat, 3´- 
CAGCAAUUAGCGCAUAUUAUGCGCAUAp) were purchased from Integrated 
DNA Technologies (Coralville, IA) (indication of modified nucleotides: “p” 
denotes a phosphate residue, lower case bold letters are 2´-deoxyribonucleotides, 
capital letters are ribonucleotides, and underlined capital letters are 2´-O-
methylribonucleotides). A 0.4% trypan blue solution in phosphate buffered saline 
was purchased from HyClone GE healthcare (Buckinghamshire, UK).  
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3.2.2 Synthesis of transferrin-polyethylenimine (Tf-PEI) conjugate  
For the first reaction, 5k PEI (1 mg/ml) dissolved in HEPES buffered saline 
(HBS) (20 mM HEPES, 150 mM NaCl, pH=7.5) was mixed with a 10-fold molar 
excess SPDP (20 mM) in dry DMSO and stirred for overnight. A Tf solution (10 
mg/ml, human or murine) was dissolved in HBS and stirred with a 5-fold molar 
excess SPDP for 2 h. Purification of PEI-SPDP and Tf-SPDP were performed via 
3,000 or 10,000 MWCO centrifugal filters (Millipore, Billerica, MA) with HBS/1 
mM EDTA (pH=7.1), respectively. To estimate the concentration of SPDP in the 
PEI-SPDP solution, 100 µl of 50-fold diluted PEI-SPDP solution was reacted with 
1 µl of a 150 mM DTT solution for 30 min, and the pyridon-2-thion release was 
measured spectrophotometrically at 343 nm in a 96-well UV plate (Corning). 
Subsequently, a 10-fold molar excess DTT was mixed and reacted with the 
remaining PEI-SPDP under nitrogen protection for 2 h. Reduced PEI-SPDP was 
purified by 3,000 MWCO centrifugal filters with HBS/20 mM EDTA (pH=7.1). 
For the coupling reaction, Tf-SPDP was added stepwise to PEI-SPDP and stirred 
overnight at 4 C°. Purification of Tf-PEI was achieved on an ÄKTA FPLC system 
(GE healthcare) equipped with 2 connected 1 ml HiTrap SP HP cation exchange 
column (GE healthcare) as described before 121. Free Tf was washed out with 0.5 
M NaCl/20mM HEPES and Tf-PEI was eluted after initial binding to the column 
after switching to 3 M NaCl/20 mM HEPES. Further purification and desalination 
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was performed by 30,000 MWCO centrifugal filters (Millipore) with HBS. The 
concentration of Tf in the Tf-PEI conjugate was determined 
spectrophotometrically at 280 nm. To determine the concentration of PEI in Tf-
PEI, a standard curve was generated by diluting PEI in a solution containing a 
constant concentration of Tf. According to the standard curve, the concentration of 
PEI in Tf-PEI conjugate was assessed at wavelength 405 nm using a TNBS 
assay122. 
3.2.3 Preparation of polyplexes  
Polyplexes were prepared in either HBS or 5% glucose. An equal volume 
of Tf-PEI or PEI was added to a defined amount of siRNA solution to yield 
different amine to phosphate ratios (N/P ratios) and incubated for 20 min before 
further measurement or transfection. Lipofecatmine 2000 (LF) lipoplexes 
preparation was performed according to the manufacturer’s protocol. Briefly, 
every 10 pmol siRNA were formulated with 0.5 µl LF. The amount of PEI or Tf-
PEI needed at different N/P ratio for 50 pmol siRNA were calculated according to 
the following equation: m (PEI in pg) = 50 pmol × 43.1 g/mol × N/P × 52 
(protonable unit of PEI = 43.1 g/mol, number of nucleotides of 25/27mer siRNA = 
52). 
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3.2.4 Hydrodynamic size and zeta-potential measurement 
For the measurement of size, PEI or Tf-PEI polyplexes were prepared with 
50 pmol siRNA in HBS at different N/P ratios. The total volume of 100 µl 
polyplexes was added into a disposal micro cuvette (Brand GMBH, Wertheim, 
Germany) and the size was measured using a Zetasizer Nano ZS (Malvern 
Instruments Inc., Westborough, MA). The measurement was set up at 173° 
backscatter angle and 15 runs were performed three times for each sample. For 
data analysis, 0.88 mPa*s for viscosity and 1.33 for refractive index were used 
with the Zetasizer Software (Malvern). Subsequently, polyplexes were diluted 
with Nanopure water (Thermo scientific) to 1 ml and transferred to a folded 
capillary cell (Malvern) and zeta-potential measurements were performed three 
times for each sample using the Zetasizer Nano ZS (Malvern).  
3.2.5 SYBR gold dye binding assay  
To measure siRNA condensation efficiency of the conjugates in 
comparison to the unmodified polymer, siRNA in 5% glucose was distributed in a 
FluoroNunc 96-wells white plate (Thermo Fisher Scientific, Waltham, MA) at a 
concentration of 50 pmol/50 µl per well followed by adding 50 µl of different 
concentration of either PEI or Tf-PEI to form polyplexes at different N/P ratios. 
After 20 min incubation, 30 µl of 4 × SYBR gold solution was added to each well 
and incubated for 10 min in the dark. SYBR gold fluoresces when it intercalates 
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with free siRNA but not if siRNA is not accessible due to condensation and 
protection by polymers. The fluorescence was quantified using a Synergy 2 multi-
mode microplate reader (BioTek Instrument, Winooski, VT) at excitation 
wavelength of 485/20 nm and emission wavelength of 520/20 nm. Fluorescence of 
free siRNA (N/P=0) represents 100% of free siRNA. 
To evaluate the stability of polyplexes, release of siRNA from polyplexes 
in presence of lung surfactant Alveofact® (Boehringer-Ingelheim, Germany) or 
mucin was determined by a modified SYBR gold assay 22. While the surfactant 
assay measures siRNA release from polyplexes by surface-active phospholipids, 
the mucus assay determines polyplexes instability in presence of mucus 
glycoproteins. Tf-PEI and PEI polyplexes were prepared with siRNA at N/P 7.5 
and distributed in a 96-well white plate at a concentration of 50 pmol siRNA/100 
µl per well. After 15 min incubation, 50 µl of 4 x SYBR gold solution was added 
to each well and incubated for 10 min in the dark. Subsequently, 50 µl of a serial 
dilution of Alveofact® or mucin was added (final concentrations: 0, 0.0005, 0.005, 
0.05, 0.25, 0.5 mg/ml) and incubated for additional 20 min in the dark before 
measurement of the fluorescence. To account for the autofluorescence of mucin, 
free siRNA samples were prepared in the presence of according concentration of 
mucin. The experiment was performed in replicates of three and fluorescence of 
free siRNA represents 100% siRNA release.  
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3.2.6 Cell culture 
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy 
donors (KCI protocol 2007-012). This protocol was approved by the Wayne State 
University Human Investigation Committee. PBMCs were cultured at a 
concentration of 106 cells/ml in RPMI-1640 with HEPES & L-Glutamine cell 
culture medium (Lonza, Walkersville, MD) supplemented with 10 % heat 
inactivated fetal bovine serum (FBS) (v/v) (Sigma), 1 x penicillin/streptomycin 
(pen/strep) (Corning, Corning, NY) and 2 mM L- Glutamine (Gibco® Thermo 
Fisher Scientific). Peripheral resting T cells in PBMCs were stimulated with anti-
CD3 monoclonal antibody (OKT3, Ortho Biotech, Horsham, PA) at a final 
concentration of 20 ng/ml and expanded with 100 IU/ml human recombinant 
interleukin-2 (IL-2), Novartis). Jurkat cells, a human T lymphocytes cell line, were 
a kind gift from Dr. Larry H. Matherly (Karmanos Cancer Institute). Jurkat cells 
were cultured in the same media as primary T cells. A549 cells, a human epithelial 
cell line derived from lung carcinoma, were obtained from ATCC (Manassas, VA, 
USA) and cultured in DMEM media (Corning) supplemented with 10% FBS and 
1× pen/strep. All cells were grown at a humidified atmosphere with 5% CO2 at 37 
C°. Primary ATCs were frozen at -130 C° in 50% FBS, 40% growth media and 10% 
DMSO on different post-activation days for later experiment.  
 
68 
 
 
 
 
3.2.7 Immunofluorescent staining  
Human ATCs, harvested on different post-activation days, or Jurkat cells 
were washed with PBS and 400,000 cells per sample were resuspended with 10 µl 
50-fold diluted human FcR binding inhibitor (ebioscience, San Diego, CA) for 5 
min on ice, followed by staining with 2 µl of PE labeled human CD71 antibody 
(OKT9, ebioscience) or PE labeled mouse IgG1 isotype control antibody 
(P3.6.2.8.1, ebioscience) for 30 min at 4 °C protected from light. Afterward, cells 
were washed twice and resuspended with 400 µl ice cold PBS/2 mM EDTA before 
they were analyzed with an Attune® Cytometer (Life Technologies). The cellular 
suspensions were measured with 488 nm excitation and the emission filter set of 
574/26 nm. On day 6 post-activation, ATCs were counterstained with a CD71 
antibody and a PE-Cy7 labeled human CD3 antibody (UCHT1, Molecular probes). 
The samples were measured with 488 nm excitation and emission filter of 574/26 
nm and 640 LP in an Attune® Cytometer (Life Technologies). A viable 
lymphocyte population was gated according to morphology based on forward and 
sideward light scattering within which 10,000 events were evaluated. All results 
are given as median fluorescent intensity (MFI). Data analysis was performed 
using Attune® cytometer software (Life Technologies).  
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3.2.8 Quantification of cellular uptake  
Amine modified siRNA was labeled with succinimidyl ester (NHS) 
modified Alexa Fluor 488 (AF488) (Life technologies) following the 
manufacturer’s protocol and purified by ethanol precipitation and spin column 
binding as described previously 123. For uptake experiments, 50 pmol siRNA-
AF488 was prepared with Tf-PEI or PEI in 5% glucose at different N/P ratios (N/P 
ratio: 5, 7.5, 10, 15, 20) or with LF. The day before the experiment, 400,000 ATCs 
or Jurkat cells were seeded in 96 well plates (Thermo scientific) at a concentration 
of 2×106 cells/ml and transfected with the polyplexes/lipoplexes for 24 h. Samples 
were washed three times and resuspended in 400 µl PBS/2 mM EDTA. For initial 
experiments, ATCs were transfected with low N/P ratio treatment groups were 
analyzed using a BD LSR II flow cytometer (BD bioscience, San Jose, CA). For 
later experiments, ATCs or Jurkat cells were transfected with high N/P ratios (10, 
15, 20, or 5, 10, 20), and samples were analyzed using an Attune® Cytometer 
(Life Technology) with 488 nm excitation and emission filter of 530/30. The cells 
were gated according to morphology within which 10,000 events were evaluated.  
For trypan blue quenching assays, ATCs were treated by Tf-PEI or PEI 
polyplexes at N/P 20 or LF lipoplexes for 24 h. Each sample was divided into two 
halves; one half was washed once with 0.4% trypan blue to quench the 
extracellular fluorescent signal then washed with cold PBS/2 mM EDTA three 
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times, the other half was only washed three times. Samples were resuspended in 
400 µl PBS/2 mM EDTA and analyzed with an Attune® Cytometer (Life 
Technology) as described above. 
For the competition cellular uptake study, 400,000 Jurkat cells were seeded 
in 96 well plates at a concentration of 4×106 cells/ml. Subsequently, Tf was 
dissolved in growth media as a Tf stock solution (20 mg/ml), and predetermined 
amounts of Tf stock solution and growth media were added into the cell 
suspension to achieve desired Tf concentrations (0, 0.1, 2 mg/ml) at a fixed cell 
concentration (2×106 cells/ml). The cells were then incubated with free Tf for 30 
min and transfected afterwards with Tf-PEI or PEI at N/P ratio 15 for 4 h. Cellular 
uptake was quantified using flow cytometry as described above. The experiment 
was conducted in duplicate. 
3.2.9 Confocal Laser Scanning Microscopy 
Jurkat cells were seeded in 96 well plates as described above and 
transfected with Tf-PEI and PEI polyplexes formulated with 50 pmol siRNA-
AF488 at N/P ratio of 15. LF was included as control. After 24 h incubation, cells 
were transferred to 1.5 ml tubes and washed once with PBS followed by fixation 
with 4% paraformaldehyde (PFA) solution in PBS (Affymetrix, Thermo Fisher) 
for 20 min. After fixation, the cells were washed with PBS and the nuclei were 
stained with 5 µM of DRAQ5 (Invitrogen, Thermo Fisher) for 5 min followed by 
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washing the cells with PBS. The cell pellet was resuspended in 20 µl Fluoromount 
mounting medium (Southern Biotech, Birmingham, AL, USA), and the cell 
suspension was dropped on slide and covered with a coverslip (Fisherbrand, 
12CIR. -1). Slides were imaged by a Leica TCS SPE-II laser scanning confocal 
microscope (Leica, Wetzlar, Germany), and the images were exported from the 
Leica Image Analysis Suite (Leica).    
3.2.10 In vitro GAPDH gene knockdown 
For gene silencing experiments, 400,000 ATCs or Jurkat cells were seeded 
in a 96 well plate and triplicates of samples were treated with Tf-PEI, PEI or LF 
polyplexes/lipoplexes prepared with 50 pmol for ATCs or 100 pmol for Jurkat 
cells for 24 h using either hGAPDH siRNA or scrambled siRNA at N/P 15. Cells 
were harvested and processed to isolate total RNA using the PureLinkTM RNA 
mini kit (Life techonologies) according the manufacturer’s protocol with DNase I 
digestion (Thermo scientific). Synthesis of cDNA from total RNA and PCR 
amplification were performed with Brilliant III ultra-fast SYBR® green QRT-PCR 
master mix kit (Agilent Technologies, Santa Clara, CA) using a Stratagene Mx 
3005P (Agilent Technologies). Cycle threshold (Ct) values were determined by 
MxPro software (Agilent Technologies). A standard curve including 5 points was 
made from a 1:5 serial dilutions of an untreated sample and assigned 
concentrations of each point (1, 0.2, 0.004, 0.0008, 0.00016) were plotted vs. their 
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corresponding Ct values. The gene expression of GAPDH was normalized by the 
expression of β-actin. Hs_GAPDH_2_SG primers for GAPDH and Hs_ACTB_2-
SG primers for β-actin (Qiagen, Valencia, CA) were used in experiment. 
3.2.11 Cytotoxicity assay 
For measuring the biocompatibility of polyplexes, 8,000 A549 cells were 
seeded in a sterile, white 96 well plate (Corning) at a concentration of 40,000 
cells/ml for 24 h. Polyplexes were prepared with Tf-PEI, 5k PEI and 25k PEI with 
50 pmol scrambled siRNA at different N/P ratios (1, 3, 5, 7.5, 10, 15, 25, 30, 40) 
and diluted with 5 % glucose to a final volume 40 µl. The polyplexes were then 
mixed with 60 µl of growth media, old media in the well plate was removed, and 
100 µl media containing polyplexes was added and incubated for 24 h. The release 
of lactate dehydrogenase (LDH) from the cells was determined using a CytoTox-
ONE™ kit purchased from Promega (Madison, WI) following the manufacturer’s 
protocol. The “no cell” control served as 0% LDH release and cells treated with 
lysis buffer represent 100% LDH release. Experiments were conducted in 
triplicate. 
3.2.12 Cellular distribution of polyplexes in a murine asthma model 
All animal experiments were approved by a Wayne State University 
Institutional Animal Care and Use Committee. Balb/c mice were purchased from 
Charles River Laboratories (Boston, MA) and used at 5 weeks’ age. The murine 
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asthma model was established as described before 75a. Briefly, animals were 
sensitized by intraperitoneal (i.p.) injection of 0.2 ml suspension of ovalbumin 
(OVA) and Al(OH)3 (10 µg OVA and 2 mg Al(OH)3) on day 0 and day 14 (Figure 
13 A). On days 24, 25, and 26, mice were challenged by inhalation of aerosolized 
1% OVA for 1 h to establish experimental asthma while mice that inhaled saline 
were used as healthy control group. On days 35, 36, 37 and 38, mice were 
intratracheally (i.t) instilled (under ketamine/xylazine anesthesia) with 50 µl Tf-
PEI or PEI polyplexes, prepared with 750 pmol Alexa Fluor 647 (Life 
technologies) labeled siRNA at N/P 7.5, or free siRNA-AF647 as control. On days 
36, 37 and 38, before the i.t. administration, a second series of daily OVA or saline 
challenges was performed. On day 39, noninvasive lung function of animals was 
determined by whole-body plethysmography. Changes in the delayed pause in 
breathing as an indicator of altered bronchial responsiveness to increasing aerosol 
challenge concentrations of β-methacholine was monitored (Buxco Electronics 
Inc., Wilmington, DE) 124. On day 40, all animals were sacrificed under i.p. 
ketamine/xylazine anesthesia, exsanguinated and perfused with PBS. 
Bronchoalveolar lavage fluid (BALF) and BALF cells were collected 125 and lung 
cell suspensions were prepared as reported before 60. BALF cells and lung 
suspension cells were counterstained with PerCP-Cy 5.5 labeled anti-CD45 (30-
F11, ebioscience), PE-Cy7 labeled anti-CD4 (GK1.5, eBioscience), a primary anti-
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prosurfactant protein C antibody (proSPC) (1:100, abcam), pacific blue labeled 
goat anti-mouse IgG secondary antibody (1:100, Life Technologies), pacific 
orange labeled anti-F4/80 (invitrogen), APC-Cy7 labeled anti-CD19 (MB19-1, 
molecular probes), and PE labeled anti-CD49d (R1-2, Molecular Probes) 
antibodies following the manufacturer’s protocols. Cell differentiation was 
performed on a BD LSR II flow cytometer (BD bioscience). The staining strategy 
was shown in Table 2. The different cell populations of macrophage/monocytes 
(F4/80+), T cells (CD4+, F4/80-), eosinophils (CD4-, CD49d+), and epithelial 
Type II pneumocytes (proSPC+) were gated, and the MFI of siRNA-AF647 in all 
different cell populations was quantified. To quantify cellular uptake of polyplexes 
in T cells only, lung suspension cells were stained with a PE-Cy7 labeled anti-
CD4 antibody. T cells were gated based on morphology, and the MFI of siRNA-
AF647 was quantified within CD4+ cells by an Attune® Cytometer (Life 
Technology). The concentration of interleukin-5 (IL-5) and interleukin-13 (IL-13) 
in BALF was determined by the mouse cytokine 20-plex panel (Invitrogen) using 
a Bio-Plex® System (Bio-Rad Lab., Hercules, CA) following the manufacturer’s 
protocol. Interleukin concentrations below the detection limitation were reported 
as 0 pg/ml. 
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Table 2 Strategy to differentiate cellular populations of BALF cells 
 
3.2.13 Statistics 
All results are given as mean value ± standard deviation (SD). One-way 
ANOVA with Bonferroni posthoc post-test and calculation of area under the curve 
(AUC) were performed in GraphPad Prism software (Graph Pad Software, La 
Jolla, CA). 
3.3 Result and Discussion 
3.3.1 Synthesis Outcome 
Transfection efficiency and toxicity of PEI are often correlated to its 
molecular weight 126. Here, low molecular weight PEI (5k Da) was chosen to 
decrease potential toxicity and non-specific transfection efficacy. Holo-Tf 
preferentially binds to TfR 57b and has been reported as a targeting ligand for 
various diseases involving TfR overexpression using lipid-based 127 or polymer-
based delivery systems carrying pDNA 44, 128, siRNA 129 or oligonucleotides 93 for 
anti-sense therapy. To target ATCs, holo-Tf was conjugated to PEI to increase the 
intracellular internalization efficiency. As shown in Figure 3, holo-Tf and 5k PEI 
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were reacted with the bifunctional crosslinker SPDP, respectively, and PEI-SPDP 
was activated by the reducing reagent DTT. Activated PEI-SPDP* (see Figure 3) 
was conjugated to Tf-SPDP to yield Tf-PEI. The final concentration of Tf was 
determined by UV absorbance at 280 nm, and the concentration of PEI was 
assessed by TNBS assay. The resulting molar ratio of Tf to PEI was approximately 
1.5: 1. Due to the difference of molecular weights between Tf (80 kDa) and LMW 
PEI (5 kDa), higher coupling degrees were not expected and could in fact be 
disadvantageous for the interaction between PEI amines and siRNA phosphate 
groups.  
 
Figure 3 Synthesis scheme of transferrin-coupled polyethylenimine (Tf-PEI). 
Transferrin (Tf, left side) and PEI (right side) are reacted with N-succinimidyl 3-
(2-pyridyldithio)-propionate (SPDP) in separate reactions. PEI-SPDP is activated 
by dithiothreitol (DTT) and coupled with Tf-SPDP to form a disulfide bond and 
the resulting Tf-PEI.  
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3.3.2 siRNA condensation of Tf-PEI 
The siRNA condensation efficiency of a polymer is an important property 
to evaluate the suitability of a carrier for siRNA. To determine whether the 
presence of Tf would affect the ability of PEI to condense siRNA, the 
condensation efficiency of Tf-PEI was determined by SYBR® Gold assays, and 
unmodified 5k PEI was used as a control. SYBR gold is a nucleic acid-
intercalating fluorescent dye. When siRNA is condensed by polymer and becomes 
inaccessible to SYBR gold, consequently a decrease of fluorescence is observed. 
As shown in Figure 4, PEI can completely condense and protect the siRNA at N/P 
5 which was consistent with previous reports 75b. On the other hand, both human 
and mouse Tf-PEI condensed siRNA to 80% at N/P 5, and complete condensation 
of siRNA was observed at N/P 7.5. The difference may be due to steric hindrance 
of Tf which impacts the interaction between siRNA and the primary amines in PEI. 
It also needs to be taken into consideration that by coupling Tf to PEI, a few 
primary amines would be expected to no longer be available for interaction with 
siRNA. However, the influence of the Tf modification on condensation efficacy of 
the conjugate is limited, with full condensation still achievable at a comparably 
low N/P ratio of 7.5. 
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Figure 4 SYBR gold assay of PEI and Tf-PEI. The siRNA condensation efficiency 
of PEI and Tf-PEI was measured by SYBR gold assay at different N/P ratios: 0, 
1.25, 2.5, 3.75, 5, 7.5, 10, 15, 20. Fluorescence of free siRNA (N/P= 0) represents 
100% free siRNA. (Data points indicate mean ﹢/﹣ SD, n= 2-3; Green square: 
PEI polyplexes, orange circle: human Tf-PEI, yellow triangle: murine Tf-PEI)  
3.3.3 Hydrodynamic diameter and zeta potential 
Optimal physicochemical properties of polyplexes such as size and surface 
charge can facilitate efficient siRNA delivery in vitro and in vivo. Therefore, Tf-
PEI or PEI polyplexes, prepared with the same amount siRNA in HBS buffer at 
different N/P ratios, were fully characterized for size, polydispersity index (PDI) 
and zeta potential by dynamic light scattering and laser Doppler anemometry. As 
shown in Figure 3.3 A, Tf-PEI formulations demonstrated small sizes ranging 
from 72 to 197 nm and PDIs ranging from 0.24 to 0.39. In comparison, PEI 
formed larger particles of 1133 nm to 1595 nm in size with PDI of approximately 
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0.3. Both formulations demonstrated acceptable size distributions with PDIs 
mostly below 0.3 indicating homogeneous morphology and little aggregation 
which is an important factor for successful transfection. Size of polyplexes is 
another key factor for efficient transfection, and small sizes (<200 nm) of the Tf-
PEI polyplexes could ensure higher stability and better intracellular uptake 
efficiency especially into ATCs compared with large PEI polyplexes (>1000 nm) 
130. Considering that Tf is a very soluble glycoprotein, it is possible that Tf 
decorates the surface of Tf-PEI polyplexes and a resulting steric stabilization of Tf 
contributes to the much smaller size of the particles 128. Consistent with this 
hypothesis, it has been reported that low molecular weight PEI tends to form large 
particles with siRNA 131 and a tendency of aggregation of PEI has been observed 
when preparing polyplexes in high ionic strength buffers such as HEPES buffered 
saline 128.  
Zeta potentials of both Tf-PEI and PEI polyplexes increased with 
increasing N/P ratio (Figure 5 B).  Tf-PEI polyplexes displayed negative charges 
in the range of -20 to -7 mV which is in agreement with the assumption that the 
negatively charged Tf may shield the positive charges of PEI and is located on the 
surface of the polyplexes, resulting in an overall negative zeta potential 132. On the 
other hand, except at N/P 2 where the zeta potential was -28.6 ± 3.9 mV, all PEI 
formulations showed slightly positive charges in the range from 8.5 mV to 26 mV. 
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Due to the relatively “rigid” structure of short duplex siRNA and the fact that not 
all positively charged groups in PEI are sterically available to interact with siRNA, 
most of the siRNA may be on the surface of the polyplexes at a low excess of 
polymer, i.e. N/P 2. This could explain why a negative charge was observed at N/P 
2. At higher N/P ratios, excess amount of PEI more efficiently interacts with the 
negative charges of siRNA resulting in positive zeta potentials of the polyplexes. 
Positive zeta potentials of polyplexes may hamper their penetration through lung 
mucus and surfactant which have negative charge 75a and also increase their 
chance of non-specific delivery via adsorptive endocytosis. Additionally, multiple 
pulmonary administrations of positively charged nanoparticles can increase local 
and systemic toxicity, while in comparison, anionic nanoparticles are well 
tolerated 133. Therefore, we hypothesize that Tf-PEI polyplexes would be a more 
efficient and safe pulmonary administrated system than PEI.  
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Figure 5 Size and zeta-potential of Tf-PEI and PEI.  (A) Hydrodynamic diameters 
(left x-axis) and polydispersity indices (PDI, right x-axis) and (B) zeta-potentials 
of Tf-PEI and PEI polyplexes formulated with 50 pmol siRNA in HEPES buffered 
saline at different N/P ratios :2, 5, 7.5, 10, 15, 20. (Data points indicate mean ﹢/
﹣ SD, n=3)  
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3.3.4 Stability of polyplexes in the presence of lung surfactant 
The instability of polyplexes in the blood stream limit their suitability for 
systemic administration. To overcome this challenge, pulmonary delivery is 
favorable for the treatment of lung diseases due to the large application area, the 
absence of serum proteins, and the reduced nuclease activity 75b. However, there 
are other biological barriers associated with using the airway route that need to be 
overcome to deliver siRNA to the lung. If epithelial cells in the upper airway are 
to be targeted, polyplexes need to penetrate a mucus layer before they reach the 
epithelium. In asthma therapy, polyplexes are mostly expected to be delivered to 
the deep lung, where the alveolar surface is covered by lung surfactant which 
presents another barrier 75a. To investigate the stability of polyplexes in the lung, a 
modified SYBR® Gold assay was performed in the presence of lung surfactant 
Alveofact® or mucin and released siRNA was quantified. Tf-PEI polyplexes 
demonstrated higher stability compared with PEI polyplexes at increasing 
concentrations of mucin (0.0005 - 0.5 mg/ml) (Figure 6 A). Similarly, at low 
concentrations of surfactant (0.0005 - 0.05 mg/ml), the ability of Tf-PEI to retain 
siRNA was also better than that of PEI. Only 1% siRNA release from Tf-PEI 
polyplexes but 4.3% from PEI polyplexes was observed at 0.05 mg/ml. At a 
concentration of 0.25 mg/ml, PEI and Tf-PEI polyplexes released 10.9% and 10.2% 
siRNA, respectively. As described above, there are indications that Tf is located 
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on the surface of the polyplexes and consequently shields PEI/siRNA from 
interaction with surfactant or mucin. In contrast, at the highest concentration of 
surfactant (0.5 mg/ml), PEI more efficiently retained siRNA than Tf-PEI (Figure 6 
B). While 13.5% of siRNA were released from PEI, 16.2% of siRNA were 
released from Tf-PEI polyplexes. High concentration of surfactant may induce 
structural changes in Tf, as a result, the ability to retain siRNA in the polyplex 
simply depends on electrostatic interaction between siRNA and PEI. It is expected 
that Tf-PEI polyplexes would release more siRNA since unmodified PEI 
demonstrated slightly better ability to condense siRNA compared with Tf-PEI. In 
2009, we reported also that PEGylated PEIs release siRNA more efficiently than 
unmodified PEI 22. It should be noted that in 2009, 25 kDa PEI was described, 
whereas here we used 5 kDa PEI which showed slightly lower stability in presence 
of surfactant and mucin compared to 25 kDa PEI complexes. However, the studied 
concentrations of surfactant, of which predominant composition is phospholipids 
(up to 70% being dipalmitoyl phosphatidylcholine (DPPC)) 134, are much higher 
than that in a reported simulated lung fluid (0.02% (w/v) DPPC), used for 
dissociation tests of inhaled pharmaceutical formulations 135. At physiological 
surfactant concentrations, Tf-PEI polyplexes therefore seem to exhibit enhanced 
stability compared to PEI polyplexes. This observation could lead to beneficial 
stability after aerosol deposition in the peripheral airways. On the other hand, 91% 
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and 97% of siRNA, respectively, were released from Tf-PEI and PEI polyplexes at 
a very high concentration of 0.5 mg/ml mucin. In comparison, complexes of 
PEGylated 25 kDa PEI which mediated highly efficient gene knockdown in the 
lung showed about 30% siRNA release at mucin concentrations as low as 0.33 
mg/ml 22. Instability of siRNA polyplexes at exaggerated mucin concentrations 
therefore seem not to hamper efficient gene knockdown at physiological 
conditions. While surfactant is only present in the alveolar region, mucus lines in 
the upper and bronchial airways where the polyplexes are expected to mediate 
their therapeutic effects. Based on our experiments, mucus stability of future 
nanocarriers should be optimized. However, it is possible that stability in presence 
of surfactant plays a more important role in vivo where Tf-modification of the 
polyplexes was advantageous. Therefore, we hypothesize that Tf could protect the 
polyplexes for sufficient stability during pulmonary administration.      
 
Figure 6 Stability of Tf-PEI and PEI polyplexes. Stability of Tf-PEI and PEI 
polyplexes at N/P 7.5 was determined by modified SYBR gold assay after 20 min 
incubation with increasing concentration of (A) mucin and (B) lung surfactant 
(0.005-0.5 mg/ml). Free siRNA represents 100% siRNA release. (Data points 
indicate mean ﹢/﹣ SD, n=3; Green square: siRNA release from PEI polyplexes, 
orange circle: siRNA release from Tf-PEI polyplexes) 
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3.3.5 Determination of expression of TfR 
To confirm the expression of TfR on human ATC 136, human PBMCs were 
activated by anti-CD3 antibody (OKT3), and the expression of TfR was quantified 
by flow cytometry over time. On day 0 (Figure 7 A), the TfR expression was at a 
basal level in PBMCs whereas the TfR expression increased dramatically from 
day 1 to day 5 after activation. T lymphocytes undergo rapid differentiation, 
proliferation, and up-regulate TfR (CD71) to meet their high consumption of iron 
118. The TfR expression level slowly decreased after day 5 post-activation, but a 
clearly increased level of TfR expression compared to day 0 was maintained up to 
day 14 post-activation. This observation may be due to the fact that T cells are 
activated very early and that activation also leads to proliferation137 118, 137. It is 
possible that a) the rate of proliferation and differentiation of T cells slows down 
after 5 days post-activation and that b) a percentage of activated T cells becomes 
apoptotic resulting in lower TfR levels compared to earlier time points. However, 
the activated status of T cells maintains a relatively high consumption of iron 
compared to the resting status 118.To characterize the lymphocyte population in 
PBMCs after activation and to confirm the high expression of TfR on T cells, on 
day 6 post-activation, activated PBMCs were immunologically counter-stained 
with antibodies against CD3 and CD71 (TfR). Of the total cell population, 
approximately 90% of the cells were CD3 positive, and within this population, 
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more than 60% cells were TfR and CD3 dual positive cells confirming activation 
stimulates T cells to overexpress TfR (Figure 7 B). Overexpression of TfR was 
also observed in Jurkat cells (Figure 7 C). These results suggest the possibility to 
target primary ATCs or Jurkat cells, as a surrogate T cell line, via TfR targeting 
strategy. 
 
 
Figure 7 TfR expression in ATCs and Jurkat cells.  (A) Human peripheral blood 
mononuclear cells (PBMCs) were activated by anti-CD3 antibody (OKT3) and 
stained with anti-CD71 antibody to determine the expression of CD71, namely 
transferrin receptor (TfR), on different post activation days. The median 
fluorescence intensity (MFI) of CD71 of cells were quantified by flow cytometry. 
(Data points indicate mean ﹢/﹣ SD, n=1-3; Compared with D0, *, p< 0.05, **, p 
< 0.01, ***, p<0.005). (B) ATCs were counterstained by CD71-PE and CD3-PE-
Cy7 antibodies on day 6 post-activation. (C) Jurkat cells were stained with anti-
CD71 antibody (TfR) or isotype antibody. The MFIs of antibody-stained of cells 
were quantified by flow cytometry. (Data points indicate mean ﹢/﹣ SD, n=2; 
One-way ANOVA, ***, p<0.005). 
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3.3.6 In vitro cellular uptake of polyplexes 
To determine the targeting efficiency of Tf-PEI, primary ATCs were 
transfected for 24 h and the cellular uptake was quantified by flow cytometry. Tf-
PEI polyplexes were formulated with Alexa Fluor 488 labeled siRNA (AF488-
siRNA) at different N/P ratios (5, 7.5, 10, 15, 20). Unmodified PEI polyplexes and 
lipofectamine 2000 (LF) served as positive controls, and treatment with free 
siRNA and an untreated group were also included as negative controls. Initially, 
cellular uptake was determined at low N/P ratios (N/P= 5 & 7.5, Figure 8 A) at 
which 100% siRNA condensation was achieved by unmodified PEI but 80% and 
100% condensation was achieved by Tf-PEI conjugates. Tf-PEI polyplexes can 
target ATCs, and significantly higher cellular uptake was observed compared with 
unmodified PEI at both N/P ratios, although only 80% siRNA were encapsulated 
inside Tf-PEI polyplexes at N/P 5 (Figure 5). These results were in line with our 
previously published results 91. Moreover, ATC-selective delivery of Tf-PEI 
polyplexes was confirmed at higher N/P ratios (N/P 10, 15, 20) (Figure 8 B). 
Increased cellular uptake of both PEI and Tf-PEI was observed with increasing 
N/P ratios from 10 to 20. Tf-PEI polyplexes achieved 3.2 fold, 4.5 fold and 4.1 
fold higher cellular uptake compared to PEI polyplexes at N/P 10, 15, 20, 
respectively. Most importantly, Tf-PEI achieved 1.8 fold more efficient cellular 
uptake at N/P 20 than LF mediated siRNA delivery. PEI polyplexes can non-
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specifically associate on the cell surface due to electrical interaction between their 
positive surface charge and negative charge of cellular membranes and induce 
adsorptive endocytosis. This mechanism contributes to non-targeted cellular 
uptake. However, PEI polyplexes are not efficiently taken up by primary ATCs. 
These results agree with a previous report from our group which focused on the 
observation that Tf-PEI can selectively deliver siRNA to ATCs overexpressing 
TfR but not resting T cells which are TfR negative 91. To estimate the percentage 
of extracellular fluorescence resulting from polyplexes that are bound but not 
internalized, 0.4% trypan blue quenching treatment was performed on ATCs 
treated by Tf-PEI (N/P 20), PEI (N/P 20), LF and free siRNA. As shown in Figure 
8 C, the MFI slightly decreased in all trypan blue treated groups except the LF 
group. This result suggests that only a limited amount of extracellular fluorescence 
is associated with the surface of the cells but most of the fluorescent polyplexes 
were taken up intracellularly. The slightly increased MFI of the LF treated group 
(Figure 8 C) could be explained by the fact that apoptotic cells with a damaged 
cell membrane are stained completely by trypan blue and therefore no longer are 
detected by flow cytometry. As it is known that LF has a strong cytotoxic effect, 
especially on primary cells, it is possible that the MFI was skewed to only viable 
cells which seem to have a slightly higher MFI. To validate our results in a cell 
culture model, transfection experiments were also performed in Jurkat cells, which 
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are often used as a T cell model cell line. Jurkat cells are an immortalized 
lymphoma cell line, however, and not as hard-to-transfect as primary T cells. In 
agreement with the results obtained in ATCs, cellular uptake of Tf-PEI polyplexes 
in TfR-overexpressing Jurkat cells (Figure 7 C) was also significantly higher than 
that of PEI polyplexes (Figure 8 D). It needs to be noted, however, that the 
transfection efficiency of LF in Jurkat cells is higher than that of Tf-PEI 
polyplexes. The cellular endocytosis profile and molecular membrane composition 
of this immortalized cell line is expected to differ significantly from primary 
ATCs. Additionally, their viability under transfection is expected to be higher than 
that of ATCs which do not withstand the cytotoxic effects of commercially 
available transfection reagents. These characteristics may contribute to efficient 
transfection of Jurkat cell with LF, while primary ATCs are especially difficult to 
transfect cells 98a and benefit from active targeting.  
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Figure 8 Cellular uptake of Tf-PEI and PEI in ATCs and Jurkat cells. MFI was 
determined by flow cytometry to evaluate the cellular uptake in primary human 
activated T cells (ATCs) of Tf-PEI, PEI and lipofectamine 2000 (LF) 
polyplexes/lipoplexes prepared with 50 pmol Alexa Fluor 488 labeled siRNA 
(AF488 siRNA) at low N/P ratios (5 and 7.5). (B) Cellular uptake of Tf-PEI, PEI 
and LF in ATC at high N/P ratio (10, 15 and 20). (C) Cellular uptake in ATCs of 
Tf-PEI, PEI and LF polyplexes at N/P 20 with or without trypan blue (TB) 
quench. (D) Cellular uptake in Jurkat cells of Tf-PEI, PEI and LF at different N/P 
ratios (5, 10 and 20). (Data points indicate mean ﹢/﹣  SD, n >2; One-way 
ANOVA, **, p < 0.01, ***, p<0.005). 
For the competition assay, Jurkat cells were transfected with Tf-PEI and 
PEI polyplexes in the presence of different concentrations of free Tf. As shown in 
Figure 9, the cellular uptake of Tf-PEI polyplexes in Jurkat cells can be inhibited 
by the presence of free Tf and this inhibition depended on the concentration of free 
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Tf. The higher concentration of free Tf (2 mg/ml) can achieve significantly 
stronger inhibition compared to the lower concentration (0.1 mg/ml). However, 
free Tf has no effect on the uptake of PEI polyplexes. This result suggests that the 
selective delivery of Tf-PEI polyplexes to Jurkat cells was mediated by the 
targeting ligand. In primary cells, this effect is even stronger, as published in 2013, 
where almost no uptake is mediated by PEI or Tf-PEI in cells that do not express 
the receptor 60. 
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Figure 9 Free Tf competition assay. The cellular uptake in Jurkat cells of Tf-PEI 
or PEI polyplexes at N/P ratio 15 in presence of free Tf (0.1 and 2 mg/ml) was 
determined by flow cytometry (Data points indicate mean ﹢/﹣ SD, n= 2; One-
way ANOVA, **, p < 0.01). 
3.3.7 Confocal Laser Scanning Microscopy (CLSM) 
To determine the cellular distribution of polyplexes, Jurkat cells were 
transfected with Tf-PEI, PEI and LF carrying siRNA-AF488 at N/P ratio of 15 for 
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24 h and a control, only treated with the according amount of free siRNA, was 
included. The cellular distribution of siRNA was observed by CLSM (Figure 10). 
As shown in Figure 10 A, negligible amounts of green dots (siRNA-AF488) can 
be observed suggesting that free siRNA cannot be efficiently delivered into the 
cells without carrier. The receptor-mediated cellular uptake of Tf-PEI/siRNA 
resulted in an even distribution of siRNA within the cytoplasm of the cells (Figure 
10 D), while delivery with PEI or LF resulted in punctuated distribution (Figure 10 
B and C). The point-shaped distribution of siRNA in the transfected cells could be 
a sign of endosomal entrapment of the LMW-PEI complexes. 
 
Figure 10 CLSM images of Jurkat cells. CLSM images of Jurkat cells transfected 
by Tf-PEI, PEI, LF and free siRNA-AF488 at N/P 15. The nuclei were stained 
with 5 µM of DRAQ5. (green: siRNA-AF488; blue: nucleus). 
 
93 
 
 
 
 
3.3.8 In vitro transfection efficacy 
Next, we investigated whether the significantly higher internalization of Tf-
PEI polyplexes could induce a corresponding fdownregulation of a targeted gene. 
Therefore, ATCs or Jurkat cells were transfected by Tf-PEI and PEI polyplexes 
prepared with siRNA against GAPDH or scrambled siRNA at N/P 15, and LF was 
included as additional positive control. GAPDH gene expression was normalized 
by β-actin gene expression and quantified via real time PCR (RT-PCR). As shown 
in Figure 11 A, GAPDH expression in ATCs treated with Tf-PEI/ siGAPDH 
polyplexes was 2 fold less than after transfection with PEI/siGAPDH. Moreover, 
significant downregulation of GAPDH expression was observed in Tf-
PEI/siGAPDH group compared with Tf-PEI/scrambled siRNA group and 
untreated control. In contrast, there was no significant difference of GAPDH 
expression among PEI/siGAPDH, PEI/scramble siRNA treated cells and the 
untreated group. Unmodified PEI polyplexes can undergo endocytosis mediated 
by electrostatic interaction between their positive surface charge and the negative 
charge of the cellular membrane as demonstrated in cellular uptake study. 
However, this limited internalization was not sufficient to induce significant 
sequence-specific gene silencing compared with receptor mediated endocytosis. 
LF was too toxic for primary ATCs, and it was impossible to isolate sufficiently 
intact RNA after transfection. Therefore, no viable results were obtained in ATCs 
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and experiments were repeated in Jurkat cells. A similar outcome of GAPDH 
knock down was observed in Jurkat cells (Figure 11 B). CLSM images of Jurkat 
cells transfected with Tf-PEI and PEI polyplexes and LF lipoplexes (Figure 10) 
revealed the possibility that Tf-PEI could mediate more efficient endosomal 
escape and release siRNA into cytoplasm. This observation, taken together with 
the less efficient uptake of non-targeted polyplexes (Figure 8) could be one reason 
for the lack of gene knockdown. According to the efficient uptake results, LF 
mediated the most efficient gene knock down in Jurkat cells, which, however, is 
not representative for the transfection of primary ATCs.  
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Figure 11 GAPDH Knockdown in ATCs and Jurkat cells. (A) GAPDH gene 
knockdown efficiency of Tf-PEI and PEI polyplexes at N/P 15 was validated in 
ATCs. (B) GAPDH gene knockdown efficiency of Tf-PEI, PEI or lipofectamine 
2000 (LF) was measured in Jurkat cells. Tf-PEI or PEI were formulated with 
siRNA against GAPDH (siGAPDH) or scrambled siRNA (siNC). GAPDH 
expression was normalized with beta-actin expression and quantified by real time 
PCR. (Data points indicate mean ﹢/﹣ SD, n =3; One-way ANOVA, **, p < 0.01, 
***, p<0.005).  
3.3.9 Cytotoxicity assay 
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Biocompatibility of polyplexes is one of the most important considerations 
before the in vivo application. The potential toxicity of PEI may induce membrane 
damage and cells apoptosis. Therefore, an assay to determine the cellular 
membrane integrity would be idea to determine the potential toxicity of Tf-PEI 
polyplexes. Tf-PEI polyplexes are proposed to be administrated pulmonarily, 
therefore, A549 cells, a lung epithelial cell line, was used in this study. A549 cells 
were treated with Tf-PEI, 5k PEI and 25k PEI polyplexes containing scrambled 
siRNA (N/P ratio: 1, 3, 5, 7.5, 10, 15, 20, 25, 30 ,40). And the LDH release from 
cells with damaged membranes was determined. As shown in Figure 12, high 
molecular weight PEI (25k Da), which served as a positive control can cause 
cytotoxicity, started to cause LDH release from N/P 7.5. As the N/P ratio of 25k 
PEI increased, increasing LDH release was observed until N/P 30. At N/P 40 of 
25k PEI, less LDH release compared to N/P 30 was measured which may be due 
to cell killing by high doses of 25k PEI polyplexes at early time points resulting in 
less cells available for the measurement of LDH release at the end point. On the 
other hand, Tf-PEI and low molecular weight PEI (5k) polyplexes treatment didn’t 
induce any increase of LDH release at all tested N/P ratios compared to the 
untreated control. This result indicated the high biocompatibility of both 5k PEI 
and Tf-PEI polyplexes. The toxicity of PEI strongly depends on the molecular 
weight. Low molecular weight PEI (< 10k Da), which is used in this study, 
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demonstrates a better safety profile compared to higher molecular weight PEI (i.e. 
25k Da). The positive charge of PEI also contributes to toxicity. As shown in 
Figure 5 B, Tf-PEI polyplexes have slightly negative surface charge which may 
also contribute to the low cytotoxicity of Tf-PEI polyplexes. 
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Figure 12 LDH release from A549 treated with polyplexes. LDH release from Tf-
PEI, 5k PEI and 25k PEI polyplexes treated A549 cells was determined by 
CytoTox- ONE. The “no cells” control represents 0% LDH release, and cells 
treated with lysis buffer represent 100% LDH. (n = 3) 
3.3.10 In vivo delivery of polyplexes 
To further validate the possibility of pulmonary delivery of siRNA to ATCs 
via Tf-PEI, a murine model of allergen-induced asthma-like inflammatory reaction 
was established as shown in Figure 13 A. Animals were i.t administrated on 4 
consecutive days with Tf-PEI or PEI polyplexes prepared with Alexa Fluor 647 
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labeled siRNA (siRNA-AF647), and administration of free siRNA-AF647 was 
included as negative control on day 35-38 (Figure 15 A). On day 39, lung function 
of animals was determined by PenH assay. Overall, the airway 
hyperresponsiveness (AHR) of asthmatic groups of animals was slightly higher 
than in corresponding saline-exposed, healthy groups of animals (Figure 15 B). 
Additionally, according to the AUC of airway responsiveness against 
methacholine concentration curve, mice within the asthmatic group treated with 
PEI/siRNA polyplexes showed the highest AHR which was significantly higher 
than within the corresponding healthy control. On the other hand, there is no 
significant difference between asthmatic mice treated with Tf-PEI/siRNA 
polyplexes and their corresponding healthy control group (Figure 13 C). This data 
may suggest that the treatment with positively charged PEI/siRNA polyplexes 
could have intensified the pre-existing lung inflammation in the asthmatic animals 
but not the treatment with Tf-PEI/siRNA polyplexes, which are shielded by the 
negatively charged glycoprotein.  
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Figure 13 Murine asthma model. (A) Establishment of a murine asthma model. 
Balb/c mice were sensitized by i.p injection of Al(OH)3 and ovalbumin (OVA) 
twice and challenged twice by inhalation of 1% OVA aerosol for 1 h daily for 3 
consecutive days to induce airway inflammation. Animals treated by inhalation of 
saline served as healthy control. Polyplexes with 750 pmol Alexa Fluor 647 
labeled siRNA (siRNA-AF647) were prepared with Tf-PEI or PEI at N/P 7.5 and 
applied intratracheally (i.t.), and free AF647 siRNA served as negative control. 
Lung function was determined on day 39. Bronchoalveolar lavage fluid (BALF), 
BALF cells and lung cells suspension were analyzed on day 40. (B) Airway 
hyperresponsiveness of methacholine-challenged mice after 4 consecutive days of 
treatment with free siRNA, PEI or Tf-PEI polyplexes. (C) Airway responses of 
animals were represented by AUC of airway responsiveness against methacholine 
concentration curve. (Data indicated as mean +/- SEM, n> 3)  
 
 
 
Figure 14 Differentiation of BALF. Strategy to differentiate cellular populations in 
BALF cells by flow cytometry.  
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On day 40, BALF, BAL cells and lung cells were collected and processed 
for determining concentration of IL-5 and IL-13, or for immunostaining, 
respectively. BAL cell populations were differentiated following the 
immunostaining strategy shown in Figure 14 and Table 2. As shown in Figure 15 
A, Tf-PEI polyplexes uptake in T cells was significantly higher than that in B cells 
and eosinophils. More importantly, cellular uptake of Tf-PEI polyplexes in T cells 
was 1.3 and 1.5 fold higher than that in macrophages and type II pneumocytes, 
one type of alveolar cells, respectively. It has to be taken into account that lung 
resident macrophages serve as first line of cellular defense in the deep lung 138 by 
actively phagocytosing foreign particles, which may result in a significant amount 
of polyplexes being cleared. Additionally, the large interaction surface of type II 
pneumocytes with aerosolized particles also increases their possibility to associate 
with polyplexes. Considering that activated macrophages have elevated levels of 
TfR 139 also and epithelial cells express TfR as well 140, Tf-PEI polyplexes 
demonstrated very efficient T cell-targeted delivery. In lung suspension cells, 
uptake of Tf-PEI polyplexes in T cells was 1.7 fold higher than PEI polyplexes in 
asthmatic animals (OVA group). Furthermore, cellular uptake of Tf-PEI 
polyplexes in T cells from asthmatic animals was significantly higher than in 
healthy animals (saline), which demonstrated minimal cellular uptake similar to 
free siRNA treatment group (Figure 15 B). Tf-PEI and 5k PEI polyplexes didn’t 
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show toxicity toward A549 cells at N/P ratios ranging from 1 to 40 as assessed by 
LDH release assay (Figure 12). However, as suggested above, intratracheal 
administration, especially of positively charged polyplexes could induce additional 
inflammation. To evaluate the potential pro-inflammatory effects of polyplexes, 
IL-5 and IL-13 were determined by a mouse cytokine 20-plex panel. As shown in 
Figure 15 C, overall, IL-5 levels were higher in all asthmatic groups, which can be 
explained by the allergic inflammation induced by the OVA-sensitization and 
challenge. However, asthmatic animals treated with PEI polyplexes demonstrated 
significantly higher secretion of IL-5. On the other hand, no significant difference 
of secretion of IL-5 in Tf-PEI polyplexes and free siRNA treated OVA-sensitized 
animals was observed compared with healthy animals. Additionally, the levels of 
cytokines in OVA-sensitized animals treated with targeted polyplexes was not 
significantly different from untreated OVA-sensitized animals (data not shown). 
The same secretion profile was observed in IL-13 (Figure 15 D). These results 
agree with the airway hyperresponsiveness results (Figure 3.11 B and C) and 
suggest that the Tf-shielding of Tf-PEI polyplexes efficiently reduces the pro-
inflammatory effect of PEI polyplexes in asthmatic animals. It is worth noting that 
the repeated treatment with low molecular weight PEI was tolerated very well in 
healthy animals (Figure 15 C and D). These results are in line with previous 
reports 51, 120.  
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Figure 15 Biodistribution and biocompatibility of Tf-PEI and PEI. (A) Cellular 
uptake of Tf-PEI polyplexes in different BALF cell populations from OVA 
sensitized-animals and (B) Cellular uptake of Tf-PEI polyplexes, PEI polyplexes 
and free AF647 siRNA in the T cell population of the lung cell suspensions from 
asthmatic and healthy mice was quantified by flow cytometry. (C) IL-5 levels in 
BALF and (D) IL-13 levels in BALF were determined by the mouse cytokine 20-
plex panel. (n>3, *, p< 0.05, **, p < 0.01, ***, p<0.005)  
3.4 Conclusion 
This study is the first attempt to deliver siRNA selectively to activated T 
cells for asthma therapy. Tf-PEI polyplexes exhibited desired physicochemical 
properties and achieved selective delivery of siRNA to ATCs followed by 
successful induction of gene knockdown. Such selectivity was also confirmed in a 
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murine asthma model. Our present work demonstrates the possibility to 
specifically deliver siRNA to ATCs via targeting TfR. Although repeated 
administration of a Tf conjugate of low molecular weight PEI was well tolerated 
in healthy animals and no toxicity was observed in our study, clinical application 
of PEI or its conjugates is still limited by concern of any possible toxicity. 
Therefore, after having established an efficient targeting strategy for primary T 
cells in the present paper, our next studies will be devoted to developing a more 
biocompatible polymer to replace PEI. Subsequently, therapeutic effects of 
downregulating clinically relevant genes such as the Th2 transcription factor 
GATA-3 will be determined. 
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CHAPTER 4 POST-TRANSCRIPTIONAL REGULATION 
OF THE GASC1 ONCOGENE WITH ACTIVE TUMOR-
TARGETED SIRNA-NANOPARTICLES 
Please note that part of the content of this chapter is from a research article, 
“Post-transcriptional regulation of the GASC1 oncogene with active tumor-
targeted siRNA-nanoparticles”, was published in Molecular Pharmaceutics (S. 
Movassaghian, Y. Xie, et al., 2016). The authors of this article include Sara 
Movassaghian, Claudia Hildebrandt, Rayna Rosati, Ying Li, Na Hyung Kim, 
Denise Conti, Sandro RP da Rocha, Zeng-Quan Yang, Olivia M Merkel and me. 
Sara Movassaghian and me are joint first authors of this research paper. 
4.1 Introduction 
Basal-like breast cancer (BLBC) accounts for the most aggressive types of 
breast cancer and currently cannot be treated specifically. Therefore, investigation 
of new targets and treatment strategies is more than necessary. One possible new 
group of targets are ‘epigenetic enzymes’ (e.g. a histone modifying and DNA 
methylating enzymes) as the causative links between genetics and epigenetics in 
cancer development are well documented 141. There is also an increasing 
appreciation that epigenetic aberrations that are often directly caused by genetic 
defects resulting in loss- or gain-of-function of epigenetic-regulators contribute 
significantly to cancer onset, severity and progression 142. Specifically, a genetic 
alteration in the gene encoding an ‘epigenetic enzyme’ can lead to changes within 
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the histone code 143, which is involved in both tumorigenesis and cancer stem cell-
generated hierarchies in multiple tumor types 143. 
The possibility of reversing epigenetic codes may provide new targets for 
therapeutic intervention. In the present work, we focused on therapeutically down 
regulating a recently discovered gene which was first identified and cloned as a 
novel cancer gene by Yang et al. 144. The gene amplified in squamous cell 
carcinoma 1 (GASC1- also referred to as JMJD2C/KDM4C) encodes a nuclear 
protein that catalyzes lysine demethylation of histones 144 and is involved in 
several cancers, including breast cancer 145. Thus, down regulation of GASC1 
expression represents an excellent therapeutic approach but is currently not 
possible in a cell specific manner. Moreover, recent findings clearly established 
that the GASC1 gene is amplified in approximately 15% of breast cancers 146, and 
its overexpression is more prevalent in basal-like breast cancers (BLBC) 111. 
Besides, GASC1 overexpression is correlated with a poor prognosis and induces 
transformed phenotypes 146b. Previous studies have demonstrated that therapeutic 
interference with GASC1 using an shRNA-based approach inhibits proliferation of 
breast cancer cells in vitro and in vivo 146b 108. However, in these studies, viral 
vectors were used to express shRNA for GASC1 knock down. Besides the 
immunologic challenges and safety issues viral vectors bear, viruses do not 
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transduce cells in a specific manner. However, targeting can be achieved with 
chemically engineered artificial viruses 147.  
Human breast carcinomas represent a heterogeneous group of tumors that 
are diverse in their behavior, outcome, and response to therapy. Breast cancer is 
generally classified in four main groups based on their expression of estrogen 
receptor (ER), progesterone receptor (PR), and Her2/neu receptor (HER2): two of 
the main groups are ER+ and include luminal A (ER+, PR+, and HER2-) and 
luminal B (ER+, PR+ and HER2+) subtypes, and two groups are ER-, HER2 
overexpressing (ER2-, PR-, HER+) and basal-like (ER-/low, PR-/low, HER2-/low) 148. 
Among the different types of breast cancer, basal-like breast cancers 
(BLBC) are particularly aggressive and are associated with high histological grade, 
prevalence of younger patient age, poor prognoses, and often relapse rapidly 148. 
The treatment for BLBC consists of standard chemotherapy regimens as no 
effective molecularly-targeted therapies have been developed 149.  
Failure in the current conventional therapies for BLBC patients urges the 
development of novel strategies to achieve favorable outcomes. 
Therefore, siRNA against GASC1, the newly identified oncogenic histone 
modifying enzyme holds promise as a potential therapy of BLBC. Nanoparticles 
offer an unprecedented opportunity in rational drug and gene delivery by 
enhancing therapeutic efficacy and reducing side effects through overcoming 
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major obstacles in cancer therapy such as nonspecific biodistribution with 
consequent dose-limiting toxicity and multidrug resistance (MDR) 150. Up-
regulation of TfR expression in a wide variety of cancers, its function and highly 
efficient recycling pathway, provides a gate for intracellular gene and drug 
delivery to BLBC in a tumor-specific manner 151. Thus, Tf-PEI could potentially 
deliver siRNA in a targeted way to BLBC overexpressing TfR.  
In this chapter, we evaluated two Tf-SPDP-PEI and Tf-SPDP-PEG-PEI 
conjugates, which were conjugated using two different linkers, SPDP and PEG4- 
SPDP, in different breast cancer cell lines or immortalized breast cell line. We 
identified a new siRNA sequence that efficiently reduces GASC1 expression if 
delivered intracellularly. Efficiency of GASC1 silencing was determined in BLBC 
cells overexpressing GASC1, and the inhibition of proliferation was investigated. 
To the best of our knowledge, this is the first report of developing a BLBC-
targeted delivery system with a newly identified siRNA for therapeutic GASC1 
gene knock down. Therefore, our approach is promising for therapeutic targeting 
of hard-to-treat BLBC and could result in new receptor mediated therapy options 
for BLBC. 
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4.2 Materials & Methods: 
4.2.1 Materials 
Polyethylenimine (PEI, MW 5 kDa) was obtained from BASF (Lupasol 
G100, Ludwigshafen, Germany). N-succinimidyl-3-(2-pyridyldithio) propionate 
(SPDP), a PEGylated SPDP (PEG4-SPDP), Lipofectamine® 2000, trypsin, 
penicillin/streptomycin, 4(2(hydroxyethyl))-1-piperazine ethanesulfonic acid 
(HEPES), heparin sodium (140,000 U/g), were purchased from Thermo Fisher 
Scientiﬁc (Waltham, MA, USA). Anti-human CD71 (transferrin receptor) PE was 
acquired from (eBioscience, CA, USA). Dithiothreitol (DTT) was purchased from 
Alfa Aesar, MA, USA. SYBR Gold dye and CellTiter-Blue® were obtained from 
Life Technologies (Carlsbad, CA, USA). RPMI-1640 medium (1X) with 2.05 mM 
L-glutamine, Ham's F-12 Medium, trypan blue (0.4%, sterile ﬁltered) was 
purchased from HyClone (GE Health Care, Pittsburgh, PA, USA). Human holo 
Transferrin (80 kDa) was obtained from Calbiochem (Billerica, MA, USA). 
Dulbecco’s phosphate buﬀered saline (PBS), fetal bovine serum (FBS), D (+)-
glucose, 2-mercaptoethanol, dimethyl sulfoxide (DMSO, ≥99.7%), sodium 
bicarbonate (NaHCO3) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
DNase I reaction buﬀer and DNase/RNase-free water were purchased from Zymo 
Research (Irvine, CA, USA). Hs_GASC1 primer (forward and reverse) and 
sequences V4, V6, and V7 (self-designed siRNA against GASC1 using the 
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GENtle software by Magnus Manske) were ordered from Invitrogen (Life 
Technologies, Carlsbad, CA, USA). Commercially available GASC1 specific 
siRNA was purchased from Qiagen (Valencia, CA, USA) for sequences A, B, C 
and D. SMART pool and sequences E, F, G and H (Table 3) were purchased from 
Dharmacon (Thermo Fisher, Waltham, MA, USA). 
Table 3 Sequence of siRNA 
 
Sequence 
name 
Sequences 
Negative 
Control 
MISSION® 
siRNA 
Universal 
Negative 
Control #1 
 
hGAPDH IDT 
5’-
GGUCGGAGUCAACGGAUUUGGUC[dG][dT
] 
3’-
UmUmCCmAGmCCmUCmAGmUUmGCmCU
mAAACCAGCA 
hGASC1 V4 
5’-ACCGAAGACAUGGACCUCU[dT][dT] 
3’-[dT][dT]UGGCUUCUGUACCUGGAGA 
hGASC1 V6 
5’-CAGAAUUUAUCAGAUCAUA 
3’-[dT][dT]GUCUUAAAUAGUCUAGUAU 
hGASC1 V7 
5’-GUGAAGAUUUCAAUGGAUA[dT][dT] 
3’-[dT][dT]CACUUCUAAAGUUACCUAU 
hGASC1- A Hs_KDM4C1 
5’-CGAAGCUUCCAGUGUGCUA[dT][dT] 
3’-[dG][dG]GCUUCGAAGGUCACACGAU 
hGASC1- B Hs_JMJD2C3 
5’-GAUAUUAAUGGGAGCAUAU[dT][dT] 
3’-[dG][dT]CUAUAAUUACCCUCGUAUA 
hGASC1- C Hs_JMJD2C4 
5’-CCAGAAGUUCGAUUCACUA[dT][dT] 
3’-[dA][dG]GGUCUUCAAGCUAAGUGAU 
hGASC1-D Hs_JMJD2C5 
5’-CAUCGGAGGGAAAGACUAA[dT][dT]  
3'-[dA][dT]GUAGCCUCCCUUUCUGAUU  
hGASC1- E J-004293-12 
5’-GAGAAGUCGUCCAAGUCAAUU 
3’-UUCUCUUCAGCAGGUUCAGUU 
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hGASC1- F J-004293-11 
5’-GCAUAUAUGAUGAGGGUGUUU 
3’-UUCGUAUAUACUACUCCCACA 
hGASC1- G J-004293-10 
5’-ACGAAGAUUUGGAGCGCAAUU 
3’-UUUGCUUCUAAACCUCGCGUU 
hGASC1-H J-004293-9 
5’-AUUACAUGCUUUCGACAUAUU 
3’-UUUAAUGUACGAAAGCUGUAU 
 
* Deoxyribonucleotides are presented in parentheses with the letter d, and 2’O-
methylated ribonucleotides are denoted with the letter m. The letter p indicates an 
additional phosphate.   
4.2.2 Cell lines characteristic and culture conditions  
The non-tumorigenic human mammary epithelial cell line MCF10A and 
human breast cancer cell line HCC1954 were purchased from the American Type 
Culture Collection (Manassas, VA, USA). The COLO824 cell line was obtained 
from DSMZ (Germany), and the cell lines SUM102, SUM225, SUM52, SUM149 
were a kind gift from Dr. Stephen P Ethier (Department of Pathology and 
Laboratory Medicine, Medical University of South Carolina). The COLO824 and 
HCC1954 cell lines were retained and grown in RPMI-1640 cell culture medium 
supplemented with 10% fetal bovine serum. MCF10A and SUMs cell lines were 
cultured in a special DMEM/F12 media, containing 1% EGF (10 ng/ml), 0.1% 
hydrocortisone (1µg/ml), and 0.5% insulin (5 µg/ml). The cell lines characteristics 
are shown in Table 4. 
4.2.3 Transferrin receptor expression study 
Selected breast cancer cell lines were used to evaluate transferrin receptor 
expression levels (CD71, TfR) by flow cytometry. Of each cell suspension, 
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200,000 cells were transferred into an Eppendorf tube and spun down (350g for 5 
min). The cell pellet was washed with PBS containing 2 mM EDTA. Afterwards, 
PE-labeled CD71 antibody and its corresponding isotype control were each added 
to assigned cell samples and incubated for 30 min at 4°C before analysis by flow 
cytometry (Attune acoustic focusing cytometer Life Technologies, Carlsbad, CA). 
Blank cells were not stained with any antibody. The excitation wavelength of 488 
nm and an emission filter at 585 nm/42 nm were used. Cell gating and data 
analysis in the Attune cytometric software were performed using cell morphology 
and mean fluorescence intensity (MFI), respectively. The mean values and 
standard deviation (SD) of experiments with n=3 are shown. 
Table 4 Different breast cell line model and their specifications 
Cell line Cell Source Subtype PR ER Her2/neu GASC1 
HCC1954 
Grade III invasive ductal 
carcinoma 
Basal - - + +++ 
COLO824 
Mammary gland 
carcinoma 
Basal - - - +++ 
MCF10A 
Mammary gland- 
immortalized 
 - - - - 
SUM102 
Intraductal 
carcinoma/microinvasion 
Basal - - - - 
SUM225 
Chest wall recurrence of 
ductal carcinoma 
HER2+ - - + - 
SUM149 
Invasive ductal 
carcinoma 
(inflammatory) 
Basal - - - + 
SUM52 Pleural effusion Luminal - + - - 
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4.2.4 Specific binding of transferrin to the corresponding receptor 
To analyze the specificity of transferrin binding to TfR, Tf was 
fluorescently labeled with FITC (Invitrogen™, life Technologies). Bovine serum 
albumin (BSA) was used as a control. Transferrin and BSA were dissolved in 0.1 
M of NaHCO3. A ten-fold molar excess of FITC (dissolved in DMSO) was 
incubated with transferrin and BSA overnight at 4°C. The protein-FITC 
conjugates were subsequently separated from unbound FITC by gel permeation 
method (Sephadex G25 M, GE Healthcare PD-10 columns) using 20 mM HEPES-
150 mM NaCl buffer. The BCA protein assay (Thermo Scientific) was used to 
measure the final concentration of transferrin and albumin after purification. The 
presence of FITC was found to not impact the measurements at the applied 
concentrations. After purification and characterization of the labeled (glyco-) 
proteins, HCC1954 and MCF10A cell lines (60,000 cells in 24 well plates) were 
incubated with different amounts of FITC-transferrin or FITC-BSA (20, 200 and 
400 pmol) for 4 h at 37°C and 5% CO2. Flow cytometry was used as described 
above to measure the binding of Tf-FITC or albumin-FITC to the cells with the 
emission filter set to 530/30 nm bandpass. 
4.2.5 Conjugation synthesis and characterization 
Two different heterobifunctional crosslinking agents, namely (N-
succinimidyl-3-(2- pyridyldithio) propionate (SPDP) and a PEGylated SPDP 
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(PEG4-SPDP) containing four ethylene glycol units were used to conjugate 
transferrin to a 5 kDa LMW PEI as described before 20. PEI (1 mg/ml) was reacted 
with SPDP or PEG4-SPDP (20 mM) in DMSO stirring at room temperature 
overnight (1:10 molar ratio relative to amines present). The intermediate products 
were purified by ultrafiltration using Amicon® Ultra 4 ml filters (MWCO 3000) 
and Vivaspin centrifugal ultra-filters (10,000 MWCO) as described 61. The 
conjugates were separated from uncoupled Tf-SPDP by ion exchange FPLC via 
ÄKTA prime plus (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) as reported 
152. The products (Tf-PEI and Tf-PEG-PEI) were preserved at 4ºC until use. The 
degree of SPDP coupling onto PEI was determined as previously reported by 
spectrophotometric detection of release of the pyridine-2-thione group 47. The 
characterization of the final products was performed by spectrophotometric 
detection of transferrin at 280 nm compared to standard curve 152 and 
quantification of PEI amines in using a modified TNBS method 153 in presence of 
the respective amount of transferrin as described by Germershaus et al. 152.  
4.2.6 Preparation of siRNA-polymer nanoparticles 
For preparing nanoparticles based on electrostatic interaction resulting in 
the formation of polyelectrolyte complexes, or polyplexes, the PEI/siRNA charge 
ratios (defined as N/P ratios) were calculated based on PEI nitrogen (N) groups 
per siRNA phosphate (P) groups. 75b. Polymer (1 mg/ml) and siRNA (100 μM) 
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stock solutions were diluted with a 5% glucose solution (pH 7.4, prepared with 
RNase free water). Equal volumes of PEI or modified PEI and siRNA solutions 
were mixed to result in the respective N/P ratio, vortexed for 30 s, and incubated 
for 20 min at room temperature before use. 
4.2.7 Analysis of hydrodynamic diameters and zeta (ζ)-potentials  
The hydrodynamic diameters and zeta potential of polyplexes prepared with 
40 pmol siRNA and polymer at N/P 7 were measured in PBS using a Zeta sizer 
Nano ZS (Malvern Instruments Inc., Westborough, MA, USA) and the refractive 
index and viscosity settings for water. Dynamic light scattering (DLS) was 
detected at 25°C at an angel of 173°. Results from triplicate samples are shown as 
Z average in nanometers ± SD. Samples were then diluted with 700 μL of PBS 
buffer for ζ-potential measurements. Results of three independent measurements 
are given in millivolts ± SD.  
4.2.8 Atomic force microscopy 
Polyplex morphology was determined using atomic force microscopy 
(AFM). For image acquisition, a drop of polyplexes prepared at N/P 7 was 
incubated for 5 min on freshly cleaved mica surface. Excess solution was rinsed 
off with deionized water, and the mica was dried and imaged at room temperature 
using a Pico LE atomic force microscope (Molecular Imaging, Agilent 
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Technologies) with a Si3Ni4 V-shaped cantilever in contact mode  as described 
before 75b.  
4.2.9 SYBR Gold condensation assays 
The capacity of the Tf-PEI and Tf-PEG-PEI to condense siRNA at different 
N/P ratios (0-20) was evaluated in SYBR Gold assays, and PEI (5 kDa) was used 
as control. Formulations with 50 pmol of siRNA per well were placed in 96-well 
plate, vortexed and incubated at room temperature for 20 min. Fluorescence 
(Ex/Em: 495/537 nm) was measured after 10 min of incubation with a 4x SYBR 
Gold solution using a Synergy 2 microplate reader (BioTek, Winooski, VT, USA).  
4.2.10 Stability of siRNA/PEI complexes - heparin dissociation assays 
Polyplex formulations with 50 pmol of siRNA per well prepared at N/P 7 
were incubated with a fixed heparin concentration (0.2 IU) over varying periods of 
time (5-180 min). Fluorescence was measured with a Synergy 2 microplate reader 
(BioTek Instruments) after adding a 4x SYBR Gold solution (Ex/Em: 495/537 
nm). The mean values of three fluorescence intensity measurements of SYBR 
Gold dye only (0) and of three samples of SYBR Gold intercalating with free 
siRNA (1) were used for normalization and calculation of the relative stability of 
the polyplexes. Results of triplicate samples are shown as mean values ± SD.  
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4.2.11 Quantiﬁcation of cellular siRNA uptake by flow cytometry 
Cells were seeded with 80,000 cells per well in 24-well plates 24 h before 
they were transfected with polyplexes prepared with 50 pmol of Alexa Fluor 488-
labeled siRNA per well at N/P 7. Negative controls included untreated cells and 
cells treated with free Alexa Fluor 488-labeled siRNA. PEI (5 kDa) was used as a 
positive control for comparison. After 4 h of transfection with 100 μL of 
polyplexes, 1 ml of medium was added and cells were incubated at 37°C and 5% 
CO2 for another 24 h. The cells were washed with PBS and trypsinized. 
Intracellular fluorescence from siRNA was detected using an Attune® Acoustic 
Focusing Flow Cytometer (Thermo Fisher Scientific, Carlsbad, CA) and 
corresponding software. For the distinction between internalized and surface-
bound siRNA, trypan blue (0.4%) was used to quench surface-bound fluorescence. 
Data were analyzed after gating for 10,000 viable cells, and median fluorescence 
intensity (MFI) values are given for three independent studies.  
4.2.12 Confocal laser scanning microscopy 
HCC 1954 cells were seeded in 8 well chamber slides at a density of 25,000 
cells per well (Permanox® Slide, Nunc, Thermo Fisher Scientific) and allowed to 
grow for 24 h at 37°C in 5% CO2. Polyethylenimine (PEI), Lipofectamine (LF) or 
Tf-PEI polyplexes made with Tye563-labeled siRNA (Ex/Em: 543/563 nm) were 
used to transfect cells as described earlier. Subsequently, the cells were washed 
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with PBS and fixed using 3% paraformaldehyde (Affymetrix, Cleveland, OH, 
USA) for 30 min, followed by nuclei staining with DAPI (Ex/Em: 405/470 nm). 
Finally, the cells were embedded using Fluorsave reagent (Calbiochem, Merck, 
Darmstadt, Germany) and covered with a coverslip. The images were recorded 
with a Zeiss LSM 780 microscope (Zeiss, Oberkochen, Germany). Representative 
pictures are shown in Figure 24  (100X magnification). 
4.2.13 Cytotoxicity of polyplexes 
Cells (HCC1954, COLO824, SUM102 and MCF10A) were seeded at a 
density of 10,000 cells in a 96-well plate (Thermo Scientific) and incubated for 24 
h at 37°C and 5% CO2. Polyplexes containing 50 pmol of siRNA were added to 
the cells, and plates were incubated for 24 h at 37°C. Subsequently, CellTiter-
Blue® reagent was added directly to each well, the plates were incubated at 37°C 
for 2 h to allow the cells to convert resazurin to resorufin.  The obtained 
fluorescence was measured at Ex/Em 560/590 nm. The percentage of cell viability 
and proliferation was calculated as the ratio between the fluorescence of a sample 
and the untreated control cells as follows: ([A] test/ [A] control) ×100%. Results 
are shown as the mean value ± SD of triplicate samples. 
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4.2.14 Knockdown measured by qRT-PCR and western blot 
HCC1954 cells were seeded with 500,000 cells per well in 6-well plates 
(Corning Incorporated) and were incubated for 24 h before transfection.  at 37°C 
and 5% CO2. PEI, Tf-PEI, and Tf-PEG-PEI polyplexes were prepared with 100 
pmol of GASC1 siRNA at N/P 7 in a total volume of 100 μL and were added to 
900 µL of cell culture medium per well. The cells were incubated with the 
polyplexes for 4 h before 2 ml of fresh medium were added to each well. The cells 
were then incubated for an additional 24 for PCR or 72 h for Western Blot 
analysis. Lipofectamine (LF) (0.5 μL/10 pmol of siRNA) was used as a positive 
transfection control. Cells were transfected with samples in fresh medium and 
subsequently cells were washed with PBS and lysed with lysis buffer (PureLink 
RNA mini, Ambion, Fisher Scientific, USA). Total RNA was then isolated from 
cells according to the manufacturer’s protocol with supplementary DNase I 
digestion; mRNA was mixed with qScript™ cDNA SuperMix kit (Quanta 
Biosciences, Gaithersburg, MD, USA), then converted into cDNA through a 
reverse transcription reaction for real time PCR (eppendorf Mastercycler gradient, 
Hauppauge, NY, USA). Primers set for GASC1 genes were ordered from 
Invitrogen (Life Technologies). A PUM1 primer (Qiagen, Valencia, CA, USA) 
was used for normalization. Semi-quantitative RT-PCR was performed using the 
FastStart Universal SYBR Green Master (ROX) using a Bio-Rad iCycler Thermal 
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Cycler (IQ 5™ multicolor read thermal PCR). Results are given as the average of 
n =3 ± SD.  
For measuring protein levels after transfection of the HCC1954 cell lines 
with modified PEI formulations, western blot analysis was performed after protein 
extraction of the transfected cells following a 7 day in vitro incubation based on 
previous protocol optimization. The cells were lysed in RIPA buffer containing 
protease inhibitor cocktail (Calbiochem, CA, USA). Samples were size-
fractionated by 7.5% SDS-PAGE (XCell SureLock™ Mini-Cell) and the blot was 
transferred to Immunobilon-PVDF membranes (Millipore, Bedford, MA, USA). 
The blot was then incubated in blocking buffer (5% milk, 0.1% Tween in TBS 
buffer) at room temperature for 1 h and subsequently incubated with rabbit anti-
JMJD2C antibody (Bethyl Laboratories, Inc. Montgomery, TX, USA) in 
precooled blocking buffer overnight at 4 °C. After washing in TBS/0.1% Tween, 
The blot was incubated with horseradish peroxidase (HRP)-labeled anti-rabbit 
secondary antibody at room temperature for 1 h. After washing with TBS/0.1% 
Tween, the blot was developed by enhanced chemiluminescence (Thermo 
Scientific SuperSignal™ West Pico, MA, USA), and visualized with a hyblot CL 
film (Denvilla, NJ, USA). 
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4.2.15 Therapeutic effects of GASC-1 gene knockdown on cell proliferation 
Therapeutic effects on cell proliferation were measured in MTT assays after 
transfection with siRNA against GASC1 or a scrambled control. In 24-well plates 
(Corning Incorporated), HCC1954 cells were seeded at a density of 8,000 cells per 
well and incubated for 24 h at 37°C and 5% CO2. Polyplexes were prepared with 
50 pmol of GASC1 siRNA or a scrambled negative control siRNA, and the cells 
were transfected on days 1, 3, and 6 after seeding. MTT assays were performed as 
described above on days 2 and 10 after seeding. The results are shown as mean 
values ± SD of 3 independent measurements in comparison to proliferation of 
untreated cells.  
4.2.16 Statistical analysis 
Results from all experiments represent at least three independent 
measurements and are presented as mean value ± SD as analyzed by Graph Pad 
Prism 6.0 software (GraphPad Software, La Jolla, CA, USA). Statistical tests were 
either one or two way ANOVA with a Bonferroni post hoc analysis (significance 
level 0.05). Significantly different results are indicated with an asterisk (*) in 
figures. Corresponding significance values are: * P < 0.05, ** P < 0.01, *** P < 
0.001 and **** P < 0.0001. 
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4.3 Results 
4.3.1 Screening for TfR expression levels 
Transferrin receptor expression levels were determined via flow cytometry 
in a series of breast cell lines which were characterized as GASC1 positive or 
negative breast cell line to select a valid cell line model and its controls for the 
targeted siRNA delivery 146b. The receptor expression of TfR (CD71) was 
compared to the MCF10A cell line, an immortalized, non-transformed epithelial 
cell line, showing no GASC1 amplification 146b. The expression was verified using 
a PE-labeled anti-CD71 antibody. Non-specific binding of the antibody was 
precluded based on experimental results using an isotype IgG (negative control) 
and non-treated cells (blank). PE-labeled CD71 antibody and its corresponding 
isotype control were each added to assigned cell samples. Figure 16 depicts that 
MCF-10A cells bear only basal levels of TfR whereas the expression level in 
HCC1954 cells was almost 9-fold higher than in MCF10A. Therefore, HCC1954 
cells were selected as cell model to verify GASC1 knock down via targeting the 
internalizing transferrin receptor. Screening of TfR expression levels in other 
breast cancer model cell lines showed that GASC1-amplified COLO824 cells 
present higher TfR expression levels than SUM102, SUM52 (p < 0.001) and 
MCF10A (p < 0.0001) but TfR levels were not significantly different between 
COLO824, SUM149, and SUM225 cell lines (P > 0.05). Therefore, all three of 
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those cell lines could be used as another valid cell culture model for therapeutic 
GASC1 knockdown. 
 
 
Figure 16 TfR expression in different breast cell lines. Screening of TfR 
expression levels in different cancer cell lines compared to MCF 10A cells. Using 
flow cytometry, TfR over-expression on the breast cancer cell line HCC1954 was 
verified, which also shows a comparably high GASC1 amplification. The 
transferrin receptor expression (CD71, TfR) was compared to the MCF-10A cell 
line, an immortalized, non-transformed epithelial cell line, showing no GASC1 
amplification. The expression was verified by using a PE-labeled anti-CD71 
antibody and non-specific binding of the antibody was precluded based on results 
with an isotype control. Data are expressed as the mean ± SD (n = 3), ns: non-
significant, **** p < 0.0001. 
4.3.2 Specific binding of Tf to transferrin receptor 
To confirm the endocytosis activity of Tf receptors on cell lines determined 
to overexpress the receptor, HCC1954 and MCF10A cell lines were incubated 
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with FITC-labeled transferrin in comparison to FITC-labeled albumin. The same 
amount of transferrin (20 pmol) as used in the Tf-PEI uptake experiment was 
chosen, and results were compared to higher amounts of transferrin or albumin 
(200 and 400 pmol). Quenching of non-internalized Tf or albumin was achieved 
by trypan blue treatment. Figure 4. clearly shows that a 2.3-fold increase in Tf 
internalization is detectable in the HCC1954 cell line compared to albumin after 
incubation with 20 pmol FITC-labeled proteins. Meanwhile, FITC-transferrin 
showed an almost 3-fold higher internalization in HCC1954 cells compared to 
MCF10A for the same amount of transferrin. There was no significant difference 
in the uptake of FITC-Tf in the MCF10A cell line compared to FITC-albumin (p > 
0.05). A notable increase in MFI of the HCC1954 cell line was detected with 
increasing the amount of FITC-transferrin from 20 to 200 and 400 pmol (p < 
0.0001), however this was not the case for FITC-albumin (p > 0.05). The MFI in 
MCF10A cell lines with basal levels of TfR, however, did not change with 
increasing the amount of transferrin from 20 to 200 pmol or 200 to 400 pmol (p > 
0.05).  
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Figure 17 Cellular binding of Tf. Comparison of FITC-Transferrin or FITC-
Albumin internalization in HCC1954 (lower left bar graph) and MCF10A (lower 
right bar graph) cell lines at different concentrations of transferrin and albumin via 
flow cytometry. Data are expressed as the mean ± SD (n = 3), ns: non-significant, 
**** p < 0.0001. 
4.3.3 Development of transferrin-PEI conjugate 
Coupling procedures for the synthesis of Tf-PEI conjugates are illustrated 
in Figure 18. SPDP and its PEGylated form (PEG4-SPDP) with a 25.7 Å ethylene 
glycol spacer are amine- and sulfhydryl- reactive heterobiofunctional cross linkers 
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that produce disulfide-containing linkages which are stable extracellularly but can 
be cleaved intracellularly 154. This design was chosen to prevent premature release 
of the targeting ligand but will mediate release of the nanoparticle from Tf and the 
recycling TfR inside the cell.  
 
Figure 18 Schematic illustration of transferrin crosslinking with PEI by SPDP.  
4.3.4 Physicochemical properties of the nanoparticles 
Based on DLS and zeta potential measurements, both Tf-PEI and Tf-PEG-
PEI more efficiently formed dense polyplexes with siRNA than non-modified 5 
kDa PEI (Figure 19). Tf-PEI/siRNA and Tf-PEG-PEI/siRNA complexes at N/P 7 
were compactly packed with 30 and 140 nm hydrodynamic diameters, respectively, 
125 
 
 
 
 
and narrow size distributions (PDI: 0.1). However, PEI/siRNA exhibited larger 
mean diameter of 700 nm with somehow broader distribution (PDI: 0.4). In 
addition, the zeta potentials of Tf-PEI (-0.6 ± 0.07 mV) and Tf-PEG-PEI (-0.01± 
0.04 mV) complexes with siRNA were lower than those of PEI (39.9 ± 7 mV) 
complexes, implying that most of the positively charged portion of PEI in was 
shielded by Tf in the Tf-modified polyplexes. These results reveal that modified 
PEI produced significantly smaller and more compact structures with siRNA 
compared to PEI at the same N/P ratio.  
 
Figure 19 Size and zeta-potential of Tf-PEI, Tf-PEG-PEI and PEI polyplexes. 
Hydrodynamic diameter (nm) and zeta potential (mV) of siRNA polyplexes made 
with PEI,  Tf-PEI, and Tf-PEG-PEI at N/P ratio of 7 at room temeprature. Data are 
expressed as the mean ± SD (n = 3). 
The same trend was observed via AFM imaging which showed the 
tendency of PEI polyplexes to aggregate into particles of several hundred 
nanometers in size, whereas the morphology of the Tf-PEI complexes was more 
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homogenous, the size distribution was narrow, and the particles didn’t show any 
aggregation tendency (Figure 20). In additional experiments, the capacity of PEI 
and the modified PEI polymers to condense siRNA at different N/P ratios was 
evaluated by SYBR Gold condensation assays. In these experiments, free 
(unbound) siRNA is accessible to the intercalating dye SYBR Gold. The free 
siRNA is thus subsequently quantified on the basis of fluorescence emitted after 
SYBR Gold treatment. Results were compared to PEI (5 kDa) as a control (Figure 
21). PEI and Tf-PEI showed better siRNA condensation at N/P ratios 1-5, but all 
formulations showed similar condensation efficiency at N/P ratio of ≥ 7.   
 
Figure 20 AFM images of Tf-PEI and PEI polyplexes. AFM topography of siRNA 
polyplexes made with PEI (left) and Tf-PEI (right) at N/P ratio of 7 and imaged 
after drying at room temeprature.  
A heparin-induced decomplexation stability test was performed to 
determine the stability of the polyplexes. The release profiles of siRNA from all 
polyplexes reached a maximum siRNA release after 30 min of incubation and then 
leveled off over the remaining incubation time (Figure 21). After 30 min of 
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incubation with 0.2 IU heparin, PEI and Tf-PEG-PEI displayed around 50% and 
85% of siRNA release, respectively, but Tf-PEI showed only 25% of siRNA 
release at that time point (Figure 22). The siRNA release from Tf-PEI polyplexes 
initially increased, then decreased gradually and remained unchanged (7%) until 
the end of the experiments (180 min) (Figure 22).  
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Figure 21 SYBR Gold assay of Tf-PEI, Tf-PEG-PEI and PEI. Condensation 
efficiency of Tf-PEI and Tf-PEG-PEI complexes with siRNA measured by SYBR 
Gold assay at different N/P ratios (1-20) compared to polyethylenimine (PEI 5 
kDa). Results are given as the average of three measurements ± SD. (n = 3). 
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Figure 22 Heparin assay of Tf-PEI, Tf-PEG-PEI and PEI. Release profile of 
siRNA from transferrin modified polyplexes (N/P 7; 50 pmol siRNA/well) 
compared to polyethylenimine (PEI 5 kDa) as a function of time (0-185 min) with 
heparin concentration of 0.2 IU per well. Results are shown as relative mean 
fluorescence ± SD. (n = 3). 
4.3.5Cellular uptake of the nanoparticles  
Cellular uptake of polyplexes with 50 pmol of Alexa Fluor 488-labeled 
siRNA (N/P 7) was quantified in different cell lines (GASC1 positive and GASC1 
negative) by flow cytometry. Trypan blue staining was employed on half of the 
samples to differentiate between surface bound and internalized siRNA.  The 
results were compared to cells that were not treated with trypan blue, while cells 
treated with trypan blue are indicated with an asterisk in Figure 23. Overall, trypan 
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blue treated cells showed slightly lower mean fluorescence intensities compared to 
cells that did not undergo quenching of surface-bound siRNA, indicating that a 
small fraction of the siRNA polyplexes was attached to the cell membrane and 
was not taken up intracellularly. However, this difference was not significant in 
any of the samples (p > 0.05). As can be seen in Figure 23, there is a significant 
difference (p < 0.0001) in uptake of PEI/siRNA in GASC1 positive cell lines 
(HCC1954 and COLO824) and GASC1 negative cells (MCF10A and SUM102). 
Interestingly, PEI alone showed better uptake in MCF10A and SUM102 which 
could be caused by higher endocytic activity of these two cell lines 155. However 
PEI conjugated transferrin (Tf-PEI and Tf-PEG-PEI) showed very high uptake in 
the HCC1954 cell line which was expected due to the higher level of TfR 
expression. The uptake efficiency of Tf-PEI polyplexes did not show any 
significant differences between HCC1954 and SUM102 cell lines (p > 0.05), 
although the TfR expression of HCC1954 cells is about 4 times higher than that of 
SUM102 cells (Figure 16). The mean fluoresce intensity in HCC1954 cells treated 
with Tf-PEI polyplexes was 2.5 and 10-fold higher than in MCF10A and 
COLO824 cells, respectively. As can be seen in Figure 23, Tf-PEG-PEI/siRNA 
polyplexes showed 2.6 times higher uptake in HCC1954 than in SUM102 cells. 
Uptake efficiency of the conjugates containing the PEG-spacer was 3.6 and 6 fold 
higher in HCC1954 than MCF10A and COLO824 cells, respectively (Figure 23). 
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Figure 23 Cellular uptake of Tf-PEI, Tf-PEG-PEI and PEI. Comparison of siRNA 
uptake with different formulations (Blank (untreated cells), PEI (positive control), 
Tf-PEI, Tf-PEG-PEI) in GACS1 positive (HCC1954 and COLO824) and GASC1 
negative (MCF10A and SUM102) cell line models after fluorescence quenching of 
membrane bound nanoparticles with trypan blue (asterisks indicate cell samples 
treated with trypan blue). Data are expressed as the mean ± SD (n = 3), ns: non-
significant. 
The intracellular uptake of the nanoparticles was then analyzed by confocal 
microscopy (Figure 24). The images obtained revealed the presence of 
concentrated fluorescence after 4 h of incubation with Tf-PEI conjugates. The 
internalization was detected using a Tye 563 labeled siRNA (Figure 24). Higher 
nanoparticle binding to the cell surface and cell entry of the Tf-PEI conjugate 
131 
 
 
 
 
compared to LF and polyethylenimine was visible. Interestingly, PEI delivered 
fluorescently labeled siRNA was not detected by microscopy which was consistent 
with the flow cytometry results showing very poor uptake of PEI polyplexes in 
HCC1954 cells. 
 
Figure 24 CLSM images of Tf-PEI and PEI. Confocal microscopy images of 
cellular interaction of different complexes with the HCC1954 cell line after 4 h 
incubation with siRNA polyplexes. HCC1954 cells were seeded with 25,000 cells 
per chamber and transfected with 25 pmol siRNA (Tye 563 labeled, indicated by 
red color) for 4 hours. Cells were fixed and the nuclei stained with DAPI 
(indicated by blue color). Representative pictures are shown (100X magnification). 
A) Blank; and siRNA polyplexes with B) Lipofectamine; C) Tf-PEI (N/P 7); and 
D) PEI (N/P 7). 
4.3.6 Cytotoxicity  
In order to test one aspect of biocompatibility of the nanoparticle systems 
investigated here, the cytotoxicity of PEI and Tf-shielded polyplexes was analyzed. 
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The rate of viability was assessed by CellTiter-Blue® assays which are based on 
the ability of active mitochondria to convert a redox dye (resazurin) into a 
fluorescent end product (resorufin). Neither the conjugate polyplexes (Tf-
PEI/siRNA and Tf-PEG-PEI/siRNA) nor PEI/siRNA at N/P 7 appeared to have 
any apparent cytotoxicity, and cell survival rates greater than 85% were 
maintained for all treatments (Figure 4.25). There is a significant change in cell 
viability observed alone in PEI treated COLO824 cells compared to Tf-PEI (p < 
0.05). No significant differences in cytotoxicity amongst the different cells lines 
were observed (p > 0.05). 
 
Figure 25 Cytotoxicity  of PEI, Tf-PEI and Tf-PEG-PEI polyplexes. Cytotoxicity 
profile of siRNA polyplexes made with Tf-PEI or Tf-PEG-PEI measured by the 
Cell Titer-Blue method compared to PEI/siRNA polyplexes. HCC1954, COLO824, 
SUM102 and MCF10A cell lines were treated with polyplexes for 4 h and the 
viability of cells was measured after 24 h. Cell toxicity is presented as impaired 
cell viability as a percentage relative to control cells. Data are expressed as the 
mean ± SD (n = 5). * P < 0.05. 
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4.3.7 GASC1 knockdown optimization 
To identify the amount of GASC1 knock-down on the mRNA level, several 
transfection parameters were optimized and determined by RT-PCR. The primary 
studies were performed with 9 commercially available siRNA sequences [(A-D) 
and (E-H and mixed)] to screen their efficacy against GASC1 since no validated 
sequences are available. LF was used as standard transfection agent. Figure 26 
shows the GASC1 knock down efficiency in HCC1954 cells with the above 
mentioned siRNA sequences. Among the different sequences, the strongest 
relative reduction in GASC1 RNA was achieved with sequence “A”. However, 
there was no significant difference between A and sequences C, D and E (p > 
0.05). Based on this result, sequence “A” was applied for further optimization 
experiments. 
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Figure 26 optimization of GASC1 siRNA sequence. GASC1 gene knock down 
optimization with different siRNA sequences [(A-D sequences from Qiagen) and 
siRNA sequences E-H and pooled siRNA from Dharmacon]. Per well, 500,000 
HCC1954 cells were transfected with lipofectamine2000 (LF) for 24 hours with 
100 pmol of different siRNA sequences against GASC1. RT-PCR was performed 
with specific GASC1 primers, normalization was carried out against the 
housekeeping gene PUM1. (NC=scrambled siRNA; error bars reflect SD, n=3). * 
P < 0.05 and ** P < 0.01. 
 Gene silencing efficiencies were investigated after 6, 17, 24, 48 h post 
transfection (Figure 27). Clearly, the GASC1 mRNA level was reduced 
significantly after 24 h but was not significantly further reduced 48 h post 
transfection (p > 0.05). However, there was no measurable gene knock down 
compared with the negative/non treated control at the 6h and 17 h time points. 
Additionally, the GASC1 mRNA levels measured at 6 h and 17 h were not 
significantly different as well as the levels measured at 17 h and 48 h post 
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transfections with sequence “A” (Figure 27). The optimum transfection time point 
of 24 h was then used to probe the effect of different siRNA doses (100, 150, 200, 
250 pmol). However, the most efficient gene knockdown was already achieved at 
100 pmol, so that further optimization was not successful.  
 
Figure 27 GASC1 gene knock down optimization. GASC1 gene knock down 
optimization with siRNA sequence A in HCC1954 cells at different time points 
(A), or different siRNA concentrations 24 h post transfection (B). 
Lipofectamine2000 (LF) was used as transfection agent and RT-PCR was 
performed with specific GASC1 primers, normalization was carried out against 
the housekeeping gene PUM1. (NC=scrambled siRNA; error bars reflect SD, n=3), 
ns: non-significant,* P < 0.05, *** P < 0.001 and **** p < 0.0001. 
As these sequences did not reach an acceptable and therapeutically relevant 
level of knock down, we designed three new sequences of GASC1 siRNA (named 
V4, V6 and V7) using GENtle software. Figure 28 A presents the results of mRNA 
knock down with the newly-designed GASC1 siRNA duplexes. GASC1 siRNA 
(V4, V6 and V7, 100 pmol) were used to transfect HCC1954 cells with LF, PEI and 
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the different Tf-modified nanobioconjugates. hGAPDH siRNA was used as a 
positive control. Among the different siRNA sequences, V7 showed the most 
efficient mRNA reduction with LF which was comparable with the positive 
control. Additionally, the Tf conjugate (Tf-PEI) also showed promising knock 
down with sequence V7. There was no significant difference between the mRNA 
knock down achieved with V7 when delivered with PEI or Tf-PEG-PEI. To verify 
the result of the RT-PCR assay, we performed western blot analysis to quantify the 
target protein levels. The analysis indicated that cells treated with the optimized 
Tf-PEI polyplexes with GASC1 siRNA (N/P 7) expressed less GASC1 protein 
compared to lysates of cells that were treated with scrambled control or non-
targeted PEI/GASC1 siRNA complexes as was predicted based on the RT-PCR 
results (Figure 28 B). 
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Figure 28 RT-PCR and western blot of GASC1 knock down. (A) GASC1 
knockdown of Tf-PEI with siRNA sequence V7 shows that the conjugate was able 
to knock down mRNA levels of GASC1 more efficient than the commercially 
available siRNA sequences in HCC1954 cells. (V4, V6 and V7 are self-designed 
GASC1 siRNA sequences. NC=scrambled siRNA; PC=positive control siRNA 
(hGAPDH), error bars reflect SD, n=3), ns: non-significant,* P < 0.05, ** P < 0.01, 
*** P < 0.001 and **** p < 0.0001. (B) GASC1 protein knockdown in HCC1954 
cells with Tf-PEI compared to PEI alone was confirmed by western blot. Alpha-
tubulin was used as the loading control. Top row shows (A: PEI/ V7GASC1 
siRNA, B: PEI/NC siRNA, C: Tf-PEI/V7GASC1, D: Tf-PEI/NC siRNA.  
4.3.8 Therapeutic effects 
To determine if this gene knockdown on RNA and protein level would 
translate into a therapeutic effect, which would be reflected by a sequence-
dependent inhibition of cell growth, MTT assays were performed after either one 
or multiple transfections. Even though a small effect on cell proliferation was 
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observed 24 h after a single transfection (2 days after seeding the cells), a more 
pronounced and clearly sequence-specific effect was observed after 3 transfections 
on day 10 after seeding the cells (Figure 29).  While the proliferation after 3 
transfections with the negative control siRNA seemed to be slightly inhibited, the 
proliferation of those cells was not significantly different from the untreated 
control cells.  
 
Figure 29 Inhibition of cell proliferation via GASC1 knockdown. Therapeutic 
effects of GASC1 knockdown with Tf-PEI polyplexes on days 2 (D2) and 10 (D10) 
after seeding measured as inhibition of proliferation of HCC1954 cells. V7 is a 
self-designed GASC1 siRNA sequence; NC=scrambled siRNA; error bars reflect 
SD, n=3). 
4.4Discussion 
Considering that epigenetics and genetics are accomplices in breast cancer 
tumor development, much attention has been paid to the investigation of molecular 
and biology insights which could lead to the design of more specifically tailored 
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therapies (e.g. gene therapy) 156. siRNA mediated RNAi has become a powerful 
tool for its specificity and efficiency to knock down targets that cannot be readily 
down regulated by conventional chemotherapy 157. However, siRNA clinical 
applications have been a very challenging task due to multiscale barriers, 
including rapid excretion of siRNA, low stability in blood serum, nonspecific 
accumulation in tissues, poor cellular uptake and inefficient intracellular release 157. 
Several delivery strategies have been developed to address these issues 158; Here, 
we aimed to design a specifically targeted nanoparticle delivery system with 
chemical modification and ligand decoration of the complexes to improve efficient 
delivery of siRNA for the down regulation of GASC1 overexpression in target 
cells. This strategy was chosen because GASC1 overexpression correlates with 
poor prognosis in BLBC patients 144. 
Low molecular weight polyethylenimine (PEI) has been researched 
extensively as a safe and efficient nucleic acid delivery system based on its ability 
to electrostatically complex siRNA molecules into nanoscale polyplex and hence, 
to protect them from nuclease degradation 159. However, PEI alone is not a suitable 
carrier for targeted gene delivery to specific cells 159b. Meanwhile, TfR is cell 
membrane-associated glycoprotein serving as the main port of entry for iron 
through a clathrin/dynamin dependent endocytosis mechanism 160 and can be used 
as a gate for delivery of PEI when conjugated to a ligand such as transferrin that 
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selectively targets TfR on receptor expressing cells. Therefore, utilizing 
knowledge about the physiological function of the transferrin–transferrin receptor 
complex and the efficiency of its receptor mediated endocytosis provides the 
rationale to develop transferrin-targeted anticancer modalities. Moreover, studies 
have shown the elevated expression levels of TfR on cancer cells compared with 
normal cells; which correlates with tumor stage and poor prognosis (The 
Nottingham prognostic index (NPI)) 135, 161. Among the different ligand targeting 
nanoparticles, there are four transferrin-conjugated nanoparticle delivery systems 
currently in early clinical evaluation studies 162. Our TfR screening study 
confirmed distinct levels of TfR among breast cancer cell models (Figure 16), and 
the cell line HCC1954 (overexpressing GASC1) posses the highest TfR expression 
compared to the healthy breast cell line MCF10A (GASC1 negative control). The 
results of the binding capacity of transferrin to actively endocytosing TfR were in 
accordance with the transferrin receptor expression data and led to the assumption 
that the fluorescently labeled Tf remained its binding capacity after FITC labeling 
and was successfully internalized by the TfR in HCC1954 cells as a valid model 
for over expression of TfR (Figure 17). 
Here, we used functionalized linkers (SPDP or PEG4-SPDP) to couple the 
targeting ligand transferrin to LMW-PEI (Figure 18). The effect of two different 
linker types and different molar stoichiometries (Tf:PEI) on nanoparticle 
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formation and efficacy were compared. The analysis of the prepared conjugates 
revealed that a Tf:PEI molar ratio between 1.3-2 results in better condensation of 
siRNA in the Tf-PEI polyplex which are considerably smaller than a ratio around 
0.4 for Tf-PEG-PEI polyplex (Figure 19). The difference in transferrin coupling 
degrees observed in this study was a result of using different linkers, i.e. SPDP vs. 
PEG4-SPDP.  However, it is also possible that the presence of PEG in the 
nanobioconjugate with the lower transferrin coupling degree interfered with dense 
condensation of siRNA based on electrostatics. The presence of PEG in the 
crosslinking agent may, however, benefit the ligand-receptor interaction of those 
conjugates as the spacer provides longer distance of the ligand from the polyplex 
and better solubility. Accordingly, this space may avoid steric hindrance of ligand-
receptor binding by the bulky nanoparticle. However, it needs to be kept in mind 
that the coupling of substances to the primary amines of PEI may reduce its charge 
density and the proton sponge effect as well as the interaction with siRNA. Indeed, 
excessive grafting influences the complexation efficacy, complex stability, and 
complex architecture, and thus requires detailed analysis prior to application in 
vivo 159b.  
The extent of siRNA condensation with transferrin conjugates was 
determined by measuring the change of the fluorescence intensity of SYBR Gold 
as nucleic acid intercalating agent at different N/P ratios. Increasing the N/P ratios 
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from 1 to 20 not only led to decreased amounts of free siRNA as shown in Figure 
21, but also higher net positive charges of the polyplexes were obtained. This 
higher net charge increases the ability of polymer to electrostatically interact with 
negatively charged siRNA and to condense siRNA more efficiently. However, 
higher positive charges of the nanoparticles also correlate with non-specific 
toxicity and non-specific cell uptake. As shown by Plank et al., nanoparticles with 
a positive surface charge can bind nonspecifically to the cell surface and, in 
addition, activate the alternative complement system 163. This interaction would 
also lead to rapid nanoparticle uptake by the reticuloendothelial system (RES) 
after in vivo administration, and as a consequence, rapid clearance of the 
nanoparticles is expected. However, modification of the polymer surface reduces 
this phenomenon 164. In our experiments, the condensation efficiency for all three 
formulations (PEI, Tf-PEI and Tf-PEG-PEI) reached a plateau at N/P ratio of ≥ 7, 
indicating the ability of efficiently complexing with siRNA. The results in Figure 
21 showed that the condensation ability of PEI was not compromised even after 
modification with transferrin. Therefore, polyplexes with N/P ratio of 7 were 
chosen as the optimal ratio for further experiments.  
Particle size and zeta potential are key factors in the biological outcomes of 
a drug delivery system as they govern the biodistribution proﬁle, their efﬁciency to 
accumulate in tumors through the enhanced permeability and retention (EPR) 
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effect and cellular uptake 165. As a rough estimation, it is believed that the design 
of rigid and spherical nanoparticles ranging in size from 10 to 200 nm improves 
circulation half-life of nanoparticles and their uptake by tumors 166. At the 
aforementioned N/P ratio, Tf-modified polyplexes displayed very promising small 
sizes with close to neutral zeta potentials (Figure 19). The latter property is of 
particular interest for potential in vivo use, since a neutral surface charge reduces 
nonspecific charge-based interactions and undesirable clearance by the RES such 
as liver and spleen macrophages, and improves the blood compatibility. Thus, 
small nanoparticles with close to neutral surface charge are expected to efficiently 
deliver anti-cancer drugs to tumor sites 167. 
The stability of polyplexes is another critical component which determines 
the nanoparticles’ efficiency. The presence of competing anions in the cell 
membrane or in serum is known to affect the stability of polyplexes which 
determines their in vivo fate 168. Since conjugation of Tf to PEI might influence 
complex stability, this issue was addressed by incubating the complexes with the 
competing model polyanion heparin 169. Results confirmed the ability of modified 
PEI (Tf-PEI) to protect the siRNA in the presence of polyanions even more 
efficiently than PEI alone, however, Tf-PEG-PEI showed lower stability compared 
to Tf-PEI and PEI alone (Figure 22). Our results reflect the enhanced stability of 
Tf-shielded polyplexes (Tf-PEI) which also has been reported by others 132. Based 
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on the zeta potential results, we hypothesize that Tf is located on the surface of the 
nanoparticles and shields the PEI/siRNA from competing polyanions. The PEG-
containing complexes, however, exhibited compromised stability which may be 
due to the less dense packaging of siRNA as hypothesized above. The peak of 
siRNA release that was especially prominent for the Tf-PEI and PEI formulation 
can be explained as an initial competition between bound siRNA and added 
heparin for binding with PEI. After longer incubation, however, a new equilibrium 
is reached, and possibly even ternary complexes of polymer, siRNA, and heparin 
are formed. A part of the initially released siRNA seems to be condensed again at 
45 min or 60 min after incubation resulting in lower fluorescence intensities. In 
case of Tf-PEG-PEI, the siRNA was released almost quantitatively upon addition 
of heparin and further incubation did not lead to a re-complexation of siRNA. The 
weak condensation of siRNA by Tf-PEG-PEI therefore precludes any in vivo 
administration of this formulation.  
The Tf-modified PEI formulations are also expected to avoid nonspecific 
cytotoxicity which is often caused by excess positive charges on PEI. This was 
confirmed by the CellTiter-Blue® assay (Figure 25). We propose that this 
modification of PEI could reduce the toxicity of the polymer backbone and also 
enhance the stability of Tf-PEI complexes as well as the circulation of polyplexes 
in vivo.  
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Superior internalization of the delivered siRNA with Tf modified PEI in 
GASC1 positive HCC1954 cell lines compared to PEI alone was confirmed by 
flow cytometry and confocal microscopy images (Figures 23 and 24). These 
interesting results implied that Tf-PEI/siRNA polyplexes undergo selective 
cellular uptake through transferrin receptor-mediated endocytosis, and therefore 
may exhibit increased therapeutic benefits through the ability to deliver high 
concentrations of relevant siRNA to the tumor site 161. However, it must be taken 
into account that the final silencing effect depends also on the endo-lysosomal 
escape and the efficient incorporation of siRNA to the RNA-induced silencing 
machinery 170.  
While the ligand choice depends on the receptor being targeted, an 
additional consideration for targeting is the type of cell entry pathway that will be 
induced after ligand-receptor binding. Therefore, the endocytic pathway which 
may be used by the vector depends on the targeting ligand, cell type and vector 
properties 171. It was surprising that in COLO824 cells with relatively high levels 
of TfR (Figure 16), no significant transfection was detected with PEI alone or 
modified PEI (Figure 23). This could be related to the cell type which may have a 
very low endocytic activity, but an accurate answer requires further investigations. 
It has been proposed that the majority of receptor-ligand complexes (e.g. 
Tf/TfR) enter cells by clathrin-mediated endocytosis 172. Receptor binding 
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typically triggers the localized accumulation of clathrin structures on the 
cytoplasmic surface of the plasma membrane as it begins to invaginate, forming 
clathrin-coated pits 172. TfR undergoes clathrin-mediated endocytosis and may 
enter two types of trafficking pathways 173. In the first pathway, within 10 min 
after uptake, the receptor undergoes rapid recycling from early endosomes to the 
cell surface. In the second pathway, the receptor undergoes slow recycling to the 
cell surface from the recycling compartment, which is slightly acidic 173. 
Importantly, studies showed that gene expression after delivery with nanoparticles 
which enter cells through clathrin-coated endocytosis is comparably less efficient 
than after delivery via other pathways, suggesting that this path is linked to 
endosomolytic degradation of the cargo. Therefore, vectors utilizing this pathway 
must incorporate a mechanism of release from either organelle 160. Here, we used 
PEI for its important buffering feature with regard to the intracellular fate of the 
complexes. The so-called ‘proton sponge effect’ postulates a proton acceptor 
function of PEI, leading to the buffering of low pH values in the 
endosomal/lysosomal system and therefore reduced nuclease activity. The influx 
of chloride counter ions and the resulting osmotic influx of water then causes 
swelling and bursting of the endo-lysosomes, which eventually leads to release of 
the endo-lysosomal contents 174. Therefore, as stated earlier, careful formulation of 
vector assembly should be taken into account not to compromise this property 
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through grafting with targeting moiety and reducing the accessible protonable 
amine groups.  
As reported by a study for Tf-targeted nanoparticles (lipoplexes), it is likely 
that other yet unidentified cell surface components (nonreceptor endocytosis) also 
mediate complex binding and uptake. This might be the reason for the rather high 
transfection efficacies of Tf-PEI nanoparticles in SUM102 cells. The underlying 
molecular mechanisms have yet to be investigated.  
It has been also demonstrated that conjugation/linker chemistry may have a 
signiﬁcant effect on transfection efﬁciency and speciﬁcity in vitro 175. In our study, 
we used two structurally different conjugates (Tf-PEI and Tf-PEG-PEI) which 
were comparable in physicochemical properties but different in transfection, 
binding, and uptake efﬁciencies. As a result, the efﬁciency of PEI conjugates 
strongly depends on the linker chemistry. The coupling of transferrin with SPDP 
to LMW-PEI was most efﬁcient. In contrast, our second approach of using PEG 
chains in the form of PEG4-SPDP showed that a slightly longer spacer may hinder 
the proper presentation of transferrin, the condensation of siRNA, and/or have an 
effect on proton sponge features of PEI. Introducing a cyclic RGD peptide as a 
targeting moiety via direct coupling or PEG spacer linking to PEI studied by 
Kunath et al. showed that only direct coupling of the peptide to PEI via SPDP 
mediated efﬁcient and speciﬁc DNA transfection, while an RGD-PEG-PEI 
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conjugate was inefﬁcient. The authors concluded that the use of a PEG spacer 
seemed to impair targeting, possibly by not only shielding PEI, but also the RGD 
ligand 176. In contrast, Moffatt et al. successfully utilized a PEG linker for coupling 
an anti-PSMA antibody to PEI/DNA polyplexes 177. Polyethylene glycol (PEG) 
spacers are expected to preserve protein function by moving the targeting moiety 
away from the surface, by providing ﬂexibility and reducing non-speciﬁc binding 
of environmental biomolecules 178. In another study, antibody-PEI conjugates were 
prepared with three different linkers (SPDP, SMCC, and IBFB 110001) to prepare 
HER2 or CD90 targeted conjugates. Using these linkers, major differences in the 
degrees of conjugation and in target cell speciﬁcity of the resulting conjugates 
were found. Interestingly, none of the conjugates prepared with SPDP as a linker 
showed target cell speciﬁcity. Because of signiﬁcant differences in the study 
design, direct comparison of these results proved to be difﬁcult, however.  
Optimization of GASC1 knockdown on the mRNA level was carried out by 
initially screening commercially available GASC1 siRNA sequences. The results 
revealed that three commercially available sequences (“A”, “C”, and “D” obtained 
from Qiagen) were able to reduce the GASC1 mRNA levels to about 75% after 
transfection with LF (Figure 26). While the general expression levels of GASC1 
can not be compared to easy-to-knock down genes like the housekeeping gene 
GAPDH, the reduction to 75% residual expression even with LF was not 
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acceptable. Therefore, several parameters such as incubation time and siRNA 
concentration were attempted to be optimized (Figure 27). Since the gene knock 
down was not improved by this approach, new siRNA sequences (V4, V6 and V7) 
were designed and transfected with LF, PEI and Tf-modified PEIs (Figure 28). 
The gene knock down efficacy was determined via RT-PCR. Among all sequences, 
V7 showed very promising results after transfecting HCC1954 cells with LF and 
acceptable results after transfection with Tf-PEI/siRNA complexes (N/P 7, Figure 
28A). This final formulation was therefore used to verify the protein knockdown 
level in HCC1954 cells after 7 days of incubation based on a previously optimized 
protocol. The western blot analysis confirmed the RT-PCR results (Figure 28B), 
indicating that the combination of Tf-PEI with V7 siRNA is a promising 
formulation for GASC1 gene knock down in BLBC.  
The question whether GASC1 gene knock down would result in efficient 
inhibition of cell proliferation was answered after optimizing the transfection 
approach. As shown in Figure 29, a single transfection did not yet lead to efficient 
inhibition of cell proliferation. This result is not surprising considering that 
previous approaches using shRNA145a or small molecule GASC1 inhibitors also 
required multiple treatments to inhibit cell proliferation.179 The results also imply 
that GASC1 may have a long biologic half-life. Figure 29 shows that multiple 
treatments with negative control siRNA can have a small but not significant 
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impact on cell proliferation in comparison to untreated cells, whereas one single 
treatment does not affect the cells, which is in line with the cytotoxicity results 
shown in Figure 25.  
4.5 Conclusions 
The establishment of an efficient and cell type-specific gene delivery 
system is a most challenging objective, which in the context of cancer therapy 
ideally would allow for the specific introduction of a therapeutic transgene or 
knock out in malignant cells. Tf-PEI demonstrated enhanced gene transfer 
efficiency in BLBC cells overexpressing TfR compared to non-modified PEI. 
Through inhibiting the epigenetically and therapeutically relevant target gene 
GASC1 which is involved in multiple signaling pathways leading to tumorigenesis, 
Tf-PEI nanoparticles treatment has revealed promising results regarding gene 
silence efficiency and inhibition of breast cancer cell proliferation. However, it 
remains to be shown whether these properties can be exploited for targeted in vivo 
gene delivery after systemic administration.  
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CHAPTER 5 TARGETED DELIVERY OF SIRNA TO 
TRANSFERRIN RECEPTOR OVEREXPRESSING TUMOR 
CELLS VIA PEPTIDE MODIFIED POLYETHYLENIMINE 
Please note that part of the content of this chapter is from a research 
article,“Targeted Delivery of siRNA to Transferrin Receptor Overexpressing 
Tumor Cells via Peptide Modified Polyethylenimine”, was published in Molecules 
(Y. Xie, et al., 2016). The authors of this article include Bryan Killinger, Anna 
Moszczynska, Olivia M Merkel and me. I am the first author of this research paper. 
I performed the experiments and wrote the manuscripts.  
5.1 Introduction 
TfR is overexpressed in many kinds of cancers due to their increased 
consumption of iron but is expressed at a low level on most cells. Therefore,  the 
upregulation of TfR in cancer cells makes it a promising target for the selective 
delivery of siRNA for cancer therapies 57b. Several strategies have been explored 
to target TfR, including the use of holo-Tf or monoclonal antibodies raised against 
TfR 180 181 which were coupled to polymers 44, and liposomes 182. We have shown 
that Tf-PEI can efficiently deliver therapeutic siRNA to breast cancer cells 
overexpressing TfR in Chapter 4. However, high concentrations of endogenous 
Tf in blood plasma (25 µM) may competitively inhibit the uptake mediated by the 
holo-Tf or the anti-TfR antibody 183. Furthermore, holo-Tf (molecular weight 
(MW) 80 kDa) and antibodies against TfR (e.g., the anti-human TfR antibody 
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5E9,  
MW= 30 kDa 180) are relatively large, and therefore, may introduce steric 
hindrance when the drug delivery system is synthesized. The stability of these 
proteins will also need to be taken into consideration in terms of synthesis 
conditions, storage, formulation, and expected shelf-life. A viable alternative to Tf 
and TfR specific antibodies is the use of TfR binding peptides. Two peptide 
sequences, HAIYPRH and THRPPMWSPVWP, discovered by phage display, 
were reported to be able to non-competitively bind to human TfR with high 
affinity and consequently trigger TfR internalization 184. The chemico-physical 
properties of these peptides are more stable and their MWs are smaller than those 
of holo-Tf and antibodies.  
The aim of this study was to develop a siRNA delivery system to target TfR 
overexpressing tumor cells. In this chapter, two TfR targeting peptides and bPEI 
were successfully coupled via two different crosslinkers, namely PEGylated 
succinimidyl 3-(2-pyridyldithio) propionate (PEG4- SPDP) and sulfosuccinimidyl 
4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC). The siRNA 
and bPEI or peptide-bPEI polyplexes were characterized regarding size, zeta-
potential, and siRNA condensation efficiency. Selective delivery of siRNA using 
peptide-bPEI was investigated in the TfR overexpressing cell line H1299 and low 
TfR expressing cell lines A549 or H460. Gene knockdown efficiency of 
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siRNA/peptide-bPEI polyplexes was measured both at the mRNA and protein 
level in H1299 cells.  
5.2 Materials and Methods  
5.2.1 Materials 
Branched 5k Da bPEI (Lupasol® G100) and 25k Da bPEI (Lupasol® HF) 
were obtained from BASF (Ludwigshafen, Germany). Succinimidyl 3-(2-
pyridyldithio) propionate (SPDP), PEGylated succinimidyl 3-(2-pyridyldithio) 
propionate (PEG4- SPDP) and sulfosuccinimidyl 4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate (sulfo-SMCC) were purchased from Thermo Fisher 
(Waltham, MA, USA). Dulbecco’s phosphate buffered saline (PBS), 1,4-Dithio-
DL-threitol (DTT), dimethyl sulfoxide (DMSO), HEPES, 
ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA), picrylsulfonic 
acid solution (TNBS, 5% w/v), sodium pyruvate, sodium bicarbonate (NaHCO3) 
and glucose were bought from Sigma-Aldrich (St. Louis, MO, USA). Human 
holo-transferrin was obtained from EMD Millipore (Billerica, MA, USA). 
Cysteine modified TfR binding peptide HAIYPRH (Cys-His-Ala-Ile-Tyr-Pro-Arg-
His) was synthesized by BACHEM Americas (Torrance, CA, USA) and 
THRPPMWSPVWP (Thr-His-Arg-Pro-Pro-Met-Trp-Ser-Pro-Val-Trp-Pro-Cys) 
was synthesized by the American Peptide Company (Sunnyvale, CA, USA). 
Enhanced green fluorescent protein (eGFP) siRNA, amine modified eGFP siRNA, 
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siRNA fluorescently labeled with Ty563 (siRNA-Ty563), human glyceraldehyde- 
3- phosphate- dehydrogenase (GAPDH) siRNA and scrambled siRNA were 
purchased from Integrated DNA Technologies (Coralville, IA, USA). 
Table 5 Sequence of siRNA. 
Name Sequence 
eGFP siRNA 
5´- pACCCUGAAGUUCAUCUGCACCACcg 
3´-ACUGGGACUUCAAGUAGACGUGGUGGC 
 
GAPDH siRNA 
5´- pGGUCGGAGUCAACGGAUUUGGUCgt 
3´UUCCAGCCUCAGUUGCCUAAACCAGCA 
 
Scramble siRNA 
5´-pCGUUAAUCGCGUAUAAUACGCGUat 
3´CAGCAAUUAGCGCAUAUUAUGCGCAUAp 
 
* Indication of modified nucleotides: “p” denotes a phosphate residue, lower case 
bold letters are 2´-deoxyribonucleotides, capital letters are ribonucleotides, and 
underlined capital letters are 2´-O-methylribonucleotides.  
5.2.2 Synthesis of Peptide–bPEI Conjugate 
The HAIYPRH peptide (HAI) was coupled to bPEI using two different 
crosslinkers, namely sulfo-SMCC and PEG4-SPDP. In the sulfo-SMCC 
crosslinking approach, as shown in Figure 30 B, 1 mg of 25k bPEI was dissolved 
in HEPES buffered saline (HBS) buffer (20 mM of HEPES and 150 mM of NaCl, 
pH=7.2) at 1 mg/mL, and 1 mg of sulfo-SMCC was dissolved in water at 10 
mg/mL. bPEI solution and sulfo-SMCC were mixed together and allowed to stir 
for 4 h at room temperature (RT). bPEI-SMCC was purified using 10,000 
molecular weight cut off (MWCO) centrifugal filters (Millipore) with HBS 
containing 2 mM of EDTA buffer. The bPEI-SMCC solution was mixed with 1 
155 
 
 
 
 
mg of HAI peptide dissolved in HBS containing 2mM of EDTA (5 mg/mL) and 
stirred overnight at RT. The next day, free HAI peptide was removed from HAI-
bPEI using 10,000 MWCO centrifugal filters. In the PEG4-SPDP crosslinking 
approach, as shown in Figure 30 A, 5 mg of 25k bPEI was dissolved in HBS 
buffer at 5 mg/mL, and 2 mg of PEG4-SPD was dissolved in DMSO at 20 mM. 
PEG4-SPDP was added drop-wise into the bPEI solution and stirred overnight at 
RT. Meanwhile, 2 mg of HAI peptide was dissolved in HBS containing 2 mM of 
EDTA buffer at 4 mg/mL and reduced by 10 molar excess DTT for 2 h. Reduced 
HAI peptide solution was transferred to a 500–1000 MWCO dialysis tube 
(Spectrum laboratories, Rancho Dominguez, CA, USA) and dialysis was 
performed against HBS containing 2 mM of EDTA buffer overnight at 4 °C. The 
next day, bPEI-SPDP was purified using 10,000 MWCO centrifugal filters with 
HBS containing 2 mM of EDTA buffer and then mixed with the reduced HAI 
peptide. The mixture was stirred for 24 h at RT followed by purification using 
10,000 MWCO centrifugal filters with HBS. The concentration of HAI peptide in 
the conjugate was measured spectrophotometrically at 280 nm. The concentration 
of bPEI in the conjugate was determined by a TNBS assay 122. Briefly, the 
according amount of HAI peptide was added into bPEI serial dilution to generate 
a standard curve in a clear 96-well plate (Corning, Corning, NY,USA). Then 30 
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µl of 3 mM of TNBS solution was added to 100 µl of bPEI/HAI solution and the 
absorbance at 405 nm was determined after 5 min.  
5k bPEI (1 mg/mL) was dissolved in HBS buffer and mixed with 100 µl 20 
mM of SPDP, stirred overnight, followed by purification via 3000 MWCO 
centrifugal filters. THRPPMWSPVWP peptide (THR peptide) was reduced by 10-
fold excess TCEP HCl (Thermo Fisher) and purified using a PD10 column (GE 
healthcare). THR peptide was mixed with bPEI-SPDP overnight while stirring at 
RT. The concentrations of THR peptide and bPEI in conjugate were measured 
spectrophotometrically at 280 nm and by a TNBS assay, respectively.  
5.2.3 Fluorescent Labeling of PEI, Transferrin, Peptide and siRNA 
bPEI was fluorescently labeled with fluorescein-5-isothiocyanate (FITC) 
(Thermo Fisher). 15 mg of bPEI was dissolved in 0.1 M NaHCO3 (pH= 9) at 2.5 
mg/mL, and 2 mg of FITC was dissolved in 200 µl of DMSO. The FITC solution 
was added drop-wise to the bPEI solution and allowed to stir for 3 h at RT. Free 
FITC was removed using 10,000 MWCO centrifugal filters, and bPEI-FITC was 
stored in water. The bPEI concentration was determined by a TNBS assay as 
described above, and the presence of FITC showed no interference with the 
results, as reported before 47. For the conjugates, 0.2 mg of FITC (1 mg/mL) in 
DMSO was added dropwise into 2 mg of HAI-bPEI synthesized via the sulfo-
SMCC approach and allowed to react for 3 h with stirring. The concentration of 
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bPEI in the conjugate was determined by a TNBS assay with a bPEI-FITC 
standard curve. Holo human Transferrin was fluorescently labeled with Texas Red 
modified with succinimidyl ester (Thermo Fisher) following the manufacturer’s 
protocol. Cysteine modified THR peptide was fluorescently labeled with a Alexa 
Fluor 488 modified with maleimide (Thermo Fisher) following the manufacture’s 
protocol. Amine modified siRNA was fluorescently labeled with Alexa Fluor 488 
modified with succinimidyl ester (Thermo Fisher) following the manufacturer’s 
protocol, followed by purification using ethanol precipitation and silica spin 
column binding as reported before 123.   
5.2.4 Preparation of Polyplexes 
To prepare the siRNA and polymer polyplexes, polymer was diluted with 
5% glucose to different concentrations. An equal volume of polymer solution was 
added to a predetermined amount of siRNA solution to yield different amine to 
phosphate ratios (N/P ratios) and allowed to incubate for 15 min at RT before 
measurement or transfection. The calculation to prepare polyplexes is based on the 
following equation: m polymer (pg) = n siRNA (pmol) × MWprotonable (g/mol) × N/P × N 
nucleotide (MWprotonable of bPEI = 43.1 g/mol, N nucleotide of siRNA = 52). 
5.2.5 . Measurement of Hydrodynamic Size and Zeta-Potential 
Polyplexes were prepared with bPEI or HAI-SPDP-bPEI and 50 pmol of 
siRNA at N/P 5 in 100 µl 5% glucose buffer as described above and were 
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transferred to a disposable micro cuvette (Brand GMBH, Wertheim, Germany). 
Size measurement was performed in three runs using a Zetasizer Nano ZS 
(Malvern Instruments Inc., Westborough, MA,USA). Results were collected and 
analyzed with the Zetasizer Software (Malvern) with settings of 173° backscatter 
angle, 0.88 mPa*s for viscosity and 1.33 for refractive index. Subsequently, the 
same polyplex solutions were diluted to 1 mL with water and transferred to a 
folded capillary cell (Malvern). The zeta-potentials of polyplexes were determined 
in three runs using a Zetasizer Nano ZS (Malvern). 
5.2.6 siRNA Condensation Measured by a SYBR Gold Assay 
SYBR Gold is a fluorescent dye which is used to stain nucleic acids. It 
intercalates into siRNA and produces fluorescence. When siRNA is condensed by 
polymer and becomes inaccessible for SYBR Gold, the fluorescence will decrease. 
Polyplexes were prepared with bPEI or HAI-SPDP-bPEI and 50 pmol of siRNA at 
different N/P ratios (1, 2, 3, 5, 7, 10) in 100 µl per well in a FluoroNunc 96 well 
white plate (Thermo Fisher). Subsequently, 30 µl of 4 × SYBR Gold was added to 
each well and incubated for 10 min in the dark. The fluorescence of SYBR Gold 
was determined by a Synergy 2 multi-mode microplate reader (BioTek Instrument, 
Winooski, VT, USA) with an excitation filter 485/20 nm and an emission filter 
520/20 nm. The fluorescence of free siRNA (N/P= 0) represented 100% free 
siRNA. The experiment was performed in triplicate.  
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5.2.7 Cell Culture 
NCI-H1299 cells (human non-small cell lung carcinoma) and A549 cells 
(human non-small cell lung carcinoma) were purchased from ATCC (Manassas, 
VA, USA). NCI-H460 cells (human large cells lung carcinoma) were a kind gift 
from Dr. Larry H. Matherly (School of medicine, Wayne State University, USA). 
H1299/eGFP is a H1299 cell line stably expressing the reporter gene eGFP. 
H1299 and H460 cells were cultured in RPMI-1640 media (GE healthcare, 
Buckinghamshire, UK) supplemented with 10% heat inactivated fetal bovine 
serum (v/v) (Sigma), 1× penicillin/streptomycin (Corning), 1× GlutaMax (Thermo 
Fisher), 10 mM of HEPES, 1.5 g/L of NaHCO3, 4.5 g/L of glucose and 1 mM of 
sodium pyruvate. A549 cells were cultured in DMEM media (Corning) 
supplemented with 10% fetal bovine serum (FBS) and 1× pen/strep. All cells were 
maintained in a humidified atmosphere and 5% CO2 at 37 °C. 
5.2.8 Immunofluorescent Staining 
H1299, H460 and A549 cells were harvested from flasks and washed with 
PBS. Each sample contained 100,000 cells and was resuspended in 10 µl of a 50-
fold diluted human Fc receptor binding inhibitor (eBioscience, San Diego, CA, 
USA) for 5 min on ice. Subsequently, 20 µl of a 20-fold diluted phycoerythrin (PE) 
labeled human CD71 antibody (OKT9, eBioscience) or 20 µl of a 20-fold diluted 
PE labeled mouse IgG1 isotype control antibody (P3.6.2.8.1, eBioscience) were 
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added to the samples and incubated for 30 min in the dark at 4 °C. Samples were 
washed with PBS/ 2 mM of EDTA three times and were resuspended in 400 µl of 
PBS/ 2 mM of EDTA. The median fluorescent intensity (MFI) of samples was 
quantified using an Attune® Cytometer (Life Technologies, Waltham, MA, USA) 
with an excitation laser 488 nm and emission filter 574/26 nm. Cell populations 
were gated according to the forward and side scattering channel, and 10,000 
events were collected. Data analysis was performed using the Attune® cytometer 
software (Life Technologies). Experiments were conducted in duplicate.  
5.2.9 Quantification of Cellular Uptake and Cellular Binding 
For cellular uptake experiments, H1299, H460 and A549 cells were seeded 
at the density of 50,000 cells/well in 24-well plates (Corning). After 24 h of 
incubation, polyplexes were prepared with 50 pmol of siRNA-AF488 and bPEI, 
HAI-SMCC-bPEI, HAI-SPDP-bPEI or THR-PEI at N/P=5. The cells were 
transfected with polyplexes at the siRNA concentration of 125 nM for 4 h. To 
reduce the potential cytotoxicity induced by concentrated polyplexes, fresh media 
were added to dilute siRNA concentration to 50 nM followed by an additional 20 
h of incubation. The cells were harvested and washed three times with PBS/2 mM 
of EDTA. All samples were resupended in 400 µl of PBS/2 mM of EDTA, and 
MFIs of samples were determined via an Attune® Cytometer (Life Technologies) 
with an excitation laser 488 nm and emission filter 530/30 nm. In each sample, 
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10,000 events were collected and data analysis was performed using the Attune® 
cytometer software (Life Technologies). Experiments were conducted in triplicate. 
For the cellular binding experiment, H1299 and A549 cells were seeded as 
described above. After 24 h incubation, different concentrations (0, 0.1, 1, 2 µg/ 
ml) of THR peptide fluorescently labeled with Alexa Fluor 488 (THR-AF488) 
were added into media and incubated for 1 h at 37 °C. The cells were harvested 
and the MFI was quantified via flow cytometry as described above. Experiments 
were conducted in duplicate. 
5.2.10 Confocal Laser Scanning Microscopy 
H1299 cells were seeded at the density of 50,000 cells/well in 24-well 
plates with a 12 mm circle cover glass (Fisherbrand, 12CIR. -1) in each well and 
were incubated for 24 h. To determine intracellular distribution of polyplexes, 
fluorescently labeled polymer bPEI-FITC and HAI-SMCC-bPEI-FITC were 
formulated with 50 pmol of siRNA-Ty563 at N/P= 5. Cells were transfected with 
polyplexes at a siRNA concentration of 125 nM for the first 4 h and 50 nM for an 
additional 44 h. Cells were washed with PBS and fixed with 4% paraformaldehyde 
(PFA) solution in PBS (Affymetrix, Thermo Fisher) for 20 min at RT at different 
transfection time points (1, 4, 24, 48 h). To investigate the co-localization of the 
HAI peptide binding part with TfR, cells were incubated with 2 µg/mL of Tf-
Texas Red and polyplexes formulated with bPEI-FITC or HAI—SMCC-bPEI-
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FITC and 50 pmol of siRNA at N/P= 5 for 1 h or 4 h. To determine the co-
localization of THR peptide binding part with TfR, cells were incubated with 2 
µg/ ml of THR-AF488 and Tf-Texas Red for 1 h. Slides were washed with PBS 
and fixed with 4% PFA. After fixation, the nuclei were stained with 5 µM of 
DRAQ5 (Invitrogen, Thermo Fisher) for 5 min and rinsed with PBS. Slides were 
mounted with a Fluoromount mounting medium (Southern Biotech, Birmingham, 
AL, USA). Slides were imaged by a Leica TCS SPE-II laser scanning confocal 
microscope (Leica, Wetzlar, Germany), and the images were exported from the 
Leica Image Analysis Suite (Leica). 
5.2.11 In Vitro GAPDH Gene Knockdown 
To determine mRNA level knockdown efficiency of polyplexes, silencing 
of housekeeping gene GAPDH in H1299 and H460 was determined by real time 
PCR (RT-PCR). Cells were seeded at the density of 50,000 cells/well in 24-well 
plates for 24 h. bPEI, HAI-bPEI or THR-PEI were formulated with 50 pmol of 
siRNA against GAPDH or scrambled siRNA at N/P= 5. Cells were transfected 
with polyplexes at a siRNA concentration of 125 nM for the first 4 h and 50 nM 
for an additional 20 h. Total mRNA was isolated from cells using the PureLink® 
RNA mini kit (Life techonologies) following the manufacturer’s protocol in the 
addition of DNase I digestion (Sigma). The brilliant III ultra-fast SYBR® green 
QRT-PCR master mix kit (Agilent Technologies, Santa Clara, CA, USA) was used 
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to reverse transcribe 100 ng of mRNA to cDNA and perform RT-PCR. RT-PCR 
was conducted in a Stratagene Mx 3005p qPCR system (Agilent Technologies) 
and cycle threshold (Ct) values were exported from MxPro software (Agilent 
Technologies). Hs_GAPDH_2_SG primers for GAPDH and Hs_ACTB_2-SG 
primers for β-actin (Qiagen, Valencia, CA, USA) were used in this experiment. 
GAPDH gene expression was normalized to β-actin gene expression for 
quantification and comparison, and the untreated group represented 100% 
GAPDH expression. Experiments were conducted in triplicate. 
5.2.12 In Vitro eGFP Knockdown 
To determine the protein level knockdown efficiency of polyplexes, 
silencing of reporter gene eGFP was determined by flow cytometry. H1299/eGFP 
cells were seeded at the density of 50,000 cells/well in 24 well-plates for 24 h. On 
the day of transfection, old media were replaced with 350 µl of fresh media with 
or without 115 µM of chloroquine. Cells were transfected with 50 pmol of siRNA 
against eGFP formulated with bPEI or HAI-bPEI at N/P= 5, 10 in total volume of 
polyplexes of 50 µl. bPEI and HAI-bPEI polyplexes containing scrambled siRNA 
at N/P= 10 were included as the negative control. Cells were transfected with 50 
µl of polyplexes and incubated for 4 h with or without 100 µM of chloroquine. To 
dilute the concentration of chloroquine and polyplexes, 600 µl of fresh media were 
added, and cells were incubated for an additional 44 h. Afterward, cells were 
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harvested and washed three times with PBS/2 mM of EDTA. Samples were 
resuspended in 400 µl of PBS/2 mM of EDTA, and the MFIs were determined by 
an Attune® Cytometer (Life Technologies) with an excitation laser 488 nm and 
emission filter 530/30 nm. In each sample, 10,000 events were collected, and data 
analysis was performed using Attune® cytometer software (Life Technologies). 
Experiments were conducted in triplicate.  
5.2.13 Statistics 
Results were represented as mean +/- standard deviation (SD). All 
statistical analysis used One-way ANOVA with Newman–Keuls multiple 
comparison post-test in GraphPad Prism software (Graph Pad Software, La Jolla, 
CA, USA). 
5.3 Result 
5.3.1 Synthesis of HAI-bPEI 
HAI-bPEI conjugates were successfully synthesized using crosslinkers 
sulfo-SMCC or PEG4-SPDP (Figure 30 A and B). To synthesize HAI-SMCC-
bPEI, sulfo-SMCC was first reacted with primary amines in bPEI, then the 
maleimide group in bPEI-SMCC was reacted with sulfhydryl in the cysteine 
modified HAI peptide. To synthesize HAI-SPDP-bPEI, PEG4-SPDP was first 
coupled with bPEI. After purification, bPEI-PEG4-SPDP was coupled to DTT-
reduced cysteine-modified HAI peptide. The molar ratios of HAI peptide to bPEI 
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were determined according to the absorbance at 280 nm and the 2,4,6-
trinitrobenzene sulfonic acid (TNBS) assay. The molar ratio of HAI peptide to 
bPEI was 18.6 for HAI-SMCC-bPEI and 18.2 for HAI-SPDP-bPEI.   
THR peptide was successfully conjugated to bPEI via crosslinker SPDP 
(Figure 30 C). bPEI first reacted with SPDP while THR peptide was activated with 
TCEP HCl. PEI-SPDP was coupled to reduced-THR peptide and yielded THR-
PEI. The molar ratio of THR peptide to bPEI is 0.4.  
(A) 
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(B) 
 
(C) 
 
Figure 30 Synthesis scheme of HAI-SPDP-PEI, HAI-SMCC-PEI and THR-SPDP-
PEI. (A) Synthesis approach of HAI-SPDP-bPEI.; (B) Synthesis approach of HAI-
SMCC-bPEI. (C) Synthesis approach of THR-SPDP-bPEI.  (bPEI: branched 
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polyethylenimine; PEG4-SPDP: 2-Pyridyldithiol-tetraoxatetradecane-N-
hydroxysuccinimide; sulfo-SMCC: sulfosuccinimidyl 4-[N-maleimidomethyl] 
cyclohexane-1-carboxylate; DTT: dithiolthreitol; SPDP: succinimidyl 3-(2-
pyridyldithio) propionate; TCEP: Tris (2-carboxyethyl) phosphine hydrochloride) 
5.3.2 siRNA Condensation Efficiency of bPEI and HAI-bPEI 
Cationic polymers, such as bPEI, can condense siRNA via ionic 
interactions. The amount of uncondensed free siRNA can be quantified by 
SYBR® Gold, an intercalating fluorescent nucleic acid staining dye. Therefore, 
the condensation efficiency of bPEI and HAI-bPEI at different anime to phosphate 
(N/P) ratios (1, 2, 3, 5, 7, 10) was examined by a SYBR Gold assay. As shown in 
Figure 31, bPEI and HAI-SPDP-bPEI demonstrated similar condensation 
efficiency. Increasing the N/P ratio resulted in less free siRNA. Both bPEI and 
HAI-bPEI can achieve complete condensation of siRNA at an N/P ratio of 2 and 
all N/P ratios above 2, respectively.    
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Figure 31 SYBR Gold assay of PEI and HAI-SPDP-PEI. The siRNA condensation 
efficiency of bPEI and HAI-SPDP-bPEI was determined by a SYBR® Gold assay 
at N/P ratio 1, 2, 3, 5, 7 and 10. At N/P= 0, the fluorescence represented 100% free 
siRNA. (Data points indicate mean +/- standard deviation (SD), n= 3.) 
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5.3.3 Hydrodynamic Size and Zeta-Potential of PEI and HAI-PEI Polyplexes 
The particle size of HAI-SPDP-bPEI and bPEI polyplexes formulated with 
50 pmol of siRNA at N/P=5 was measured by dynamic light scattering (Figure 32 
A). HAI peptide modified bPEI polyplexes, as expected, had a slightly larger 
hydrodynamic diameter of around 144 nm with a polydispersity index (PDI) of 
around 0.3. Unmodified bPEI polyplexes exhibited a hydrodynamic diameter of 
around 117 nm with a PDI of around 0.2. The zeta-potential of HAI-SPDP-bPEI 
and bPEI polyplexes were also determined. As shown in Figure 32 B, the zeta-
potentials of both polyplexes were slightly positive, and HAI-SPDP-bPEI 
polyplexes demonstrated a lower positive surface charge (13.3 +/- 1.7 mV) than 
bPEI polyplexes (17.2 +/- 9.2 mV).  
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Figure 32 Size and zeta-potential of HAI-SPDP-PEI and PEI. (A) Hydrodynamic 
diameters (left y-axis) and polydispersity index (PDI, right y-axis) and (B) zeta-
potential of bPEI and HAI-SPDP-bPEI polyplexes containing 50 pmol of siRNA 
at N/P= 5. (Data points indicate mean +/- SD, n= 3.) 
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5.3.4 TfR Expression 
TfR expression levels in H1299, H460 and A549 cells were measured via 
flow cytometry. Cells were immunostained with a fluorescently labeled anti-CD71 
antibody, namely the anti-TfR antibody, and with an isotype control antibody. As 
shown in Figure 33 A and B, median fluorescent intensity (MFI) across all three 
cell lines was unchanged when stained with the isotype antibody, indicating that 
little fluorescence was caused by non-specific binding of the antibody. On the 
other hand, H1299 cells demonstrated a significantly higher MFI after being 
stained with the anti-CD71 antibody compared with A549 and H460 cells. 
Therefore, H1299 cells were considered as a TfR overexpressing cell model while 
A549 and H460 cells were considered as TfR low expressing cell models for later 
studies. 
 
Figure 33.  TfR expression in H1299 and A549. (A) H1299 and A549 cells were 
immunostained by the anti-CD71 antibody which binds to transferrin receptors 
(TfR) and by the isotype antibody which served as a control of non-specific 
binding. Median fluorescence intensity (MFIs) were quantified via flow 
cytometry. (B) H1299 and H460 cells were immunostained by the anti- CD71 
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antibody and by the isotype antibody (Data points indicate mean +/- SD, n= 2. *** 
p <0.001).  
5.3.5 Cellular Uptake of bPEI and HAI-bPEI Polyplexes 
The bPEI modified by HAI peptide via two different crosslinkers—sulfo-
SMCC or PEG4-SPDP, HAI-SMCC-bPEI or HAI-SPDP-bPEI—were tested in this 
study. The cellular uptake of HAI-SMCC-bPEI or HAI-SPDP-bPEI polyplexes 
compared with bPEI polyplexes were determined in the TfR overexpressing cell 
line H1299, and in TfR low expressing cell lines H460 or A549 via flow 
cytometry. Cells were transfected by HAI-SMCC-bPEI, HAI-SPDP-bPEI or bPEI 
polyplexes containing siRNA labeled with Alexa Fluor 488 at N/P= 5 for 24 h. As 
shown in Figure 34 A, significantly stronger fluorescence was determined in 
H1299 cells treated with HAI-SMCC-bPEI polyplexes than in A549 cells. On the 
other hand, only a slightly stronger MFI was observed in H1299 cells treated with 
bPEI polyplexes than in A549 cells. In A549 cells, cellular uptake mediated by 
HAI-SMCC-bPEI polyplexes was only slightly higher than that mediated by bPEI 
polyplexes, however, the difference between cellular uptake mediated by HAI-
SMCC-bPEI and bPEI polyplexes was more significant in H1299 cells. A 
comparison of the cellular uptake mediated by HAI-SPDP-bPEI and bPEI 
polyplexes was performed in H1299 and H460, as shown in Figure 34 B, and a 
similar cellular uptake profile was observed. 
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Figure 34 Cellular uptake of PEI and HAI-SPDP-PEI. (A) The cellular uptake of 
bPEI and HAI-SPDP-bPEI polyplexes was determined in TfR overexpressing cells 
H1299 and TfR low expressing cells A549. Polyplexes were prepared with 50 
pmol of siRNA fluorescently labeled with Alexa Fluor 488 at N/P= 5 and 
transfected for 24 h. The MFIs were quantified by flow cytometry. (Data points 
indicate mean +/- SD, n= 2. **, p <0.01, *** p <0.001). (B) The cellular uptake of 
bPEI and HAI-SPDP-bPEI polyplexes was determined in TfR overexpressing cells 
H1299 and TfR low expressing cells H460. (Data points indicate mean +/- SD, n= 
3. *** p <0.001) 
5.3.6 Cellular Binding and Cellular Uptake of THR Peptide and THR-PEI 
                
The cellular binding of THR-AF488 was determined in H1299 cells and 
A549 cells and quantified via flow cytometer. With increasing concentration of 
THR-AF488, the MFI of H1299 cells overexpressing TfR increased dramatically 
and was higher than the MFI of A549 cells expressing low level of TfR (5.6 a). 
The cellular uptake of THR-PEI or PEI polyplexes was also determined in H1299 
and A549. Cells were transfected by THR-PEI or PEI polyplexes formulated with 
50 pmol siRNA-AF488 at N/P=5 for 24 h. The MFIs of cells were quantified by 
flow cytometry.  The cellular uptake mediated by THR-PEI polyplexes in H1299 
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and A549 was similar. Moreover, non-modified PEI mediated higher cellular 
uptake in both cell lines compared to THR-PEI (Figure 35 B). 
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Figure 35 Cellular binding of THR peptide and cellular uptake of THR-PEI. (A) 
The cellular binding of THR-AF488 with H1299 and A549 were quantified by 
flow cytometry. (Data points indicate mean +/- SD, n= 3) (B) The cellular uptake 
of bPEI and THR-bPEI polyplexes was determined in H1299 and A549 cells and 
quantified by flow cytometry. (Data points indicate mean +/- SD, n= 2-3).  
5.3.5 Imaging of Uptake by Confocal Laser Scanning Microscopy (CLSM) 
To determine the sub-cellular distribution of polyplexes, H1299 cells were 
transfected by HAI-SMCC-bPEI fluorescently labeled by fluorescein 
isothiocyanate (HAI-SMCC-bPEI-FITC) and bPEI-FITC polyplexes containing 
siRNA fluorescently labeled with Ty563 at N/P= 5 for 48 h. The cellular 
distribution of polyplexes was observed at several time-points (1, 4, 24, and 48 h) 
by CLSM (Figure 36). H1299 cells treated with HAI-SMCC-bPEI polyplexes 
(Figure 36, lower panel) showed denser distribution of the red signal representing 
siRNA-Ty563 than cells treated with bPEI polyplexes (Figure 36, upper panel). At 
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24 and 48 h, bright yellow dots, representing co-localization of polymer-FITC 
(green) and siRNA-Ty563 (red), were observed in both cells treated with HAI-
SMCC-bPEI and bPEI polyplexes. There were some red dots (siRNA-Ty563) 
evenly distributed in the cytoplasm of cells treated with HAI-SMCC-bPEI 
polyplexes, however, siRNA-Ty563 was exclusively co-localized with bPEI 
(yellow dots) and not present as free siRNA in cells transfected with bPEI 
polyplexes.  
 
Figure 36 CLSM of subcellular distribution of PEI and HAI-SMCC-PEI 
polyplexes. Subcellular distribution of bPEI and HAI-SMCC-bPEI polyplexes in 
H1299 was imaged by confocal microscopy. H1299 cells were transfected with 
bPEI and HAI-SMCC-bPEI polyplexes prepared with 50 pmol of siRNA 
fluorescently labeled with Ty563 at N/P= 5 for 1, 4, 24 and 48 h. The polymers 
were fluorescently labeled with FITC and shown in green. siRNA-Ty563 was 
shown in red, and DRAQ5TM stained nuclei were shown in blue. 
To investigate the pathway of cellular internalization mediated by the HAI 
peptide, H1299 cells were incubated with 2 µg/mL of transferrin which was 
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fluorescently labeled with Texas Red (Tf-Texas Red) and HAI-SMCC-bPEI-FITC 
or bPEI-FITC polyplexes formulated with non-fluorescently labeled siRNA at 
N/P= 5 for 1 and 4 h. As shown in Figure 37, upper panel, after 1 h of incubation, 
more yellow dots representing co-localization of Tf-Texas Red (red) and polymer-
FITC (green) were observed in cells treated with HAI-SMCC-bPEI polyplexes 
than in bPEI polyplexes transfected cells. At 4 h (Figure 37, lower panel), there 
was noticeably more co-localization between Tf and polymers in both bPEI and 
HAI-SMCC-bPEI transfected samples when compared with samples at 1 h (Figure 
37, upper panel). The intensity of the co-localization was stronger in samples 
treated with HAI-SMCC-bPEI polyplexes than in bPEI polyplexes-transfected 
cells (Figure 37, lower panel).  
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Figure 37 CLSM of co-localization of Tf and PEI or HAI-SMCC-PEI. Co-
localization of transferrin (Tf) and bPEI or HAI-SMCC-bPEI polyplexes in H1299 
was imaged by confocal microscopy. H1299 cells were incubated with Tf 
fluorescently labeled with Texas Red (Tf-Texas Red) and bPEI or HAI-SMCC-
bPEI polyplexes prepared with 50 pmol of siRNA at N/P= 5 for 1 and 4 h. The 
polymers were fluorescently labeled with FITC and shown in green. Tf-Texas Red 
was shown in red, and DRAQ5 stained nuclei were shown in blue. The arrows 
pointing to the yellow dots represent co-localization spots of polyplexes and Tf. 
To determine the co-localization of the cellular binding site of THR peptide 
with TfR, H1299 cells were incubated with 2 µg/mL of Tf-Texas Red and THR-
AF488 for 1 h. As shown in Figure 38, red dots represented Tf-Texas Red evenly 
distributed in the cells, but green dots represented THR-AF488 and formed large 
aggregate on the cellular surface.  
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Figure 38 CLSM of co-localization of Tf and THR peptide. 2 µg/mL of THR-
AF488 and Tf-Texas Red were incubated with H1299 for 1 h at 37 °C. The 
cellular distribution of THR-AF488 and Tf-Texas Red was observed under 
confocal laser scanning microscopy (CLSM). 
5.3.6 In Vitro GAPDH Gene Knockdown 
To investigate the selective delivery of siRNA with HAI-SPDP-bPEI or 
HAI-SMCC-PEI, we next measured the efficacy of HAI-SPDP-bPEI or HAI-
SMCC-PEI/ siRNA polyplexes to silence GAPDH in H1299 cells. Cells were 
transfected with either HAI-SPDP-bPEI, HAI-SMCC-PEI or PEI polyplexes 
containing siRNA against GAPDH (siGAPDH), or scrambled siRNA at N/P= 5 
for 24 h. GAPDH gene expression was normalized to β-actin gene expression. As 
shown in Figure 39 A, significantly higher GAPDH silencing was achieved by 
siGAPDH/HAI-SPDP-bPEI polyplexes compared with the group treated with 
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scrambled siRNA/HAI-SPDP-bPEI polyplexes, and with the untreated group. 
However, there was no significant difference among siGAPDH/bPEI, the 
scrambled siRNA/bPEI treated group, and the untreated group. On the other hand, 
HAI-SMCC-PEI failed to mediate significant GAPDH knockdown compared to its 
scramble siRNA control (Figure 39 B).  
To further confirm the GAPDH gene silence mediated by HAI-SPDP-PEI, 
the GAPDH knockdown experiment was conducted in H460 cells which expressed 
low levels of TfR. As shown in Figure 39 C, there was no significant difference 
regarding GAPDH expression among the HAI-SPDP-PEI polyplexes treated group, 
PEI polyplexes treated group and untreated group.   
H
A
I-S
P
D
P
-P
E
I
P
E
I
un
tr
ea
te
d
0
50
100
150
%
 G
A
P
D
H
/ 
b
e
ta
-a
c
tin **
**
ns
ns
GAPDH knockdown in H1299
H
A
I-S
P
D
P-
P
E
I
P
E
I
un
tr
ea
te
d
0
50
100
150
200
%
 G
A
P
D
H
/ 
b
e
ta
-a
c
ti
n
ns
GAPDH knockdown in H460
siGAPDH
siNC
untreated
GAPDH knockdown in H1299
H
A
I-S
M
C
C
-P
E
I N
P
5
P
EI
 N
P
5
un
tr
ea
te
d
0.0
0.5
1.0
1.5 ns
**
G
A
P
D
H
/b
e
ta
-A
c
ti
n
(A) (B) (C)
 
Figure 39 GAPDH knockdown in H1299 and H460. (A) H1299 were transfected 
with bPEI or HAI-SPDP-bPEI. (B) H1299 were transfected with bPEI or HAI-
SMCC-bPEI polyplexes. (C) H460 cells were transfected with bPEI or HAI-
SPDP-bPEI polyplexes. All polyplexes were formulated with 50 pmol of siRNA 
against GAPDH (siGAPDH) or scrambled siRNA at N/P= 5 and the cells were 
transfected for 24 h. The expression of GAPDH was determined by RT-PCR and 
normalized to the expression of β-actin. Untreated control represented 100% or 1 
GAPDH/β-actin.  (Data points indicate mean +/- SD, n= 3. ns, p > 0.05, **p < 
0.01). 
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5.3.7 In Vitro eGFP Knockdown  
To further determine the gene silencing efficiency of HAI-SPDP-bPEI 
polyplexes at the protein level, the in vitro knockdown efficiency of the reporter 
gene enhanced green fluorescent protein (eGFP) by HAI-SPDP-bPEI polyplexes 
was determined in a H1299 cell line stably expressing eGFP. Cells were 
transfected with HAI-SPDP-bPEI or bPEI polyplexes formulated with siRNA 
against eGFP (siGFP) or scrambled siRNA at N/P= 5 and 10 for 48 h with or 
without chloroquine treatment, a drug reported to increase the endosomal release 
of siRNA 185. The MFIs of eGFP in cells were quantified by flow cytometry. As 
shown in Figure 40 A, there was no significant difference of MFI between cells 
transfected with bPEI and HAI-SPDP-bPEI polyplexes containing siGFP without 
chloroquine treatment at either N/P= 5 or 10. However, with additional 
chloroquine treatment (Figure 40 B), HAI-SPDP-bPEI polyplexes achieved 
significantly more eGFP knockdown compared with bPEI polyplexes at both 
N/P=5 and 10. Both HAI-SPDP-bPEI and bPEI polyplexes containing scrambled 
siRNA did not reduce the MFI of eGFP, indicating that the eGFP knockdown was 
not contributed to by the polymer, but by the siRNA against eGFP released in the 
cytoplasm.  
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Figure 40 GFP knockdown in H1299. (A) H1299/eGFP cells were transfected with 
bPEI and HAI-SPDP-bPEI polyplexes for 48 h without chloroquine treatment. (B) 
H1299/eGFP cells, stably expressing eGFP, were transfected with bPEI or HAI-
SPDP-bPEI polyplexes prepared with 50 pmol of siRNA against eGFP (siGFP) or 
scrambled siRNA at N/P= 5 and 10 for 48 h with chloroquine treatment. The MFIs 
of eGFP were quantified by flow cytometry. (Data points indicate mean +/- SD, 
n= 3. ns, p > 0.05, *p < 0.05) 
5.4 Discussion 
The selective and efficient delivery of siRNA to tumors is hindered by 
many biological barriers 95. Numerous modifications of polymers have been 
discovered to target tumor cells including folic acid 19, transferrin 20, epidermal 
growth factor (EGF) 186 and the tripeptide arginine-glycine-aspartate RGD 47. In 
this study, two human TfR binding peptides, HAIYPRH (HAI peptide) and 
THRPPMWSPVWP (THR peptide), were tested for gene delivery in TfR positive 
cells. Both peptides contain a distal cysteine to introduce an additional thiol group 
for further modification. The THR peptide was first evaluated since it 
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demonstrated a high affinity to TfR (1.5 × 10−8 M) compared to the affinity of 
native ligand Tf to TfR of 2.8 × 10−9 M; in contrast, the affinity constant of the 
HAI peptide was 4.4 × 10−4 M 184. The THR peptide was successfully coupled to 5 
kDa bPEI via linker SPDP as shown in Figure 30 C. Despite the fact that the THR 
peptide, which was fluorescently labeled with Alexa Fluor 488 (THR-AF488), did 
preferentially bind to TfR overexpressing H1299 cells compared to TfR low 
expressing A549 cells (Figure 35 A), the cellular uptake mediated by THR-bPEI 
polyplexes in H1299 cells was lower than that of bPEI polyplexes and showed no 
difference compared with A549 cells (Figure 35 B). It has been reported that the 
THR peptide conjugated with a chelator for radiolabeling demonstrated negligible 
uptake in a TfR positive cell line 187 and that THR modified gold nanoparticles did 
not efficiently cross the blood brain barrier without the addition of a hydrophobic 
peptide to facilitate membrane binding 188. Therefore, it is possible that the binding 
cavity of the THR peptide to TfR is sterically very strict and only allows limited 
modification in the peptide. Consequently, THR modified with a small fluorescent 
probe, AF488 (MW= 720.66 Da), still demonstrated preferential binding to H1299 
but THR conjugated to a large polymer, bPEI (MW= 5000 Da), cannot mediate 
significantly higher cellular uptake in H1299 cells compared with A549 cells. 
Another possible reason of low selective cellular uptake could be low receptor 
internalization efficiency. Confocal imaging revealed that THR-AF488 can bind to 
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the membrane of H1299 but little internalization was observed (Figure 38), and 
the co-localization of THR-AF488 and Tf was absent. Thus, THR may not be an 
optimal candidate for the TfR targeting of polyplexes.  
The other peptide discovered in the same study, the HAI peptide, 
demonstrated different properties during evaluation for polyplex targeting. Firstly, 
the HAI peptide was successfully conjugated to 25k Da bPEI via two different 
linkers: sulfo-SMCC and PEG4-SPDP. The coupling degrees were similar in both 
approaches and were around 18 HAI peptides per bPEI. It has been reported that 
protein/peptide modifications in polymer may result in less nucleic acid 
condensation efficiency compared to the non-modified polymer due to the 
introduction of steric hindrance 61, 189. The siRNA condensation efficiency of bPEI 
and HAI-SPDP-bPEI was therefore determined by a SYBR Gold assay, and the 
results demonstrated that HAI-peptide modification did not have any negative 
impact on bPEI’s condensation of siRNA (Figure 31). Chemico-physical 
properties of polyplexes are very important for successful and efficient siRNA 
delivery. Therefore, bPEI and HAI-SPDP-bPEI polyplexes (N/P=5) were fully 
characterized in terms of the hydrodynamic diameter, PDI and zeta-potential. As 
shown in Figure 32 A, HAI-SPDP-bPEI and bPEI polyplexes had narrow size 
ranges with PDIs of around 0.3, indicating that uniform polyplexes were formed 
with little aggregation. HAI-SPDP-bPEI polyplexes were slightly larger than bPEI 
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polyplexes which may be due to steric hindrance of the peptide during polyplexes 
formation. However, both polyplexes resulted in very small sizes (100–150 nm). 
These results suggested that both polyplexes may readily be taken up by cells 130, 
avoid rapid clearance from macrophages in the liver and spleen after systemic 
administration, and could potentially easily accumulate in a tumor through the 
EPR effect 24. Both polyplexes demonstrated slightly positive surface charge (<30 
mV) (Figure 32 B). Since HAI-SPDP-bPEI and bPEI can completely condense 
siRNA at N/P= 2 (Figure 31), it was expected that at N/P =5, an excess amount of 
cationic polymer formulated with siRNA would result in positive surface charges. 
HAI-SPDP-bPEI polyplexes exhibited a less positive charge than bPEI polyplexes 
which may be due to the assumption that the conjugated HAI peptide locates on 
the surface of the polyplexes and can shield some positive charge from bPEI. 
Another possible reason for the reduced surface charge of HAI-SPDP-PEI is that 
the SPDP coupling reaction consumed some of the primary amines in bPEI. A 
slightly positive surface charge could facilitate the binding between polyplexes 
and cellular membranes. Moreover, the HAI peptide located on the surface is 
expected to increase the possibility to interact with TfR, suggesting that efficient 
cellular uptake may be achieved by this formulation. 
The TfR expression status of three different cell lines—H1299, A549 and 
H460—was determined by flow cytometry after immunostaining with the anti-
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CD71 (TfR) antibody. Based on the results (Figure 33 A and B), H1299 cells 
served as a TfR overexpressing cell model, and A549 and H460 served as TfR low 
expressing cell models for later studies. The peptide mediated TfR selectivity was 
investigated by confocal microscopy. HAI-SMCC-bPEI and bPEI were 
fluorescently labeled with FITC (HAI-SMCC-bPEI-FITC, bPEI-FITC 
respectively), and polyplexes were formed with non-fluorescently labeled siRNA. 
H1299 cells were incubated with Tf-Texas Red and the aforementioned polyplexes. 
As shown in Figure 36, HAI-SMCC-bPEI polyplexes showed more binding (green 
dots) on the cell surface and more co-localization (yellow dots) with Tf-Texas Red 
(red dots) than bPEI polyplexes after 1 and 4 h of the co-incubation period, 
indicating that the HAI peptide can mediate selective binding to TfR 
overexpressing cells. Furthermore, HAI-SMCC-bPEI can achieve more co-
localization with Tf, suggesting that HAI-SMCC-bPEI polyplexes may enter cells 
via a TfR mediated pathway in a non-competitive manner as reported before 184. 
The subcellular distribution of both polyplexes over time was observed under the 
confocal microscope (Figure 36). H1299 cells were transfected with HAI-SMCC-
bPEI-FITC or bPEI-FITC polyplexes (green dots) containing siRNA-Ty563 (red 
dots). HAI-SMCC-bPEI polyplexes clearly achieved more cellular binding on the 
membrane than bPEI polyplexes during the first 1 and 4 h, suggesting that HAI-
SMCC-bPEI preferentially bound to TfR overexpressing cells compared with 
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bPEI polyplexes. At later time points (24 and 48 h), both bPEI and HAI-SMCC-
bPEI polyplexes formed bright yellow dots in vesicle like structures, indicating 
that many of both types of polyplexes had accumulated and were trapped in 
endosomes or lysosomes. However, it is worth nothing that more siRNA 
distributed in the cytoplasm in the HAI-SMCC-bPEI treated group than in bPEI 
transfected cells. According to the cellular uptake results (Figure 34 A), it is 
possible that HAI-SMCC-bPEI polyplexes mediated higher cellular uptake in 
H1299 cells than bPEI polyplexes, consequently more siRNA escaped into the 
cytoplasm. The TfR specific cellular uptake mediated by the HAI peptide was also 
confirmed by flow cytometry (Figure 34 A and B). Both HAI-SMCC-bPEI and 
HAI-SPDP-bPEI polyplexes showed specific binding to the TfR overexpressing 
cell line (H1299 cells) compared with TfR low expressing cells (A549 and H460). 
Furthermore, both HAI peptide modified bPEI polyplexes mediated significantly 
higher cellular uptake in H1299 cells compared with non-modified bPEI, 
suggesting a specific interaction between the HAI peptide in the polymer and TfR 
on the cell membrane. 
The gene knockdown efficiency of the HAI peptide, modified bPEI and 
non-modified bPEI was determined by RT-PCR, and the housekeeping gene 
GAPDH was targeted. Surprisingly, HAI-SMCC-bPEI polyplexes did not mediate 
efficient GAPDH gene knockdown, as shown in Figure 39 B, which did not agree 
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with the cellular uptake result (Figure 34 A) and the confocal microscopy result 
(Figures 35 and 36). It is possible that the HAI peptide modification reduced the 
number of primary amines in bPEI and consequently reduced the buffering 
capacity of bPEI. Furthermore, TfR rapidly recycles back to the cell surface after 
internalization 190, therefore, HAI-SMCC-bPEI polyplexes that are still bound to 
TfR are recycled back to the cell surface before siRNA can be released. To 
address this problem, HAI-SPDP-bPEI was synthesized using a linker PEG4-SPDP. 
PEG4-SPDP (25.7 Å) is longer than sulfo-SMCC (8.3 Å) which may make the 
HAI peptide more accessible to TfR and increase the binding efficiency. Moreover, 
it introduced a disulfide bond into the HAI-SPDP-bPEI conjugate which can be 
reduced in the endosomal compartment 191 and may facilitate the release of 
bPEI/siRNA complexes from the HAI peptide/TfR complexes before TfR recycles 
back to the cell surface. The GAPDH gene knockdown efficiency of HAI-SPDP-
bPEI polyplexes was determined in H1299 and H460 cells. In line with previous 
cellular uptake results (Figure 34 B), HAI-SPDP-bPEI polyplexes can achieve 
more efficient GAPDH gene knockdown in H1299 cells (Figure 39 A) compared 
with bPEI polyplexes but not in H460 cells (Figure 39 C). These results revealed 
that the introduction of a long and reducible linker into target moiety-polymer 
conjugates may increase their transfection efficiency. Additionally, it was shown 
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that the transfection efficiency of HAI-SPDP-bPEI polyplexes is highly dependent 
on the TfR expression status of the targeted cells. 
Next, the gene silencing efficiency of HAI-SPDP-bPEI polyplexes at the 
protein level was investigated in H1299/eGFP cells. H1299/eGFP cells were 
treated with HAI-SPDP-bPEI and bPEI polyplexes for 48 h, and the eGFP 
expression was determined by flow cytometry. However, as shown in Figure 40 A, 
there was no significant difference among the polyplexes treated groups and the 
untreated group. Based on the confocal images (Figure 36), it is possible that most 
polyplexes were trapped in the endosome and only a small amount of siRNA was 
released into the cytoplasm. Therefore, mRNA level silencing can be observed 
since mRNA is the direct target of siRNA. However, it is more difficult to achieve 
protein level silencing. A sufficient amount of siRNA needs to be released into the 
cytoplasm. Additionally, the silencing efficiency also depends on the half-life of 
the targeted protein, and wild type GFP has a relatively long half-life (around 26 
h) 192. To increase the release of siRNA from endosomes, H1299/eGFP cells were 
transfected with HAI-SPDP-bPEI and bPEI polyplexes in media containing 
chloroquine, which is a chemical that can dramatically increase the transfection 
efficiency by disrupting the endosomal membrane 185. As shown in Figure 40 B, 
significantly higher eGFP knockdown can be achieved by siGFP/HAI-SPDP-bPEI 
polyplexes compared with siGFP/bPEI polyplexes in a dose dependent manner.         
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5.5 Conclusion 
In conclusion, our optimized HAI-bPEI conjugate has desired chemico-
physical properties as a siRNA delivery vector. It can achieve selective delivery of 
siRNA to TfR overexpressing tumor cells and efficient gene knockdown at the 
mRNA level. This study demonstrates the feasibility to target TfR using HAI 
peptide. However, results also indicate the need for further optimization of this 
conjugate to achieve better endosomal escape.  
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Gene therapy is thought to be a solution for various difficult to treat 
diseases such as cancer. Small interfering RNA (siRNA) as a promising class of 
anti-sense molecules can specifically silence disease related genes and has been 
evaluated in different diseases. However, lack of safe and efficient siRNA delivery 
systems limits the application of siRNA therapy in the clinic. Transferrin receptor 
(TfR) is an essential transmembrane receptor involved in iron uptake. TfR is 
universally expressed in most cells/ tissues but is upregulated in certain cells, for 
example, many cancer cells and activated T cells (ATCs).  To overcome the 
biological barriers and increase siRNA delivery efficiency, in this dissertation, 
various TfR targeted siRNA delivery systems have been developed. Holo-Tf was 
conjugated to PEI via reducible linker succinimidyl 3-(2-pyridyldithio) propionate 
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(SPDP) or PEG4-SPDP to generate Tf-PEI. Tf-PEI was firstly evaluated for 
potential therapy of asthma. Tf-PEI demonstrated satisfactory physicochemical 
properties and can efficiently deliver siRNA to human primary ATCs ex vivo. 
Furthermore, pulmonary administration of Tf-PEI in a murine asthma model 
resulted in ATCs selective delivery of siRNA and minimum toxicity.  
Gene amplified in squamous cell carcinoma 1 (GASC1) is an oncogene 
overexpressed in basal like breast cancer (BLBC), an aggressive type of breast 
cancer, and is an essential epigenetic factor involved in tumorigenesis. Tf-PEI 
polyplexes containing siRNA against GASC1 gene were exploited as a potential 
treatment of BLBC. Tf-PEI can selectively deliver siRNA to BLBC 
overexpressing TfR and achieve efficient silencing of GASC1 gene leading to 
inhibition of proliferation of BLBC. 
Two TfR binding peptides, HAIYPRH (HAI) and THRPPMWSPVWP 
(THR), as alternative TfR targeting moieties were conjugated with PEI via 
reducible linker PEG4-SPDP or non-reducible linker sulfosuccinimidyl 4-[N-
maleimidomethyl] cyclohexane-1-carboxylate (SMCC). Both peptide-PEI 
conjugates were investigated in lung cancer cells expressing low or high level of 
TfR. HAI-PEI preferentially bound to cells overexpressing TfR while THR-PEI 
didn’t demonstrate TfR selectivity. Reducible HAI-SPDP-PEI achieved better 
gene silencing ex vivo than non-reducible HAI-SMCC-PEI. In conclusion, the 
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present study described the feasibility to efficiently deliver siRNA to ATCs in 
asthma and cancer cells via targeting TfR. These results could help the 
development of siRNA therapies for asthma and cancer.  
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